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  Sumário 
Existem inúmeros modelos de prognóstico clínico na área médico e particularmente no 
prognóstico do cancro da mama. Previamente à sua utilização clínica, os modelos de 
prognóstico necessitam de ser aplicados a pacientes provenientes de diferentes centros 
médicos, de forma a que sejam submetidos a uma rigorosa validação. Esta tese avalia a 
precisão preditiva de um modelo flexível com uma regularização Bayseana, o PLANN-ARD. 
Para tal utiliza uma base de dados composta por 4016 registos de pacientes com cancro da 
mama, diagnosticados de 1989 a 1993 e identificados pelo BCCA, Canada, com um follow-up 
de 10 anos. Este método é comparado com  a regressão de Cox, sendo considerado o modelo 
mais utilizado neste género de análise. 
Ambos os métodos foram ajustados a 931 pacientes cujos dados de rotina foram adquiridos 
e diagnosticados entre 1990 e 1994 no Christie Hospital, UK, com um follow-up de 5 anos. 
Nesta tese foram desenvolvidos avanços metodológicos significativos que suportam a 
validação externa desta rede neuronal com dados clínicos, nomeadamente: imputação dos 
dados em falta em ambas as bases de dados, treino e validação e um índice de prognóstico que 
permite a estratificação dos pacientes em grupos de risco diferentes. A precisão preditiva dos 
modelos foi medida empiricamente utilizando o índice de descriminação standard, Ctd e uma 
medida de calibração utilizando o teste estatístico, Hosmer-Lemeshow. 
Verificou-se que ambos os modelos, regressão de Cox e PLANN-ARD têm uma 
discriminação semelhante, sendo que a rede neuronal demonstrou uma precisão preditiva 
marginalmente superior durante o período de 5 anos de follow-up. Para além desta melhoria, a 
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rede neuronal regularizada tem a vantagem substancial de ser adaptada para efectuar 
previsões da função de risco e sobrevivência de pacientes individuais.  
São propostas quatro diferentes abordagens de estratificação de pacientes em grupos de 
risco, cada qual com um fundamento diferente. Embora tenha sido verificado que as quatro 
metodologias são concordantes entre elas, foram identificadas diferenças importantes entre 
elas. Foram extraídas e comparadas as regras das duas metodologias de estratificação, o “log-
rank bootstrap” e a aplicação directa das árvores de regressão, e para as duas metodologias de 
extracção de regras, OSRE e CART, respectivamente. 
Os índices de prognóstico clínico de cancro da mama, como o NPI, TNM e St. Gallen 
consensus rules foram também comparados com os modelos de prognóstico propostos 
representados como árvores de regressão, onde se pôde concluir que as abordagens propostas 
podem melhorar a prática clínica corrente. 
Por fim, é proposto um sistema clínico Web de suporte à decisão para médicos 
oncologistas e para pacientes com cancro da mama, onde é efectuada uma avaliação 
prognóstica, adaptada às características particulares de cada paciente.  
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  Abstract 
There are several clinical prognostic models in the medical field. Prior to clinical use, the 
outcome models of longitudinal cohort data need to undergo a multi-centre evaluation of their 
predictive accuracy. This thesis evaluates the possible gain in predictive accuracy in multi-
centre evaluation of a flexible model with Bayesian regularisation, the (PLANN-ARD), using 
a reference data set for breast cancer, which comprises 4016 records from patients diagnosed 
during 1989-93 and reported by the BCCA, Canada, with follow-up of 10 years. The method 
is compared with the widely used Cox regression model.  
Both methods were fitted to routinely acquired data from 743 patients diagnosed during 
1990-94 at the Christie Hospital, UK, with follow-up of 5 years following surgery. 
Methodological advances developed to support the external validation of this neural network 
with clinical data include: imputation of missing data in both the training and validation data 
sets; and a prognostic index for stratification of patients into risk groups that can be extended 
to non-linear models. Predictive accuracy was measured empirically with a standard 
discrimination index, Ctd, and with a calibration measure, using the Hosmer-Lemeshow test 
statistic.  
Both Cox regression and the PLANN-ARD model are found to have similar discrimination 
but the neural network showed marginally better predictive accuracy over the 5-year follow-
up period. In addition, the regularised neural network has the substantial advantage of being 
suited for making predictions of hazard rates and survival for individual patients.  
Four different approaches to stratify patients into risk groups are also proposed, each with 
a different foundation. While it was found that the four methodologies broadly agree, there 
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are important differences between them. Rules sets were extracted and compared for the two 
stratification methods, the log-rank bootstrap and by direct application of regression trees, and 
with two rule extraction methodologies, OSRE and CART, respectively. 
In addition, widely used clinical breast cancer prognostic indexes such as the NPI, TNM 
and St. Gallen consensus rules, were compared with the proposed prognostic models 
expressed as regression trees, concluding that the suggested approaches may enhance current 
practice. 
Finally, a Web clinical decision support system is proposed for clinical oncologists and for 
breast cancer patients making prognostic assessments, which is tailored to the particular 
characteristics of the individual patient. This system comprises three different prognostic 
modelling methodologies: the NPI, Cox regression modelling and PLANN-ARD. For a given 
patient, all three models yield a generally consistent but not identical set of prognostic indices 
that can be analysed together in order to obtain a consensus and so achieve a more robust 
prognostic assessment of the expected patient outcome.     
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Symbols and Notations  
Symbols and Notations Description 
AIC Akaike’s Information criterion 
AJCC American Joint Committee on Cancer 
ANN Artificial neural network 
ARD Automatic Relevance Determination 
BCCA British Columbia Cancer Agency 
CART Classification and Regression Trees 
CCI Crude cumulative incidence 
DFS Disease-free survival 
EPV Events per variable 
ER Oestrogen receptor 
FIGO International Federation of Gynecology and Obstetrics 
HER2 Human epidermal growth factor receptor 2 
KM Kaplan Meier 
MAR Missing at random 
MCAR Missing completely at random 
MI Multiple Imputation 
MLP Multilayer perceptron 
MNAR Missing not at random 
NPI Nottingham Prognostic Index 
OS Overall Survival 
OSRE Orthogonal Search Rule Extraction 
PgR Progesterone receptors 
PI Prognostic Index 
PLANN-ARD Partial Logistic Artificial Neural Networks with Automatic 
Relevance Detection 
PLSPL Partial logistic spline 
PVI Peritumoural vascular invasion 
ROC Receiver operating characteristic 
TNM Tumour, Nodes, Metastasis 
VIII 
Index of Contents 
Chapter 1 - Introduction ............................................................................................................ 1 
1.1 ­ Contribution of the thesis............................................................................................................... 8 
1.2 ­ Articles accepted ............................................................................................................................... 9 
Chapter 2 - Analytical methodologies ..................................................................................... 11 
2.1 ­ An overview of classical survival methods ............................................................................11 
2.1.1. Censorship and their importance ..........................................................................................................13 
2.1.2. Survivor function and Hazard function ...............................................................................................14 
2.1.3. Actuarial/Descriptive Model – Kaplan Meier ...................................................................................15 
2.1.4. Piecewise Linear Models – Proportional Hazards (Cox regression Model) ..........................17 
2.2 ­ Flexible Models ................................................................................................................................20 
2.2.1. Generally of Artificial Neural Networks .............................................................................................20 
2.2.2. Neural Network Training .........................................................................................................................25 
2.2.3. ANN application in prognostic modelling ..........................................................................................28 
2.2.4. Misuses in Applications of ANN for prognostic models .................................................................31 
2.2.5. Advantages of using Neural Networks in Prognostic Modelling.................................................32 
2.2.6. Bayesian Regularisation framework ....................................................................................................32 
2.2.7. PLANN-ARD in prognostic modelling.................................................................................................37 
2.3 ­ Prognostic index stratification and Boolean Rules extraction methodology............42 
2.3.1. Log-rank Test ...............................................................................................................................................44 
2.3.2. Minimum p-value methodology..............................................................................................................46 
2.3.3. Log-rank bootstrap methodology ..........................................................................................................47 
2.3.4. Regression Tree Methodology ................................................................................................................49 
2.3.5. Clustering Methodology ...........................................................................................................................50 
2.3.6. Clustering methodology based on learning metrics ........................................................................50 
2.3.7. OSRE rule extraction algorithm ............................................................................................................54 
2.4 ­ Clinical Prognostic Indices...........................................................................................................55 
2.4.1. NPI (Nottingham Prognostic Index).....................................................................................................56 
2.4.2. TNM prognostic index...............................................................................................................................57 
2.4.3. St. Gallen Classification...........................................................................................................................58 
Chapter 3 - Study Design for Prediction Models .................................................................... 61 
3.1 ­ Choice of covariates........................................................................................................................61 
3.2 ­ Sample size considerations .........................................................................................................63 
3.3 ­ Missing Covariate Data..................................................................................................................64 
IX 
3.4 ­ Predictive accuracy and Validation of predictive models................................................70 
3.5 ­ Modelling strategy..........................................................................................................................74 
Chapter 4 - Results ...................................................................................................................77 
4.1 ­ Databases...........................................................................................................................................77 
4.2 ­ Analysis of variables’ missingness............................................................................................83 
4.2.1. Christie Hospital data set Missingness ............................................................................................... 83 
4.2.2. BCCA data set Missingness .................................................................................................................... 87 
4.3 ­ Imputation results ..........................................................................................................................89 
4.3.1. Modelling breast cancer overall mortality using Cox proportional hazards ......................... 92 
4.3.2. Sensitivity analysis of Nodes involved variable..............................................................................100 
4.3.3. Cox Proportional hazards model validation ...................................................................................102 
4.4 ­ PLANN­ARD Modelling and its validation ........................................................................... 108 
4.5 ­ Comparison between Cox and PLANN­ARD modelling................................................... 112 
4.6 ­ Stratification methodologies ................................................................................................... 114 
4.6.1. Log-rank bootstrapping methodology and minimum p-value methodologies.......................115 
4.6.2. Regression tree stratification methodology .....................................................................................122 
4.6.3. Unsupervised clustering stratification methodology ....................................................................131 
4.6.4. Clustering methodology based on learning metrics......................................................................137 
4.6.5. Comparison between the different stratification methodologies...............................................139 
4.7 ­ OSRE and CART rules comparison ......................................................................................... 146 
4.8 ­ Interval estimates of individual prognosis......................................................................... 147 
4.9 ­ Comparison between the existent prognostic groups and the proposed ones ..... 149 
4.9.1. Comparison between NPI with Cox and PLANN-ARD modelling ...........................................149 
4.9.2. Comparison between TNM with Cox and PLANN-ARD modelling .........................................152 
4.9.3. Comparison between St. Gallen with Cox and PLANN-ARD modelling................................154 
4.10 ­ PLANN­ARD prognostic indexes and comparison with Cox prognostic index .... 156 
4.10.1. Analysis of the different PLANN-ARD prognostic indexes calculation................................156 
4.10.2. Cox proportional hazards and PLANN-ARD prognostic indexes comparison ..................158 
4.11 ­ Models with different variables’ comparison ................................................................. 159 
4.12 ­ Treatments distribution ......................................................................................................... 162 
Chapter 5 - Online Breast Cancer decision support systems .................................................167 
5.1 ­ Online breast cancer prognostic estimate – AdjuvantOnline ...................................... 168 
5.2 ­ Proposed Breast cancer survival Web decision support system................................ 170 
Chapter 6 - Conclusions and Future Work.............................................................................177 
X 
 
Index of Figures 
Figure 2.1 – Example of a Kaplan-Meier curve ...................................................................... 17 
Figure 2.2 – Constitution of a neuron (Computation in the brain). ........................................ 21 
Figure 2.3 – Constitution of a synapse (Computation in the brain). ....................................... 21 
Figure 2.4 – Example of a perceptron. .................................................................................... 22 
Figure 2.5 – Representation of possible neural networks activation functions....................... 23 
Figure 2.6 – Example of a multilayer perceptron.................................................................... 24 
Figure 2.7 – Neural network weighting versus error .............................................................. 25 
Figure 2.8 – Partial logistic artificial neural network structure............................................. 37 
Figure 2.9 – Distribution of Risk index versus the log-rank score and p-value. ..................... 47 
Figure 2.10 – Distribution of group membership. ................................................................... 49 
Figure 3.1 – This figure represents all the three phases of multiple imputation. .................... 67 
Figure 4.1 – KM curves for Christie Hospital 1990-94 data set variables’. ........................... 84 
Figure 4.2 – Bar chart comparing the frequency of the categories for different variables..... 85 
Figure 4.3 – KM curves BCCA data set variables’. ................................................................ 87 
Figure 4.4 – Bar chart comparing the frequency of the categories for different variables..... 88 
Figure 4.5 – Scatter plot between the imputed and not imputed model................................... 98 
Figure 4.6 – Scatter plot between the cross-validated PI and the PI not cross-validated. ... 103 
Figure 4.7 – Scatter plot between different prognostic indexes. ........................................... 104 
Figure 4.8 – Calibration plots for the 4 different models for the training data set............... 105 
Figure 4.9 – Calibration plots for the 4 different models, for the validation data set. ......... 108 
Figure 4.10 – Calibration plots for the 4 different models, for the training data set............ 110 
Figure 4.11 – Calibration plots for the 4 different models, for the validation data set......... 111 
Figure 4.12 – Comparison between Cox and PLANN-ARD PI for the training data set. ..... 112 
Figure 4.13 – Comparison between Cox and PLANN-ARD PI for the validation data set... 113 
Figure 4.14 – Actuarial estimates of survival obtained with KM for the training data set. .. 115 
Figure 4.15 – Actuarial estimates of survival obtained with KM for the validation data set.116 
Figure 4.16 – KM curves using the log-rank bootstrapping methodology for both PI. ........ 118 
Figure 4.17 – Final classification tree using the PI obtained with PLANN-ARD................. 123 
Figure 4.18 – Final classification tree using the PI obtained with Cox regression. ............. 124 
Figure 4.19 – Box-plots for the different risk groups. ........................................................... 125 
XI 
Figure 4.20 – KM curves using the regression tree stratification method for both PI. .........125 
Figure 4.21 – Box-plots for the different groups....................................................................129 
Figure 4.22 – KM curves using the regression tree stratification method for both PI. .........130 
Figure 4.23 – Concordance plot for different number of clustering. .....................................132 
Figure 4.24 – Separation measure (y axis) versus concordance measure (x axis) plot.........133 
Figure 4.25 – Cramer Area plot.............................................................................................133 
Figure 4.26 – Box plots for the 3 (top figures) and 4 (bottom figures) cluster solution. .......134 
Figure 4.27 – KM curves the 4 cluster solution. ....................................................................134 
Figure 4.28 – KM curves for the 4 cluster solution, using the validation data set. ...............137 
Figure 4.29 – KM curves and cluster in the space of two prognostic indices........................138 
Figure 4.30 – Cluster projections on different components. ..................................................139 
Figure 4.31 – Survival curves obtained for the patients’ cross-tabulation............................141 
Figure 4.32 – Survival curves obtained for the patients’ cross-tabulation............................142 
Figure 4.33 – Survival curves obtained for the patients’ cross-tabulation............................144 
Figure 4.34 – Survival curves obtained for the patients’ cross-tabulation............................145 
Figure 4.35 – Survival Distribution for an individual patient. ..............................................148 
Figure 4.36 – Box plots of individual survival estimates to 5 years. .....................................148 
Figure 4.37 – KM survival curves for the NPI. ......................................................................150 
Figure 4.38 – Matrix of KM curves for NPI vs Cox for the validation data set.....................151 
Figure 4.39 – Matrix of KM curves for NPI vs PLANN-ARD for the validation data set. ....152 
Figure 4.40 – TNM KM survival curves applied to the Christie Hospital data set. ..............153 
Figure 4.41 – Consensus rules agreed by the St. Gallen group KM survival curves. ...........155 
Figure 4.42 – KM curves for the different PI calculation for the training data set. ..............157 
Figure 4.43 – Scatter plots comparing different prognostic indices. .....................................159 
Figure 4.44 – KM curves for the different four variables models, for the training data set. .161 
Figure 5.1 – Home page of breast cancer decision support system.......................................171 
Figure 5.2 – Home page of breast cancer decision support system after the introduction of a 
registration user .............................................................................................................171 
Figure 5.3 – Prognostic assessments for a particular patient. ..............................................174 
Figure 5.4 – Treatments information on the web-site. ...........................................................174 
Figure 5.5 – Matrix with KM curves for a patient choosing NPI and PLANN-ARD. ............175 
Figure 5.6 – KM curve after clicking in the cross-matching survival curves web-page........176 
 
XII 
 
Index of Tables 
Table 2.1 – Example for a Kaplan-Meier curve calculation ................................................... 16 
Table 2.2 – Example of s inputs and outputs for the PLANN-ARD model. ............................. 37 
Table 2.3 – St. Gallen risk categories 2007. ............................................................................ 58 
Table 3.1 – Relative efficiency of multiple imputation. ........................................................... 68 
Table 4.1 – Variables’ description and marginal distributions............................................... 79 
Table 4.2 – Continuation of variables’ description and marginal distributions. .................... 80 
Table 4.3 – Continuation of variables’ description and marginal distributions. .................... 81 
Table 4.4 – Cross tabulations between some Christie Hospital variables. ............................. 85 
Table 4.5 – Missingness associations for Christie Hospital data set. ..................................... 86 
Table 4.6 – Missingness associations for the BCCA data set.................................................. 88 
Table 4.7 – Results of the missing data imputation with 10 and 20 iterations. ....................... 90 
Table 4.8 –  Missing data imputated compared with original data for both data sets. ........... 91 
Table 4.9 – Relation between the event other causes of death and some variables. ............... 93 
Table 4.10 – Models chosen using the bootstrapping ordered by their frequency.................. 94 
Table 4.11 – Beta values for Cox proportional modelling ...................................................... 94 
Table 4.12 – -2LogL statistic for different fitted models. ........................................................ 95 
Table 4.13 – Models parameters for the imputed data sets. .................................................... 96 
Table 4.14 – Models parameters for the not imputed data sets............................................... 97 
Table 4.15 – Beta values comparison for imputed and not imputed model............................. 99 
Table 4.16 – Imputation results comparison. ........................................................................ 101 
Table 4.17 – Models chosen using bootstrapping, coding missing as a different attribute. . 101 
Table 4.18 – Models chosen using bootstrapping applied to the imputed data sets. ............ 102 
Table 4.19 – Models Calibration and discrimination assessment. ........................................ 105 
Table 4.20 – Models Calibration and discrimination assessment. ........................................ 107 
Table 4.21– Models Calibration and discrimination assessment. ......................................... 109 
Table 4.22 – Models Calibration and discrimination assessment. ........................................ 110 
Table 4.23 – Log rank pairwise comparisons for the validation data set. ............................ 117 
Table 4.24 – Log-rank pairwise values for the different risk groups. ................................... 119 
Table 4.25 – Log-rank pairwise values for the different risk groups. ................................... 119 
Table 4.26 – Rules obtained with OSRE. ............................................................................... 120 
XIII 
Table 4.27 – Rules obtained with OSRE. ...............................................................................121 
Table 4.28 – Mean KM survival values at the end of follow up (5 years)..............................122 
Table 4.29 – Log-rank pairwise values for the different risk groups. ....................................126 
Table 4.30 – Rules obtained with regression tree using the Cox proportional hazards PI. ..127 
Table 4.31 – Rules obtained with regression tree using the PLANN-ARD PI. ......................128 
Table 4.32 – Mean KM survival values at the end of follow up (5 years)..............................129 
Table 4.33 – Log-rank pairwise values for the different risk groups. ....................................131 
Table 4.34 – Log-rank pairwise values for 4 cluster solution................................................135 
Table 4.35 – Rule-based characterization of the patient cohorts. .........................................135 
Table 4.36 – Patients’ cross tabulation using the application of nearest records and rules. 136 
Table 4.37 – Log-rank pairwise values for the 4 cluster solution and validation data set. ...137 
Table 4.38 – Log-rank pairwise values for the 5 cluster solution ..........................................138 
Table 4.39 – Patients’ cross tabulation between two different stratification methodologies.140 
Table 4.40 – Risk groups’ cross tabulation between different models...................................143 
Table 4.41 – Mean and 95% confidence intervals. ................................................................148 
Table 4.42 – Cross-tabulation between different classification schemes...............................150 
Table 4.43 – Log-rank pairwise values for TNM applied to the training data set.................153 
Table 4.44 – Cross-tabulation between different classification schemes...............................153 
Table 4.45 – Risk group consensus rules agreed by the St. Gallen group. ............................154 
Table 4.46 – Cross-tabulation between different classification schemes...............................155 
Table 4.47 – Cross tabulations between different PI calculations for the training data set..158 
Table 4.48 – Cross tabulation between patients’ risk group allocation. ...............................160 
Table 4.49– Distribution of the different treatments for the different risk groups. ................162 
Table 4.50 – Distribution of the different treatments for the different risk groups................162 
Table 4.51 – Distribution of the different treatments for the different risk groups................162 
Table 4.52 – Higher Treatments’ Risk group Ratio for different models, for the training data 
set....................................................................................................................................163 
Table 4.53 – Distribution of the different treatments for the different risk groups................163 
Table 4.54 – Distribution of the different treatments for the different risk groups................164 
Table 4.55 – Distribution of the different treatments for the different risk groups................164 
Table 4.56 - Higher Treatments’ Risk group Ratio for different models, for the validation data 
set....................................................................................................................................164 

 1 
Chapter 1 - 
Introduction 
Predictions of the prognosis for a patient diagnosed with cancer has an important clinical 
role in informing decisions on the choice of adjuvant therapy, in particular to minimise the 
risk of under- or over-treatment. Current interest in the development of personalised medicine 
increasingly requires the specialisation of clinical outcome predictions at the level of the 
individual patient. Moreover, patient empowerment for “shared decision-making” makes 
physicians and patients both active participants in deciding on the choices for therapeutic 
interventions. This requires accurate communication and transparent explanations about the 
prognosis of the disease, in order to permit a well-founded assessment of the risks and 
benefits of particular treatment choices. In clinical practice, prediction models inform patients 
and their physician on the probability of a diagnosis or a prognostic outcome as well as 
stratifying the patients according into risk groups, which can be useful for communication 
between physicians. Stratification is also important for promoting consistent care protocol 
between physicians and in the design and assessment of clinical trial outcomes by comparing 
like-for-like patients. 
However, it is imperative for the application of the model that its predictions are reliable, 
quantifying how accurate the predictions from the model are, which is the “Model 
Performance”. Furthermore, the gold standard for performance evaluation is to carry out an 
external validation, that is to say predicting for patients from a clinical centre that is different 
from the clinical centres from which patient data were acquired for model development 
(Lisboa, 2002). 
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There are several clinical prognostic classification schemes proposed for breast cancer 
patients, some of which discriminate between the survival of different risk groups defined 
from the patient characteristics. A general criterion defined by the World Health Organisation 
is the so-called Tumour, Nodes and Metastasis (TNM) staging system, which is a rule-based 
filter whose arguments are the ordinal representations of tumour size (T), the extent of spread 
of the disease to the lymph nodes (N) and the presence of clinical signs of metastatic spread 
(M). The strength of this index is that it only requires clinical information, which is obtained 
by the clinician without resort to laboratory tests.  
A limitation of TNM staging is that its discrimination power is best for separating severe 
from early-stage disease. Clinically, it is important to differentiate between the severity of 
illness of patients with non-metastatic disease, sometimes referred to as the ‘operable group’ 
since, for them, there is the possibility of completely removing the cancer.  However, this 
requires the addition of histological information about the stage of advancement of the 
cancerous tissue cells. This is provided in one of the most widely used early stage clinical 
indices for breast cancer, the Nottingham prognostic index (NPI) (Haybittle, Blamey, Elston, 
Johnson, Doyle, Campbell, Nicholson, Griffiths, 1982). This index combines the pathological 
size of the tumour, measured in cm, together with an integer index of histological grade in 
three discrete groups (good, moderate and poor differentiation) and the number of axillary 
lymph nodes affected, also in three groups.  
Note that this index comprises a linear combination of discrete categories, forming an 
analytical scoring index which can be represented as β.x in a Cox regression model.  The 
second point to note about this robust and time honoured score is that is relies on a careful 
non-uniform discretisation of the categorical variables of histology and nodes affected. It is 
therefore a non-linear index, albeit expressed linearly in terms of discrete indicators.  The 
model was fitted to explain the variation in survival, lending itself naturally to the derivation 
of a discrimination index that has since undergone extensive multi-centre validation (Galea, 
Blamey, Elston, Ellis, 1992).  
Prognostic indexes have been proposed both as a continuous score, providing a risk 
estimate for individual patients, and on a discrete basis, for defining a limited number of risk 
groups from which non-parametric grouped survival estimates can be obtained, for instance 
using Kaplan-Meier, or actuarial, methods. A further score is the consensus rules agreed and 
periodically reviewed by the St. Gallen group (Harbeck, Jakesz, 2007).  
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More recently, there was much interest in deriving predictive indices to estimate the likely 
survival of individual patients, rather than discriminating between different risk groups.  One 
such model is AdjuvantOnline (Ravdin, Sminoff, Davis, Mercer, Hewlett, Gerson, Parker, 
2001), which goes further than pure prognosis and reports also the impact on 10-year survival 
from different choices of adjuvant therapy.  This model is derived from meta-analysis, rather 
than by fitting a single empirical data set from a longitudinal cohort study, although it has 
been validated using the same cohort with 10-year follow-up that serves as the reference data 
set for this study (Olivotto, Bajdik, Ravdin, Speers, Coldman, Norris, Davis, Chia, Gelmon, 
2005). However, it does not report confidence intervals for its predictions.  
Although the final power of any index is limited by the substantial unexplained prognostic 
heterogeneity and the data accuracy of the adopted retrospective databases, it is relevant to 
ask whether a generic non-linear database methodology can be developed. This will remove 
the need to limiting assumptions such as the proportionality of hazards in Cox regression and 
to remove also the need to discretise continuous variables in order to obtain piecewise linear 
models using linear-in-the-parameter methodologies.  These models have the potential to 
provide better accuracy than traditional methodologies because of their flexibility due to a 
semi-parametric formulation using distributed nodes, in the case of artificial neural networks. 
Clearly the generalisation of the model needs to be controlled with a robust regularisation 
framework and evaluated empirically with a carefully designed external validation study. 
This thesis evaluates the possible advantages of a non-linear, time dependent neural 
network methodology for survival modelling of a single risk, or outcome.  This is the Partial 
Logistic Artificial Neural Network regularized with a Bayesian network using a Laplace 
approximation of the evidence, known as Automatic Relevance Determination (MacKay, 
1995), hence PLANN-ARD.  In particular, the thesis reports the first large-scale performance 
evaluation of this methodology for an external data set, using imputation and risk 
stratification. This is benchmarked with the stalwart linear model for survival, Cox regression.  
According to an easier interpretation of covariate effects, the non-linearities that are inherent 
in outcome modelling of medical data are often naïvely taken into account implicitly by 
collecting real-valued covariates binned into discrete groups. Consequently, in such a 
framework, a flexible model such as the neural network can only improve modelling accuracy 
by implicitly modelling non-additive (interactions) effects between covariates and non-
proportional covariate effects, which in linear models need to be parameterised explicitly. 
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The PLANN-ARD model takes account of censorship that occurs when a patient drops out 
of the study before the event of interest is observed, for instance being lost to follow-up 
without a definitive outcome being recorded.  
A related matter of clinical relevance is the choice of outcome to model, i.e. the choice of 
risk.  In general there are three possibilities, for breast cancer. The most generic and best 
defined risk is that of overall mortality, since this a well-defined endpoint in prognostic 
assessment. It has the limitation of combining together the effects of breast cancer and age-
related mortality.  However, the alternative of specifying breast specific death suffers from 
potential inaccuracies in the attribution of the cause of death, for instance in the case of 
patients who die from a heart attack which may potentially reflect the health load resulting 
from radiotherapy to the left side of the chest or the toxicity of chemotherapy. A third 
possibility is to track local and distal recurrences of the disease. This represents multiple 
competing risks and suffers from potential bias because of the absence from the available 
databases of follow-up for the occurrence of second primary tumours. Taking all of these 
factors into consideration, current prognostic decision support systems such as Adjuvant 
report overall or relative mortality. This thesis focuses on the primary modelling stage for 
both of these outcome indicators, which is the risk of overall mortality as a function of age 
and clinical and histological measurements specific to breast cancer. 
This thesis also takes in account with the important issue of variable selection by making a 
carefully analysis in order to incorporate the best predictors of the outcome variables given 
the cohort sample size. 
In addition to the above issues, routinely acquired data from clinical practice commonly 
contain missing values. Moreover, the data is not missing at completely at random since there 
may be a reason for missing, for instance because the variables concerned are of no 
consequence to the choice of therapy. So it is that the survival of the patient group with a 
particular variable missing do not always lie between the survival groups for extant values, 
but sometimes are close to the extremes of survival.  However, the data used is missing at 
random, in the sense that the missing can be reasonably imputed from ancillary information, 
such as the eventual choice of therapy, by representing missing values as random variables 
(Fernandes, Jarman, Etchells, Fonseca, Biganzoli, Bajdik, Lisboa, 2008). Missing values were 
incorporated in the benchmark linear model, Cox proportional hazards and the non-linear 
model, the PLANN-ARD and both were compared.  
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When considering out-of-sample predictions it is necessary to distinguish between 
modelling the training data, which may have missing values; then predicting on an out-of-
sample cohort which may also have missing values, possibly in a different set of covariates 
than the training data, or missing with a different distribution; and predicting for a single new 
patient, for which data imputation may not be possible. Therefore, this work analyses how 
these issues can be overcome. 
Both prognostic models being compared in this study define a different prognostic index 
that ranks patient data by severity of the illness that incorporate all the issues mentioned in 
model developing and were extended to the out-of-sample cohort. 
A critical performance indicator in the validation of prognostic models, is the assessment 
of discrimination and calibration accuracy, both of which are highly relevant in decision 
support.  This performance assessment is carried out in two different ways. First, by a detailed 
analysis of the predicted vs observed survival over the five years of follow-up for the training 
data. Second, a prognostic index is defined, with which to assess the discrimination between 
patient groups, to be evaluated against the crude empirical event rate over the full follow-up 
period for the validation data, which has a 10 year timeframe.  
Once the risk score is defined, the population of patients at risk needs to be stratified for 
the purpose of tailoring adjuvant therapy and to enable comparisons to be made between 
patient cohorts from different clinical centres, or subject to different clinical interventions, to 
be made between patients at similar risk by outcome. This involves the application of 
significance tests, which in survival analysis is usually the log-rank statistic. However this 
statistic finds the different patient risk groups by thresholding only the Prognostic Index, 
making an assumption that the threshold separates distinct patient populations, while in 
practice it may be cutting across a single patient population.  It would be desirable to stratify 
by identifying distinct patient populations directly from the prognostic factors. Therefore, this 
thesis make an analysis between 4 different stratification methodologies: the first is a log-rank 
bootstrap aggregation methodology, which uses the log-rank statistic at its core but carries out 
bootstrap re-sampling of the population of prognostic indices in order to gain robustness over 
a maximum significant search. The second methodology is based on regression trees, applied 
to the continuous value prognostic scores. The third methodology is a robust unsupervised 
clustering methodology that uses k-means where only patient covariates without any 
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knowledge of outcome are considered. The fourth one uses informed clustering based on the 
principle of learning metrics. 
Models were trained on a cohort of patients with operable breast cancer recruited at 
Christie Hospital, Manchester, between 1990-93 (n=743) and were the subject of an external 
predictive evaluation for overall mortality by applying the model to a database acquired by 
the British Columbia Cancer Agency (BCCA), Vancouver, during the period 1989-93 
(n=4,016). 
This study also enhances the existing classification schemes proposed for breast cancer 
previously mentioned, by comparing them with the PLANN-ARD and Cox proportional 
hazards modelling followed by a robust stratification methodology. The survival for patient 
sub-groups was compared for the different methods, revealing the heterogeneity among the 
prognostic groups of the existent classification schemes. An advancement achieved by 
PLANN-ARD is to reliably stratify the NPI group 3 of breast cancer patients, which is 
thought to contain a mixture of patient groups with different severity of illness. The results 
reported in the thesis identify three sub-groups with statistically different 5 year survival. 
Finally, a web decision support system for breast cancer patients was developed in order to 
incorporate patient’s risk group models, such as the known NPI, the Cox proportional hazards 
prognostic index and the PLANN-ARD prognostic index both followed by a stratification 
methodology. The derived explanatory rules, the different treatments received by patients and 
the KM survival curves were also incorporated to help on the visualisation of relevant existing 
patient data an interpretation of inferences in clinical terms. It is important to mention that the 
aim of the proposed decision support system is to enhance the oncologists’ current practices, 
rather than to replace them. In this decision support framework, the predictive model 
represents an analytical window into the evidence base comprised of historical patient 
records. In particular, the model serves to provide a context for the patient, using the risk 
score and risk group strata, as well as an individualised inference of the expected prognostic 
outcome, through the predicted hazard for that patient. 
Chapter 2 of this thesis presents an overview of the classical survival models and flexible 
models, including the semi-parametric linear model and PLANN-ARD model, explaining 
how it can be applied to prognostic modelling. It also describes the existing and proposed 
stratification methodologies as how Boolean rules extraction can be achieved. In addition, 
chapter 2 gives a description of the existing classification schemes and their importance.  
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Chapter 3 starts by outlining  the main issues that must be taken in account while 
developing prediction models which were introduced and analysed in this work. Secondly, it 
defines how the predictive accuracy and validation must be analysed and the modelling 
strategy  that must be taken in account when developing prognostic models.   
Chapter 4 describes the validation results obtained with the flexible modelling approach. It 
begins with an explanation of the two datasets used for training and external validation and a 
study of the missing data and the application of multiple imputation. Second, the integration 
of the multiple imputation into the linear and non-linear modelling methodologies is 
described, leading to the evaluation of the predictive performance for the two alternative 
models, each applied to an external validation data set which was not used at all during the 
optimisation of model fitting to the training data, and in fact from a completely different 
patient sample, recruited in a different country.  The results from the different stratification 
methodologies, applied to the proposed prognostic models are presented and compared. 
Finally the relative validation performance of the existent and new prognostic and risk 
stratification schemes is presented, explaining how these new methodologies can improve 
those currently used in clinical practice.  
Finally, chapter 5 presents an overview of the existing online breast cancer prognostic 
models, with particular emphasis the AdjuvantOnline. It also defines the web clinical decision 
support system for breast cancer patients that incorporates the prognostic models proposed in 
this thesis. 
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1.1 - Contribution of the thesis 
The present thesis makes an important contribution to both technical innovation and 
clinical application as several important novelties were added or changed to current practice. 
Currently there are several survival models which are in use described previuosly, such as 
NPI and other Cox proportional hazards models. It is intended to augment NPI by adding 
more variables considered to be important in the prognostic model. Moreover, it was intended 
to define a prognostic model to become predictive rather than explanatory as well as 
modelling non-linear dependences, with PLANN-ARD.  
This thesis also takes account of missing data and censorship within principled 
frameworks, applying multiple imputation in combination with neural network models for 
time-to-event modelling, where a new prognostic index was also considered, which able the 
stratification of patients into risk groups.  
Moreover a new stratification methodology was developed, based on decision trees, which 
adds a more robust path to identify the patient’s risk group and the explanatory rules that 
characterize risk group membership, based on patient’s characteristics. Flexible modelling, 
incorporating the missing data was also subjected to a very accurate validation. 
Finally, a new web decision support system contributes to technical innovation as it 
implements both the previously mentioned models, where all can be compared. 
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1.2 - Articles accepted 
? “Assessment of benefit vs. risk of drug therapy: the potential for outcome analysis with 
flexible models”, accepted at “2010 International Joint Conference on Neural Networks”, 
Barcelona (Spain), 18-23 July 2010, Lisboa, P.J.G, Fernandes, A.S., Fonseca, J.M., 
Bajdik, Chris, Biganzoli, Elia. 
? “Cohort-based Kernel Visualisation with Scatter Matrices”, accepted at “2010 
International Joint Conference on Neural Networks”, Barcelona (Spain), 18-23 July 2010, 
Romero, Enrique, Fernandes, A.S., Mu, Tingting, Lisboa, P.J.G.  
? “A clinical decision support system for breast cancer patients”, accepted at “Doctoral 
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Bacciù, D., Etchells, T.A., Jarman, I.H., Fonseca, J.M., Lisboa, P.J.G. 
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T.A., Jarman, I.H., Fonseca, J.M., Lisboa, P.J.G. 
? “Evaluation of missing data imputation in longitudinal cohort studies in breast cancer 
survival”; Int. J. Knowledge Engineering and Soft Data Paradigms, Vol. 1, No. 3, 2009, 
pp. 257-276; Fernandes, A.S., Etchells, T.A., Jarman, I.H., Fonseca, J.M., Biganzoli, Elia, 
Bajdik, Chris, Lisboa, P.J.G. 
?  “Stratification methodologies for neural networks models of survival”, Proceedings of the 
10th International Work-Conference on Artificial Neural Networks (IWANN2009), 
Salamanca, Spain; vol. 5517 – Pág. 989-996; Springer (2009); Fernandes A.S., Etchells 
T.A., Jarman, I.H., Fonseca, J.M., Biganzoli, Elia, Bajdik, Chris, Lisboa, P.J.G. 
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Proceedings of the 12th International Conference on Knowledge-Based and Intelligent 
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Springer; Etchells T.A., Fernandes, A.S., Jarman, I.H., Fonseca J.M.,Lisboa P.J.G. 
? “Stratification of severity of illness índices and out-of-sample validation: a case study for 
breast cancer prognosis”, chapter in “Computational Intelligence in Human Cancer 
Research”; KES Rapid Research Results Series; Etchells, T.A., Fernandes, A.S., Jarman, 
I.H., Fonseca, J.M., Lisboa, P.J.G. 
 
 11 
 
Chapter 2 -  
Analytical methodologies 
This chapter introduces the survival models and artificial intelligence techniques used in 
this thesis and it is divided in four different sections. The first section gives an overview of 
classical survival methods, which explains in detail the benchmark model used in this thesis, 
the Cox proportional hazards modelling. The second section describes flexible models and 
how these can incorporate survival analysis, introducing the PLANN-ARD model, which is 
used in this thesis. This chapter also provides a description of the stratification methods that 
can be applied to a prognostic index obtained with survival modelling. Finally, an overview 
of clinical prognostic indexes is presented, making a higher emphasis on the existing 
prognostic indexes in breast cancer field.    
2.1 - An overview of classical survival methods 
Survival Analysis is composed by statistical methods used to study the occurrence and 
timing or the events. It analyses the data from a specific time of origin until the occurrence of 
a particular event. These methods were designed to apply in the study of deaths. However, the 
survival analyses can be applied in other kind of events, such as equipment failure, 
automobile accidents, stock market crashes, job terminations, births, marriages, divorces, 
arrests, and other. 
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In medical research, the time origin corresponds to the recruitment of the individual and 
the end-point can be the death of the patient, relief of pain, recurrence of symptoms. The 
result of the first end-point referred is literally survival times. 
Survival analysis was designed for longitudinal data on the occurrence of events, and it is 
very important to clarify the events in the study. The event can be characterized as a 
qualitative change (transition from one state to another, such as being alive to being death) 
and a quantitative change (a stock market crush could be defined as a single day life loss of 
more than 20% in the market index). However, in survival analysis it is needed to know more 
than a qualitative or a quantitative change. You also have to situate this event on time. 
The survival analysis can be performed considering only the time of events, but a usual 
aim of these methods is to estimate causal or predictive models in which the risk of an event 
depends on the covariates These covariates can be constant over the period of study, such as 
sex and race, or can change over the period of study, such as age, blood pressure, marital 
status. There are some reasons to consider why survival data can’t be obtained with 
conventional statistical procedures. The first one is related with the fact that survival data is 
not symmetrically distributed and consequently this type of data does not have a normal 
distribution. Transforming the data to give a more symmetric distribution could solve this 
feature. However, a more satisfactory approach is to adopt alternative distributional model to 
the original data. 
Besides this feature, the survival data has also other two features that are difficult to handle 
with conventional statistical procedures, which are censoring and time-dependent-covariates. 
The following example illustrates both problems: a sample of X prisoners was followed one 
year after release. The event of interest is the first arrest and the aim of the study is to 
determine how the occurrence and timing of arrest depends on some covariates. Some of 
these covariates are constant during the period of study, such as sex or race, others could 
change ate any time during the period of follow-up. How can this data be analysed using 
conventional methods? The conventional methods ignore the information about timing of 
arrest. Ignoring this information should reduce the precision of the estimates. One solution to 
this problem is to make the dependent variable the length of time between the release and first 
arrest and then estimate a conventional linear regression model. But what can be made with 
the persons who were not arrested during the follow-up period? Such cases are called 
censored. 
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Another problem is how to deal with a time-dependent variable, such as employment 
status. This variable can be incorporated in the data estimating 52 indicator variables (one 
variable for each week indicating the employment status). This can lead to a computational 
awkwardness and statistical inefficiency. Aside to this, there is a more fundamental problem, 
such as the employment indicators for weeks after an arrest might be a consequence of the 
arrest rather than the cause. In particular, someone who is jailed after an arrest is not likely to 
be working full time in subsequent weeks. 
In conclusion we can say that conventional methods are not efficient dealing either with 
censoring and time-dependent covariates. However, the survival analysis methods allow 
censoring, and many also allow time-dependent covariates. 
2.1.1. Censorship and their importance 
Censorship is the main feature of survival analysis. The survival time of an individual is 
said to be censored, not only when the end-point of interest has not been observed for that 
individual but also, if at the end of the study the individual has not experienced the event. 
During the follow-up it is necessary to know if the event has occurred or not and when did it 
occur. Sometimes, the survival status of an individual cannot be known, as that individual has 
been lost to follow-up. For example, consider that the recruited individual, after being 
recruited, moves to another country and his survival experience cannot be traced.  The only 
information available is the last date he or she was known to be alive. 
Another reason for a survival time being considered censored is when the event 
experienced is different from the event of interest, which happens due to a cause that is 
known to be unrelated to the specific study. However, this type of censoring is difficult to be 
sure that is not related to the study. For example, consider a patient in a clinical trial to 
compare alternative therapies for prostatic cancer who experiences a fatal road traffic 
accident. The accident could have resulted from a side effect of the treatment. If so, the death 
is related with the treatment and cannot be considered censored. A breast cancer patient who 
dies due to a cause unrelated with the disease, has to be considered censored. This kind of 
event is known as competing risk events. Suppose also that a breast cancer patient undergoes 
a prophyletic oophorectomy after surgery to breast cancer. This prophyletic treatment 
substantially reduces the probability of developing ovarian cancer. So it is considered a 
competing risk event when calculating ovarian cancer incidence. A competing risk may 
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preclude the onset of the event of interest, or may modify the probability of the event of 
interest. An individual who experiences a competing risk event is censored in an informative 
manner. However it is necessary to analyse the data and the event of interest to conclude if 
the informative censoring makes any influence in the estimate of the probability of the event 
of interest. If it does not make any influence, the informative censoring can be ignored. For 
example, death to other causes may not be related to having breast cancer unlike breast 
cancer-specific mortality. Here, the informative censoring does not influence the estimates of 
breast cancer mortality. It is important to verify if censoring is noninformative, because 
otherwise a bias is introduced in survival analysis methods. Resuming, good patient follow-up 
and avoidance of unnecessary drop-out is the best solution (Bradburn, Clark, Love, Altman, 
2003). 
2.1.2. Survivor function and Hazard function 
In survival analysis there are two functions of central interest such as the survivor 
function and the hazard function. The survivor function represents the probability that an 
individual survives from the time origin to some time beyond t: 
S(t) = P(T ≥ t)  (1) 
 
The hazard function is widely used to express the risk or hazard of an event at time t, and 
is obtained from the probability that an individual experience the event at time t, conditional 
on he or she having survived to that time: 
 
h ( t) = limδt → 0
P ( t ≤ T < t + δt | T ≥ t)
δt
⎧ ⎨ ⎩ 
⎫ ⎬ ⎭ =
f ( t)
S ( t)
 (2) 
where 
f (t) = dF (t)
dt
 (3) 
and 
F (t) = Pr( t ≤ T ) = f (u)dt = 1 − S(t)
t= 0
T∫  (4) 
This function can also be called hazard rate, instantaneous death rate or force of mortality 
and represents the approximate probability that an individual dies in the interval (t,t+δt), 
conditional on that person having survived to time t. The hazard rate is known as the 
conditional rate of failure. This is the rate of an event, given that a person has survived up to 
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that time. It can vary from 0 to infinity. It can increase or decrease or remain constant over 
time. The function H(t), called cumulative hazard, can be obtained from the Survivor 
function, since: 
H ( t ) = − log S ( t )  (5) 
 
Supposing that in a single sample of survival times none of the observations are censored, 
the survival function S(t) can be estimated by the empirical survival function, given by: 
S(t) = Number  of individuals with survival times ≥  t
Number  of  individuals  in  the  data  set
 (6) 
 
The estimated survivor function is assumed to be constant between two adjacent death 
times. The overall survival probability is the probability of being event-free at least up to a 
given time. The cumulative incidence of an event at a given time is one minus the overall 
survival probability at that time. 
Consider, for example, the event of interest to be death. Suppose that 100 patients lived for 
at least 1 year and 5 patients died. The estimated survival at 1 year is 95%. Suppose, at 2 
years, 10 patients died. The estimated survival at 2 years is 85/95=89,5%. The estimated 
overall survival probability up to 2 years is the probability of having survived to first and 
second year, which is 95*89,5=85%.  The cumulative incidence of mortality at 2 years is the 
sum of mortality at first and second years, which is, in the previous example 
(95/100)+((95/100)*(10/95)) =15%. 
2.1.3. Actuarial/Descriptive Model – Kaplan Meier 
There are some methods for the estimation of the survival function and the hazard 
function. Methods for estimating these functions from a single sample of survival data are 
said to be non-parametric or distribution free, since they do not require a specific assumption 
to be made about the distribution of the survival times. 
The Kaplan-Meier approach provides a non-parametric estimate of the overall survival 
probability of an event of interest. It adequately deals with censored data, and provides 
attractive graphs on the relationship between predictor values and the outcome over time. The 
cumulative incidence is calculated as 1 minus this survival probability. Every individual in 
the data set has a follow-up time and status (event or censored). In order to estimate the 
survivor function, the follow-up times where an event has occurred are ordered from the 
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smallest to the largest. Then a series of time intervals are constructed. These intervals begin at 
the time when an event has occurred and end at the time before the next event occurs. No 
intervals begin at a censored time. It can be noticed that there can be ties, since more than one 
individual can die simultaneously. 
Considering nj the number of event free individuals up to time tj and dj the events occurred 
at time tj, the estimated survival probability at time tj is given by (nj-dj)/nj. The overall 
survival probability up to time tj, denoted S(tj) is the probability of surviving up to tj, 
including time tj. Therefore the overall survival probability up to tj is the product of the 
probability of surviving trough the interval tj-1 to tj and all preceding intervals. Then it can be 
said that a product of series of estimated probabilities forms the Kaplan-Meier estimate: 
S(t j ) = S( t j − 1) × n j − d jn j
 (7) 
 
S(t) = ni − di
nii=1
k∏  (8) 
 
A plot of the Kaplan-Meier estimate of the survival function is a step-function, where the 
estimated survival probabilities are constant between adjacent death times and decrease at 
each death time. In the absence of censoring the Kaplan-Meier estimate is simply the 
empirical survivor function. Therefore, it can be concluded that the Kaplan-Meier estimate is 
a generalisation of the empirical survivor function that accommodates censored observation. 
In the following example it can be observed how the Kaplan-Meier curve is calculated: 
 
Time 
interval 
Hazard at 
the 
beginning of 
interval 
Censored 
during the 
interval 
Hazard at 
the end of 
interval 
Deaths in 
the interval
Survival at the 
end of interval
Overall survival at the 
end of interval 
0-1 7 0 7 1 6/7=0,86 0,86 
1-4 6 2 4 1 ¾=0,75 0,86*0,75=0,64 
4-10 3 1 2 1 ½=0,5 0,86*0,75*0,5=0,31 
10-12 1 0 1 0 1/1=1 0,86*0,75*0,5*1=0,31 
Table 2.1 – Example for a Kaplan-Meier curve calculation 
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Figure 2.1 – Example of a Kaplan-Meier curve 
 
When competing risk events are present in the data, it is necessary to make some 
considerations about the Kaplan-Meier estimate. Satagopan et al (Satagopan, Ben-Porat, 
Berwick, Robson, Kutler, Auerbach, 2004) makes some illustrations of a non-parametric 
estimation of the cumulative incidence function for an event of interest in the presence of 
competing risk events 
2.1.4. Piecewise Linear Models – Proportional Hazards (Cox regression Model) 
The actuarial or descriptive methods described can be useful in the analysis of a single 
sample of survival data or in the comparison of two or more groups of survival times. 
However, in most studies, supplementary information (explanatory variables) is also recorded 
for each recruited individuals. The analysis, using this information is much more complex 
than the analysis considered before. In order to analyse the relationship between the survival 
experience and the explanatory variables of the individuals it is used an approach based on 
statistical modelling. There are two main reasons for modelling survival data. First, one 
objective of the modelling process is to determine how the explanatory variables affect the 
hazard function. Another objective is to obtain an estimate of the hazard function for an 
individual, in order to estimate the median survival time. This value can be estimated for 
current or future individuals with particular values of the explanatory variables. 
When the survival times are assumed to follow a statistical distribution, it should be used a 
fully parametric model. There are different distributions and the identification of a suitable 
one is a crucial step in modelling the survival data. What distinguishes between the existing 
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parametric models is the shape of the hazard they assume the data follows. If the hazard is 
always increasing and decreasing, the Weibull and Gompertz distributions are appropriate. If 
the hazard rises to a peak and then decreases or always decreases, then the Log-Logistic 
distribution should be used. Log-Normal or Generalised Gamma models are preferable used 
when the hazard rises to a peak and then decreases. In the Exponential model, the hazard is 
constant over time. 
If there is no need to assume a particular form of the probability distributions for the 
survival times S(t), then the Cox regression model is used. In medical studies, the Cox 
proportional hazards model it the most often used method of survival outcomes. This model is 
based on the assumption of proportional hazards, that is, assumes that the log(-log (S(t))) for 
different subjects are equidistant over time or equivalently that the hazard function for any 
two subjects are proportional over time. Therefore, this model is referred as semi-parametric 
model. 
As stated before, the Cox regression model is based on the assumption of proportional 
hazards. The following example can explain this property of the model. 
Suppose two patients are randomised to receive a standard treatment or a new treatment. 
hS(t) is the hazard of dead at time t the first treatment and hN(t) is the hazard of the second. 
According to the proportional hazards model: 
hN ( t ) = ψhS ( t )  (9) 
 
This assumption implies that the corresponding true survivor functions for individuals on 
the new and standard treatment do not cross. The ψ value corresponds to the ratio of the 
hazards of death at any time for an individual on the new treatment relative to an individual 
on the standard treatment. The ψ value is known as the relative hazard or hazard ratio. 
In the Cox regression model a reference group called the baseline population specifies all 
time dependence, which is characterized by a zero covariate vector (h0(t)). The values of these 
covariate will be assumed to have been recorded at the time origin of the study. The set of 
values of the explanatory variables for each individual will be represented by x. The hazard 
function can be written as: 
h p ( x p , t ) = ψ ( x p )h 0 ( t )  (10)
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As the relative hazard cannot be negative, it can be written has eηp, where ηp is the linear 
combination of the explanatory variables of the individuals. This quantity is the linear 
component of the model and it is also known as the risk score or prognostic index for the ith 
individual. The dependence of the covariate variables is then aggregated into the scalar βTxp.  
Consequently, the general proportional hazards model is as follow: 
hp (x p , t) = e(β
T x p )h0 (t)  (11)
 
This model can be re-expressed in: 
log hi(t)
h0(t)
⎧ ⎨ ⎩ 
⎫ ⎬ ⎭ = β
T x p  (12)
 
The hazard function may depend on two types of variables namely variates and factors. A 
variate is a variable that takes numerical values that are often on a continuous scale of 
measurement, such as age. A factor is a variable that takes a limited set of values which are 
known as the levels of the factor, such as the variable gender. If we have a situation where the 
hazard function depends on two variables, X1 and X2 the proportional hazards for the ith 
individual, can be written as: 
hi ( t ) = e ( β 1 x1 + β 2 x 2 )h 0 ( t)  (13)
 
Using this model, the logarithm of the hazard ratio is considered linear, due to: 
log hi(t)
h0(t)
⎧ ⎨ ⎩ 
⎫ ⎬ ⎭ = β1x1 + β2x2  (14)
 
Considering the ratio of the hazard of death for an individual with the value x+1 for X 
relative to one with value x, it obtains: 
e β (x +1){ }
eβx
= eβ  (15)
This ratio shows that when a variable with a single beta is included in the model, the 
hazard ratio when the value of X is changed by r units does not depend on the actual value of 
X. This means that the hazard ratio for an individual with value 60 for a variable, related to 
one with value 55 for the same variable, is the same for an individual with value 20 related to 
one with value 15 for the same variable. This is a result of fitting X as a linear term in the 
proportional hazards model. 
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Supposing that the dependence of the hazard function on a single factor A is to be 
modelled where A has a levels, the proportional hazards model for an individual with factor 
A at level j is e (α j )h 0 ( t )  . Here, the baseline hazard function has to be defined as the hazard for 
an individual with values of all explanatory variables equal to zero. Consequently, one of the 
αj must be taken to be zero. If the constraint α1=0 is adopted, the term αj can be included 
defining a-1 indicator variables, X2,X3,….Xa, which take the values shown below: 
 
Level of A X2 X3 …. Xa 
1 0 0 …. 0 
2 1 0 …. 0 
3 0 1 …. 0 
…. …. …. …. 0 
a 0 0 …. 1 
 
For each ith individual it is only possible to have one variable for each factor, and the 
proportional hazards model can be written as: 
 
h i ( t ) = e ( β 2 x 2 + β 3 x 3 + ... + β a x a )h 0 ( t )  (16)
 
Using this model, the logarithm of the hazard ratio is considered piece-wise linear, because 
each covariate has the number of betas equals to the number of levels that exist. 
 
However, it is important to mention that equation 12 represent the Cox Regression Model 
in continuous time. When the model is in discrete time equation 12 is re-expressed as in the 
following equation: 
x
th
th
xh
xh β+⎟⎟⎠
⎞
⎜⎜⎝
⎛
−=⎟⎟⎠
⎞
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⎛
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)(log
)(1
)(log
0
0  (17)
 
2.2 - Flexible Models 
2.2.1. Generally of Artificial Neural Networks 
An artificial neural network (ANN) is a mathematical model or computational model 
originally inspired on the central nervous system and neurons. 
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As described in (Bar-Yam, 1997), the basic computational unit in the nervous system is the 
nerve itself, or neuron. A neuron has dendrites, cell body and axon. A biological neuron 
receives input from other neurons. The input zone is composed by the dendrites. When the 
potential reaches a threshold, the cell fires and an action potential propagates along the axon 
(output) to other neurons, through an electrical signal. Transmission of an electrical signal 
from one neuron to the next is affected by neurotransmitters chemicals, which are released 
from the first neuron and bind to receptors in the second. This link is called a synapse. 
 
 
 
 
 
 
Figure 2.2 – Constitution of a neuron (Computation in the brain). 
 
Brain learns by altering the strengths of connections between neurons, and by adding or 
deleting connections between neurons. Brain learns based on experience, which means that 
connexions between neurons are dynamic. Connexions highly used are strengthened and 
connexions less used tend to disappear.  The same phenomenon happens in neural networks. 
 
 
Figure 2.3 – Constitution of a synapse (Computation in the brain).  
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There are several properties of the nervous system that are of particular interest in the 
biologically inspired Neural Networks models, which are: 
1. Parallel and distributed information processing 
2. High degree of connectivity among basic units 
3. Connections are modifiable based on experience 
4. Learning is a constant process 
5. Learning is based on local information 
6. Performance degrades gracefully if some units are removed 
 
The basic computational element (model neuron) is often called a node or unit. It receives 
input from other units or from an external source. Each input has an associated weight w, that 
is modified while the model learns. The “electrical” information is simulated using numerical 
values stored in these weights. The unit computes a function f of the weighted sum of its 
inputs. This resembles the perceptron model of Rosenblatt (1962), which is a linear 
discriminant model. In a simplistic neural network the summed value is compared with a 
certain threshold, in order to propagate the signal or not. However nowadays, instead of a 
threshold activation functions are used. Using the perceptron of Rosenblatt the nonlinear f 
function is given by the step function and the algorithm used to determine the parameters w of 
the perceptron is an error function known as the perceptron criterion. 
 
yi = f ( wij∑ x j ) (18)
 
 
 
 
 
 
 
 
Figure 2.4 – Example of a perceptron.  
 
Σ f yi 
x1 
. 
. 
. 
xj 
 
 
x0 = 1 (bias) 
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The output can serve as the input to other units. The function f(x) is the unit’s activation 
function. This activation function describes the output behaviour of a neuron. There are 
several activation functions that can be used. The choice of the activation function is 
determined by the nature of the data and the assumed distribution of target variables. 
Activation functions for the hidden units are needed to introduce nonlinearity into the 
network. Without nonlinearity, hidden units would not make nets more powerful than just 
plain perceptrons (which do not have any hidden units, just input and output units). The 
reason is that a linear function of linear functions is again a linear function. However, it is the 
nonlinearity (i.e., the capability to represent nonlinear functions) that makes multilayer 
networks so powerful. Almost any nonlinear function does the job, except for polynomials. 
Following are some of the commonly used activation functions: 
 
 
  
 
Figure 2.5 – Representation of possible neural networks activation functions. 
The top pictures are from left to right, the step, identity and sigmoid function, respectively. The bottom 
pictures are the symmetric sigmoid function and the radial basis functiony. 
 
If several perceptrons or weighted neurons are connected to each other, i.e., the output of a 
perceptron is the input of another perceptron, there will be a neural network model, or also 
known a multilayer perceptron or MLP. In a MLP the neurons are organized in layers, which 
number differs from network to network. The input nodes receive signals from “outside” the 
network and the output nodes send the signals “outside” the network. If there is a layer 
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constituted by several nodes, but their signals are not received from outside the network nor 
are sent to outside the network, then it is called hidden layer. A multilayer perceptron have 
several hidden layers, some input nodes and some output nodes, which is represented by the 
following figure: 
 
Figure 2.6 – Example of a multilayer perceptron. 
It has 1 hidden layer, 3 input nodes and 2 output nodes 
 
The weight parameters are represented by the links between the nodes and the arrows 
denote the direction of information that flows through the network during forward 
propagation. There was however introduced a new element, called “bias”, which defines the 
neuron trend, subject to modifications during the network training. Bias units can also be 
weighed and connect an unitary input to each neuron. 
The number of neurons on each layer is always equal to the number of variables. Although 
the number of hidden layers may differ, it is almost always equal to two or three. This is a 
result of a study done by Bishop (Bishop, 2006), where he shows that any network with two 
hidden layers can approximate any function independently of its complexity. One the one 
hand we should consider to use always a powerful network (three layers), on the other hand 
this network can create overfitting problems (there is a lost of a generalisation capacity). 
Combining these various stages to give the overall network function, using sigmoidal 
output activation, the final network takes the form: 
 
yk (x,w) = σ wkjh w jixi + w j 0
i=1
N∑⎛ ⎝ ⎜ 
⎞ 
⎠ ⎟ j=1
M∑ + wk0⎛ ⎝ ⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ (19)
where 
σ (a) = 1
1+ e−a  (20)
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There is however a key difference between these model and the perceptron model, that is 
the neural network uses continuous sigmoidal nonlinarities in the hidden unit, whereas the 
perceptron uses step function nonlinearities. This means that the neural network function is 
differentiable with respect to the network parameters, and this property will play a central role 
in network training. 
2.2.2. Neural Network Training 
Neural networks try to simulate the learning ability of the human brain. However, unlike 
the human brain, the neural network structure is fixed, not modifiable and constituted by a 
fixed number of neurons and connexions between them, which have some values (weights). 
What changes, on neural networks’ learning process are the weights’ values, increasing if the 
information is to be transported and decreasing otherwise. There is no indication of what 
should be the weights values in the beginning of the network training, so they are initialized 
randomly. Then these values are adjusted after processed one individual or at the end of all 
individuals processing. 
Training a neural network essentially means selecting one model from the set of allowed 
models, or in a Bayesian framework determining a distribution over the set of allowed models 
that minimizes the cost criterion. There are numerous algorithms available for training neural 
network models; most of them can be viewed as a straightforward application of optimization 
theory (weights adjustment in order to minimize the error) and statistical estimation. In the 
following picture it can be observed the purpose of network training, that is through the 
adjustments done in weightings, minimize the error produced by the network. 
 
 
Figure 2.7 – Neural network weighting versus error 
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Most of the algorithms used in training artificial neural networks employ some form of 
gradient descent. This is done by simply taking the derivative of the cost function with respect 
to the network parameters and then changing those parameters in a gradient-related direction. 
With this method, the adjustment can be calculated at each point in order to minimize the 
network error function, that is given a training set comprising a set of input vectors x n{ }  
,where n= 1…N, together with a corresponding set of target vectors t n{ }, the error function 
E(w) must be minimized: 
E (w) = 1
2
y( x n ,w ) − tn 2
n =1
N∑  (21)
 
The value of w found by minimizing this function corresponds to the maximum likelihood 
solution. As the function error E(w) is a smooth continuous function of w, its smallest value 
will occur at  a point in weight space such that the gradient of the error function is equal to 0. 
However it is difficult to find the solution to the previous equation, iterative numerical 
procedures are used to find a solution. Moreover, the use of the gradient information can lead 
to significant improvements in the speed with which the minima of the error function can be 
located. The simplest approach to using gradient information is to choose the weight update 
to comprise a small step in the direction of the negative gradient, so that: 
w (τ +1) = w (τ ) − η∇ E (w (τ ) )  (22)
 
where the parameter η is the learning rate. After each update the gradient is re-evaluated for 
the new weight vector and the process is repeated. At each step the weight vector is moved in 
the direction of the greatest rate of decrease of the error function, and so this technique is 
known as gradient descent. 
In order to find a good minimum it may be necessary to run a gradient-based algorithm 
multiple times, each time using a different randomly chosen starting point and comparing the 
resulting performance on an independent validation data set. 
If the gradient descent technique is used to train a multi-layer network, there will be a 
difficulty that is the absence of the target value for the hidden units. Therefore it was found an 
efficient technique for evaluating the gradient of an error function for a feed-forward neural 
network, which is the backpropagation algorithm. The name of this algorithm is based on 
the idea of backpropagate the error obtained in the output of the network.  
The backpropagation learning process works in small iterative steps: 
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1. The example cases are applied to the network producing some output based on the 
current state of its synaptic weights (initially, the output will be random). 
2. The output is compared to the desired output, and a mean-squared error signal is 
calculated. 
3. The error value is then propagated backwards through the network, and small 
changes are made to the weights in each layer. The weight changes are calculated 
to reduce the error signal for the case under study. 
4. The whole process is repeated for each example in the training set, then back to 
the first case again. 
5. The cycle is repeated until the overall error value drops below some pre-defined 
threshold. 
At this point we say that the network has learned the problem. It is important to refer that 
the network will never exactly learn the ideal function, but rather it will asymptotically 
approach it. 
For backpropagation learning, the activation function must be differentiable, and it helps if 
the function is bounded; the sigmoidal functions (such as logistic and tanh) and the Gaussian 
function are the most common choices. Functions such as tanh or arctan that produce both 
positive and negative values tend to yield faster training than functions that produce only 
positive values such as logistic, because of better numerical conditioning. 
For hidden units, sigmoid activation functions are usually preferable to threshold 
activation functions. Networks with threshold units are difficult to train because the error 
function is stepwise constant, hence the gradient either does not exist or is zero, making it 
impossible to use backpropagation or more efficient gradient-based training methods. With 
sigmoid units, a small change in the weights usually produces a change in the outputs, making 
possible to tell whether the change in the weights is good or bad. With threshold units, a small 
change in the weights will often produce no change in the outputs. 
For the output units, the activation function should be chosen to suit the distribution of the 
target values: 
• For binary (0/1) targets, the logistic function is an excellent choice (Jordan, 1995). 
• For categorical targets using 1-of-C coding, the softmax activation function is the 
logical extension of the logistic function. 
• For continuous-valued targets with a bounded range, the logistic and tanh 
Chapter 2 – Analytical Methodologies 
28 
functions can be used, provided either scale the outputs to the range of the targets 
or scale the targets to the range of the output activation function ("scaling" means 
multiplying by and adding appropriate constants). 
• If the target values are positive but have no known upper bound, the exponential 
output activation function can be used. 
• For continuous-valued targets with no known bounds, the identity or "linear" 
activation function can be used. 
 
Multilayer networks can approximate any smooth function as long as there are enough 
hidden nodes. However, having this great flexibility can cause the network to learn the noise 
in the data and be over-trained or over-fitted. There are several ways to control the 
complexity to avoid this over-fitting. One way is to add a regularization term to the error 
function, also known as weight decay, giving a regularized error of the form: 
 
E
~
(w) = E (w) + λ
2
w T w  (23)
 
An alternative to regularization as a way of controlling the effective complexity of a 
network is the early stopping procedure. The training of nonlinear network models 
corresponds to an iterative reduction of the error function defined with respect to a set of 
training data. However, the error measured with respect to independent data often shows a 
decrease at first followed by an increase when the network starts to over-fit. Training can 
therefore be stopped at the point of smallest error with respect to validation data set. 
2.2.3. ANN application in prognostic modelling 
Artificial neural networks are non-linear, semi-parametric models that have been 
considered as alternative methods for prognostic models in the presence of censorship 
(Lisboa, 2002). The most common applications of neural networks have been for diagnosis or 
prognosis, that is to decide which class k, k ∈⎨0,…,K⎬, in terms of prognostic risk, an 
individual belongs by using information on a set of p covariate values x=(x1,…xp). The usual 
aim is to construct a decision rule for individuals with known covariate values but unknown 
class level. The usual approaches to construct such decision rules are based on estimating the 
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conditional probability of observing an individual with a certain class level given the 
covariates: 
 
p (Y = class level | X = x ) = f ( x ,β )  (24)
 
β is the vector of unknown parameters, which are called “regression coefficients” in statistics 
and weights in neural networks modelling. In neural networks modelling, the input layer 
corresponds to the covariates. The hidden units are the result of applying the activation 
function to a weighted sum of the input units plus a constant (w0). The value of a hidden unit 
hj is given by: 
h j = φ(w0 j + wi j
i=1
p∑ xi)  (25)
where φ is the activation function, w0j the bias. 
The value of that output unit y is calculated by applying another activation function, as 
follows: 
y = f (x,w) = φ W0 + W j
j=1
r∑ φ w0 j + wi j
i=1
p∑ xi⎛ ⎝ ⎜ 
⎞ 
⎠ ⎟ 
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ (26)
 
There is a large literature on the use of neural networks for other kinds of classification 
tasks have been published in the area of medicine (Lisboa, 2002). The application of feed-
forward neural networks to survival data has been discussed in the past years and it is an 
extension of the previous equation. Here, the output yK corresponds to the conditional 
probability of dying in the kth time interval Ik. Data for the nth individual consists of a vector 
of covariate variables y=(y1,…,ykn) and a vector which indicates the interval I where the 
individual has died. Thus y1,…,yKn-1 are all zero and yKn is equal to 1 if the individual died in 
Ikn and equal to zero if the individual was censored. This implies that the network has a 
randomly varying number of output nodes according to those time intervals where the 
individual is at risk. 
Some studies have showed that by treating the time interval as an input variable in a 
standard feed forward network with logistic activation and entropy error function, it was 
possible to estimate smoothed discrete hazards as conditional probabilities of failure. This 
proposed artificial neural network (ANN) approach can be applied to the estimation of the 
functional relationships between covariates and time in survival data to improve model 
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predictivity in the presence of complex prognostic relationships (Biganzoli, Boracchi, 
Mariani, Marubini, 1998). 
There have been other proposals for analysing survival data using feed-forward neural 
networks, as using the network with only one output unit using the number k of the time 
interval as additional input and consider the unconditional survival probability of dying 
before tk rather than the conditional as output (Ravdin, Clark, 1992), (Ravdin, Clark, 
Hilsenbeck, Owens, Vendely, Pandian, McGuire, 1992). Here, time was entered as a 
predictor, and each patient had as many entries in the model as the number of intervals during 
which it was alive. The intervals were derived from Kaplan-Meier estimates. It was 
introduced some bias, due to the introduction of coding time as covariate. This work was one 
of the first studies, which addressed the use of neural networks for survival analysis using real 
clinical data, producing accurate estimations for survival of breast cancer patients and raising 
the important issue on how to deal with censored data in neural network implementations for 
survival analysis. Another form of neural networks that can be applied to survival data is the 
called “single time-point models”. Here a single time point t is fixed and the network is 
trained to predict the t year survival probabilities. This approach is used by (McGuire, 
Tandon, Allred, Chamness, Ravdin, Clark, 1992), (Kappen, Neijt, 1993), (Burke, 1994). The 
common drawback of these approaches is that they do not allow incorporating censored 
observations. Neither omission of the censored observations nor treating censored 
observations as uncensored is a valid approach. 
Other approach to use neural networks in survival analysis has been the use of hierarchical 
neural networks, which predict the survival in a stepwise manner. This approach predicts for 
the first time interval, than for the second interval and so on. The system produces a survival 
estimate for patients at each interval, given relevant covariates and it is able to handle 
continuous and discrete variables, as well as censored data. They can predict absolute, 
cumulative survival as well as instantaneous, conditional survival. Ohno-Machado (Ohno-
Machado, Walker, Musen, 1995) compared three neural network models for survival analysis 
and for AIDS patients. He concluded not only that the hierarchical neural-networks models 
for survival analysis could learn infrequent patterns faster than could a non-hierarchical 
model, but also that they provide better accuracy in predicting death for the used cohort. 
However, this can lead to inconsistent answers such as give a higher predicted probability for 
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death in year 1 or 2 than for deaths in years 1,2 or 3.Other approach is to model conditional 
probabilities: 
 
p(die in ith interval | survive  first i - 1 intervals, x) = g( η i )  (27)
 
where g is usually the logistic function. The patient dying in the ith interval contributes with 
log(g(ηi)(1-g(ηi-1))…(1- g(η1))) to the likelihood, and a patient lost to follow up interval 
log((1-g(ηi-1))… (1- g(η1)). The scores η1, …, ηk are given by the output of a neural network 
with k linear outputs. 
Ripley and Ripley (Ripley, Ripley 1998) tried several methods to compare neural networks 
and linear methods to classify binary outcomes, 1year period proportional odds, regression, 
proportional hazards, Weibull survival and log-logistic survival. They obtained a neural 
network with a specificity, sensitivity and accuracy higher for almost the methods than linear 
methods. 
Delen et al (Delen, Walker, Kadam, 2005) reported a research where they developed 
several prediction models for breast cancer survivability, especially ANN. They used a binary 
categorical survival variable where survival is represented with value of “1” and non-survival 
is represented with “0”. They measured their accuracy, which was very good, and compared 
with other methods. The conclusion was that ANN are better than linear methods, such as 
logistic regression. 
2.2.4. Misuses in Applications of ANN for prognostic models 
Schumacher et al (Schwarzer, Vach, Schumacher, 2000) concluded that most applications 
of artificial neural networks for prognostic and diagnostic models suffer from methodological 
deficiencies, such as: 
1. Biased or inefficient estimation or misclassification due to inappropriate splitting of 
the data set. 
2. The size of the test set is usually very small, leading to an inefficient estimation. 
3. Insufficient number of events for the number of variables used. 
4. Regularization terms to avoid over-fitting (tune the neural network to the peculiarities 
of the examples rather than to extract the salient dependencies of the whole 
population) are rarely used. 
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5. The ANN performance must be compared with adequate statistical competitors, like 
nearest neighbour, CART, generalized additive models or logistic regression and 
performance must be well calculated with relevant measures. 
6. Some applications of ANN did not guarantee monotonicity of the estimated survival 
curves. 
7. Some applications of ANN used the number of the time interval as additional input 
unit. 
8. Naïve application of ANN models due to inappropriate handling of censoring. 
2.2.5. Advantages of using Neural Networks in Prognostic Modelling 
Previous studies (Neal, 2001), (Lisboa, Wong, Harris, Swindell, 2003), (Lisboa, 2002), 
(Taktak, Antolini, Aung, Boracchi, Campbell, Damato, Ifeachor, Lama, Lisboa, Setzkorn, 
Stalbovskaya, Biganzoli, 2007) have found several advantages of using artificial neural 
networks in prognostic modelling, which gives confidence in their use, such as: 
1. ANN are capable of modelling extremely complex non-linear functions. 
2. ANN overcomes the limitation of proportional hazards modelling assumption that the 
time development of the hazards is proportional to a fixed baseline population. 
3. ANN overcomes the limitation of proportional hazards modelling assumption that the 
covariates influence the model through explicit linear terms. 
4. The overfitting overcoming of ANN can be avoided using Bayesian methods. 
5. ANN do not rely on the availability of prior knowledge. 
2.2.6. Bayesian Regularisation framework 
In Neural network training section, the learning framework was focused on the use of 
maximum likelihood. In a Bayesian framework the network must be marginalized over the 
distribution of parameters in order to make predictions. The aim is to construct a probability 
distribution over the possible values of the parameters in the network. There are several 
advantages of Bayesian learning over maximum likelihood methods (Neal, 2001), (Antolini, 
Boracchi, Biganzoli, 2005), (Bishop, 2006), (Mackay, 1992): 
1. Model overfitting is unlikely in contrast with the maximum likelihood approach 
that is prone to overfitting when the number of network parameters is large in 
relation to the number of training cases (Biganzoli, Boracchi, Marubini, 2002). 
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2. The model is automatically regularized. 
3. The uncertainty in predictions can be obtained. 
 
In the conventional maximum-likelihood approach, a single weight vector is found, which 
minimizes an error function. In contrast, the Bayesian framework considers a probability 
distribution over the network weights, which is described by a prior distribution p(w) and it is 
modified when the data D=⎨(x,t)⎬ is observed. The process can be expressed by the Bayes 
theorem, which aim is to approximate the posterior distribution by a Gaussian distribution: 
p(w | D,α ,H ) = p(D | w,α ,H ) p(w |α ,H )
p(D |α ,H )  (28)
 
where w denotes the set of weights, D the data set, α the penalty parameters and H the model 
hypothesis. Using Bayes formula, the prior and the data likelihood can be transformed into a 
posterior distribution. 
To evaluate the previous equation it is necessary to find the expressions for the prior 
p(w|α,H) and for the likelihood p(D|w,α,H). The prior over the weights reflect the knowledge 
we have about the network we want to build, if there is any. The function must have a 
multivariate normal density with zero mean and diagonal covariance matrix with elements 
1/αK. The weights that are centered in zero have higher probability: 
 
p(w | α ) = N (w | 0,α −1I )  (29)
 
p(w |α ,H ) = e
− E (w ,α )
Z w (α )
 (30)
where 
E(w,α) = 1
2
αm wmn2
n=1
Nm∑
m=1
Nα∑  (31)
 
α (inverse variances) are the regularization parameters, called hyper-parameters, because they 
control the distribution of the network parameters (Neal, 2001). These hyper-parameters 
should be different for each input, as some inputs have more influence than others. Hidden 
layers must look at different subsets of the inputs and the hyper-parameters must control how 
much each layer contributes to the function (Bakker, Heskes, 1999). Zw(α) is a normalisation 
Chapter 2 – Analytical Methodologies 
34 
constant calculated from a product of univariate normal distribution, also called the evidence. 
The index n indicates a group of weights wmn sharing a common regularization parameter αm 
of which there are Nm. These weights correspond to attributes from a single field or variable. 
As the training progresses, the αm for variables with little predictive power increase in size, 
forcing the corresponding weights towards zero, adjusting the effect of each covariate 
according to its relevance to the model protecting against overfitting of the data. The term 
“weight decay” is commonly used for this regularization method. 
The likelihood given the weights can be obtained for discrete or continuous time cases by 
using the hazard function. For the continuous time case: 
 
Lc = d pi
i
∑
p=1
cardinality  of  the  set∑ log hc (x p , ti ) − hc (x p ,u)du
0
ti∫  (32)
 
 
For discrete time case, the log-likelihood is: 
 
G = − dpk log hp (x p , tk )( )+ (1− dpk ) log 1− hp (x p , tk )( )[ ]
k=1
t1∑
p=1
sample  size∑  (33)
 
In the latter case the likelihood term reflects the status of the patient p at a time tk. This is 
achieved with an indicator label or target dpk which assumes the value of 0 if the patient is 
observed to be alive and 1 to indicate a death attributed to breast cancer in the time interval tk. 
t1< t ≤ tk. t1 is the month when the patient was last observed. 
Previous research (Eleuteri, Aung, Taktak, Damato, Lisboa, 2007) has been done in order 
to compare both models, in the continuous and discrete time. The first approximates the 
logarithm of the hazard rate function, and the other models the log-odds ratio of the hazard 
probability. It was concluded that both models exhibit good discrimination and calibration 
capabilities, although the continuous time model has the advantage of providing error bars on 
its estimates. From now on it will be used the discrete-time model. With this 
p ( D | w ,α , H ) = e L p , where Lp is the log-likelihood function. 
Once the expressions for the prior and the noise model are given, the posterior distribution 
can be evaluated as: 
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p(w | D,α , H ) = e
−G e− E ( w ,α )
Z (α )  (34)
 
The posterior distribution is usually considerably complex and multimodal. A solution is to 
integrate out the parameters separately from the hyper-parameters by making a Gaussian 
approximation for the mode with respect to the hyper-parameters. (Bishop, 2006) and 
(Mackay, 1992) mentioned that this procedure gives a good estimation of the posterior 
probability, particularly for distributions over high-dimensional spaces. The posterior and 
evidence are maximized until a consistent solution ⎨wMP, αK⎬ is found. 
Generally hyper-parameters can be adjusted with empirical measures such as cross-
validation. However, this approach is computationally very expensive and may not be robust. 
A solution is to use the Bayesian framework: 
 
p(α | D,H ) = p(D |α,H ) p(α | H )
p(D | H )
∝ e −S(w
MP ,α )( )
Zw (α ) (2π )
N w / 2 det( A)−1/ 2 (35)
 
where 
S(w,α ) = G + E (w,α )  (36)
 
A is the Hessian of S with respect to the weights. The posterior of the hyper-parameters can be 
calculated analytical approximating the evidence p(D|α,H) with a Taylor expansion about the 
current value of the weights, which are known as the “most probable” values wMP. 
2.2.6.1 Marginalization of the network predictions 
In survival modelling the distribution of the target is extremely skewed, due to the scarcity 
of the events and the large number of time steps used in the analysis. Therefore, there is 
usually a highly unbalanced distribution of the target values. This conflicts with the implicit 
prevalence of the output of the network, where high levels of uncertainty shifts the network 
output to 0.5. Using the bayesian regularization framework, it is assumed that the weight 
values have a posterior distribution and the predicted hazard must be marginalised over this 
distribution, which is parameterised by a normal density function for the output node 
activation: 
a ~ N (aMP , s
2 ) ~ N (aMP , g
t A −1g)  (37)
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where aMP is the most probable output and g is the activation function of the output node. 
The predicted hazard is the mean calculated from the distribution of the activation 
function: 
 
s
e
e
daDtxaPagtxh
saa
apg
MP
π21
1),,|()(),(
22 2/)(−−
−∫ ∫ ⎟⎠⎞⎜⎝⎛ +==  (38)
 
where 
g(a) = 1
1+ e−a  (39)
 
However, this integral is not analytical, but it can be approximated using: 
hg (x, t) ≈ g aMP (x,t)
1+ (π /8)gt A−1g
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟  (40)
 
With the implicit prevalence of the previous equation, high levels of uncertainty, 
characterized by high values of s2, as it was noticed previously, the network output 
h g (⋅) → s → ∞ 1 /2 . To overcome this situation it is necessary to update the standard 
regularisation framework to take into account the prevalence of the targets (Pτ) by re-scaling 
the log-likelihood: 
 
G = − 1
2Pτ
τ pk log h p (x p , tk )( )+ 12(1− Pτ ) (1− τ pk ) log 1− h p (x p , tk )( )
⎡ 
⎣ ⎢ 
⎤ 
⎦ ⎥ k=1
t1∑
p=1
sample  size∑  (41)
 
The marginalised network prediction h
~
g (x p , t)   needs to be compensated so the maximum 
uncertainty in the network predictions is the empirical estimate of the prevalence: 
 
hg (x p , t) = h
~
g (x p , t)Pτ
h
~
g (x p , t)Pτ + (1− h
~
g (x p , t))(1− Pτ )
 (42)
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2.2.7. PLANN-ARD in prognostic modelling 
ANN models are considered alternative methods for survival analysis in the presence of 
censorship. These models are an extension of the discrete time proportional hazards. The 
partial logistic artificial neural network with automatic relevance determination (PLANN-
ARD) (Lisboa, Wong, Harris, Swindell, 2003) is a development of the PLANN method 
proposed by Biganzoli et al. (Biganzoli, Boracchi, Marubini, 2002), (Biganzoli, Boracchi, 
Mariani, Marubini, 1998). The network structure is represented as follows: 
 
 
Figure 2.8 – Partial logistic artificial neural network structure. 
  
In figure 2.8, X1, X2… are the covariates and tK is the time value observed. The outcome 
observed corresponds to the event indicator at each time k, that is, if the event occurs at a 
certain time t, then the outcome is 1, otherwise is 0. The covariates are replicated for each 
observation period, alongside a monotonically increasing interval measure of the discrete time 
interval, until the event indicator is observed. The output of the network is the hazard at each 
time t. As an example, for an individual sample, if the event occur in t=4 and not previously, 
the covariates for this sample are imputed to the network 4 times, where the time value 
changes. The event indicator is 0 for t=1,2 and 1 for t=4. 
 
Attributes Time value Event indicator 
X1…Xj 0,5 0 
X1…Xj 1,5 0 
X1…Xj 2,5 0 
X1…Xj 3,5 1 
Table 2.2 – Example of s inputs and outputs for the PLANN-ARD model. 
)|()( 1−>≤= kkk ttttPth
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The PLANN-ARD method uses the MLP structure with time as input, where the discrete 
time implementation is strictly a proportional model for the odds-ratio. The associated 
logistic link (activation) function makes it natural to extend the feedforward model by adding 
flexibility in the form of a multi-layer perceptron neural network. As result the analytical 
expression for the network becomes: 
 
hp (x p , tk )
1− hp (x p , tk )
= exp whg wih x pi + wtk + bh
i=1
Ni∑⎛ ⎝ ⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ + b
h=1
Nh∑⎛ ⎝ ⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟  (43)
 
where i and h denote the input and hidden node layers respectively, bh is the bias (intercept) 
term in the hidden layer, b is the bias (intercept) term in the output layer and the non-linear 
function g(.) is the sigmoidal function at the hidden nodes: 
g(a) = 1
1+ e−a  (44)
 
In addition, the model must take into account the loss to follow-up, or right censorship. 
This is reflected, under the assumption of independent censoring, in the form of the objective 
function, which is the log-likelihood summed over the observed status of the patient with a 
binary indicator when the patient status is observed alive or has died, using target values τpk 
as indicator labels and tl as the time index: 
 
G = − τ pk log hp (x p , tk )( )+ (1− τ pk ) log 1− hp (x p , tk )( )[ ]t1∑No.  patients∑  (45)
 
If the sigmoidal function was replaced by a linear function the argument of the exponential 
would be βTxp + θ1tk + θ2. This represents the factorisation of the dependence of the discrete 
time hazard on the explanatory variables and time. The previous function can be compared 
with proportional hazards modelling because, for discrete time intervals, it parameterises the 
odds of survival, as follows: 
h( x i, t k )
1 − h( x i, t k )
= h0 (t k )
1 − h0 (t k )
e β
T x p  (46)
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h(x i, tk ) = h0 (tk )e
β T x p
h0 (tk )(e
β T x p − 1) + 1 =
1
1 + 1 − h0 (tk )
h0 (tk )
e− β
T x p
= 1
1 + e− β T x p − β 0
 
(47)
where 
β0 = log h0(tk )1− h0(tk )
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟  (48)
 
As − β T x p − β 0   corresponds to a summed output of the hidden nodes multiplied by the 
weights whg wihxpi + wtk + bh
i=1
Ni∑⎛ ⎝ ⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ + b
h=1
Nh∑  , the hazard will be calculated applying the sigmoidal 
function to this value.  
Once the hazard estimate is available, the probability of the event occurring up to a time 
threshold, that is to say, the survival probability can be directly estimated for discrete data by 
the successive products of the conditional estimates of survival in each individual time 
interval (Marubini, Valsecchi, 1995). 
Sp (xp,tk ) = P(t ≤ tk | xp ) = 1− h(xp ,tl )( )
l=1
tk∏  (49)
 
Once the modelling process is complete it is necessary to define a prognostic index for 
each patient (as it can be done using Cox proportional hazards modelling). This index 
identifies the patients with a lower and higher mortality risk. Equivalent to the linear 
prognostic index βx, previous studies has showed that the prognostic index obtained with 
PLANN-ARD was: 
Prognostic  index(xp ) =
hp (xp,tk )
1− hp (xp, tk )
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ 
i=1
T∑
T
 
(50)
 
where T is the number of time intervals (Lisboa, Wong, Harris, Swindell, 2003). An 
improvement of this prognostic index was done in (Fernandes, Jarman, Etchells, Fonseca, 
Biganzoli, Bajdik, Lisboa, 2008), where better results were obtained: 
 
Prognostic index(xp ) = 1T S(ti−1)i=1
T∑ ln hp (xp,tk )1− hp (xp,tk )
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ (51)
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As this index must be as accurate as possible, there have been other studies that justify the 
improvement of the previous index, too. These studies were based on using competing risk 
methodologies. Although competing risks has not been mentioned in PLANN-ARD 
modelling, the prognostic index to use must be the same, in single risk and competing risk 
modelling. Therefore, the prognostic index proposed is: 
 
Pr ognostic  index ( x p ) = ln( − ln( 1 − CCI )) = ln( − ln( S ( t )))  (52)
 
where the CCI is the crude cumulative incidence, identified as the probability of the 
occurrence of a specific event of interest (Ambrogi, Biganzoli, Boracchi, 2008) and S(t) is the 
estimated survival at the end of the follow up period, i.e. 60 in this study.   
This flexible model accounts implicitly for non-linear and non proportional covariate 
effects. The neural network does not seek merely to explain the observed variation in 
survival, as a function of covariate effects. Instead, it fits the hazard function directly, without 
resort to proportionality assumptions about the covariate effects.  In this way, it is suited to 
making individual predictions of the event rate. Automatic Relevance Determination (ARD) 
has the effect of suppressing covariate effects that are least informative about the predicted 
outcome. An essential feature of flexible models is the requirement to control model 
complexity in order to prevent over-fitting to the training data.  
 This was done using the well-known Bayesian framework of Automatic Relevance 
Determination (MacKay, 1995), where a separate weight–decay index is allocated to each 
covariate, taking care to apply the same value of the regularisation hyper-parameter to all of 
its binary coded attributes.  A Laplace approximation of the evidence is calculated in the 
usual way (MacKay, 1995), to allow an iterative estimate of the most likely value of each 
weight decay to be obtained.   
The application of this principled regularisation framework brings two advantages to the 
model. First, it enables a set of hyper-parameter values to be optimised efficiently.  Second, 
this framework explicitly models the activation of the output nodes in a probabilistic way, 
which forms a second, natural extension, of linear models – this time in respect to the 
estimates of uncertainty, represented by the variance of the model predictions, from which 
confidence intervals can be obtained.  This extension defines the Partial Logistic Artificial 
Neural Network regularised with Automatic Relevance Determination (PLANN-ARD) 
(Lisboa, 2002). This has the important advantage of automatically adjusting the effect of each 
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covariate according to its relevance to the model, protecting against over-fitting of the data 
without requiring hard model selection. 
2.2.7.1 PLANN-ARD evaluation 
A. Taktak et al. (Taktak, Antolini, Aung, Boracchi, Campbell, Damato, Ifeachor, Lama, 
Lisboa, Setzkorn, Stalbovskaya, Biganzoli, 2007) provided a double-blind evaluation and 
benchmarking of the accuracy in out-of-sample prediction of mortality from two generic non-
linear models, using artificial neural networks (Partial logistic neural networks model with 
auto-relevance determination and Partial logistic basis function networks) against a partial 
logistic spline, log-normal and Cox-regression model. In this study, it was concluded that the 
recent and flexible modelling algorithms show a comparative predictive performance to that 
of more established methods from the medical and biological literature.  
Moreover it has showed that PLANN-ARD obtained overall the best calibration 
performance. PLSPL, LOGN and PLANN-ARD showed similar performance on both model 
and test data set. P.J.G. Lisboa et al. (Lisboa, Etchells, Jarman, Aung, Chabaud, Bachelot, 
Perol, Gargi, Bourdès, Bonnevay, Négrier, 2008) has also showed that PLANN-ARD seemed 
to generalise better than Cox model, and appear to be more specific to identify patients at the 
extremes of high and low risk. 
2.2.7.2 Individual prognostic predictions with confidence intervals 
There has been a very high interest in predictive inference of prognosis for individual 
patients. The individual prediction of survival with confidence intervals can be obtained 
using either PLANN-ARD or Monte Carlo methods (Jarman et al, 2008).  
As described previously PLANN-ARD model provides a prediction of smooth estimates 
of the discrete time hazard. At time ti the estimated summed weights to each output unit is 
approximated by a Gaussian distribution N(ai, σ2i).  
The individual prognosis for a patient x is calculated by first taking a random sample ãi 
from N(ai, σ2i), calculating h~ i = g(a~ i)  and finally estimating survival S~ (tk ) . Regarding 
imputation, h
~
i must be computed for each trained network, applying the following equation: 
h(x p , tl ) = h(x p , tl | μ)∫ P(μ)dμ ~ 1T h(x p , tl | μi)μ i
10∑  (53)
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 and the survival estimate may then be obtained.  
These steps are repeated n times until there are enough survival points for each patient in 
order to build a distribution. The personalised prognosis with 95% posterior density intervals 
is the mean survival with 95% intervals determined by omitting the upper and lower 2.5% of 
the sample estimates.  
To better represent the individual prognostic predictions with its confidence intervals, the 
pseudocode is as follows, for an individual patient with covariate set ‘x’:   
i. Sample the output node activation in the PLANN-ARD model, 
a~N(a_most_probable(x,t), variance) ~ N(ai, σ2i) for each trained network. 
ii. Propagate this value of ‘a’ through the sigmoid function to obtain a sample of h(x,t) 
for each trained network. 
iii. Obtain the final h_final(x,t), being the average of the obtained samples of h(x,t) for 
each network. 
iv. Repeat this procedure over time and calculate S(x,t)=Product_t (1-h_final(x,t)). 
v. Repeat the complete procedure 1000 (necessary to stabilise the distribution of S(x,t)). 
vi. Sample the mean and confidence intervals from this distribution. 
2.3 - Prognostic index stratification and Boolean Rules extraction 
methodology 
In clinical environment, the comparison of two survival distributions is frequently used in 
the evaluation of treatments or on the impact of prognostic factors on survival, especially to 
stratify patients by risk. As an example, Boracchi et al. (Boracchi, Coradini, Antolini, Oriana, 
Dittadi, Gion, Daidone, Biganzoli, 2008) presents a case study concluding that reliable 
outcome prediction is necessary for treatment allocation, exploiting the predictive potential of 
consolidated clinical and biological variables. 
There are a variety of parametric and non-parametric methods for comparing distributions 
in the complete data, but there are fewer options for comparing two survival distributions in 
the presence of censored data. For this kind of data, the most widely used test is the log-rank 
test from which the statistical significance for pairwise data partitions can be measured. Given 
that, the test only applies in a pairwise manner, that is to say, for separating two cohorts at a 
time. This requires a search for the most appropriate threshold to divide the distribution of 
prognostic index scores. However, in the literature the approach to splitting risk indices into 
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risk groups is not always stated clearly, sometimes stating the cut-off points of the respective 
risk scores without a clear indication of how these were obtained (Guerra, Algorta, Diaz de 
Otazu, Pelayo, Farina, 2003), (Sebastian, Gonzalez, Paricio, Perez, Flores, Madrona, Romero, 
Tebar, 2000). Where the split of the indices is at all explained, expert knowledge has been a 
factor as in the case for the widely used NPI.  
In another approach the indices are split into equal sized groups as suggested by Harrell et 
al. (Harrell Jr., Lee, Mark, 1996). This tutorial in biostatistics suggests using deciles as a 
starting choice and in a prognostic model for ovarian cancer Clark et al. (Clark, Stewart, 
Altman, Gabra, Smyth, 2001) used quartiles to partition the risk score. A suggestion for an 
automated method is to use successive top-down splits by maximising the log-rank test 
statistic (Williams, Mandrekar, Mandrekar, Cha, Furth, 2006). This approach can be called as 
“minimum P-value approach”. However, the optimization of these cut-points results in an 
overestimation of the relative risk between the two prognostic groups. Usually, there is 
instability of the p-value in the minimum p-value approach, as there are some cut-points that 
can be considered minimum, because their p-values are all significant, so choosing the 
optimal cut-point is not the best approach (Altman, Lausan, Sauerbrei, Schumacher, 1994). 
Moreover, it should be kept in mind that the cut-point obtained is highly data dependent and it 
would be expected that this value vary markedly between different data sets, which is not the 
main goal for the model validation. 
In order to improve the existing methodologies, a new one is proposed to make the 
stratification of risk indices more robust. This technique based on bootstrapping re-sampling 
technique can be used applying it to the prognostic indices, as these are calculated from the 
original data set.  
Bootstrapping is a re-sampling method, which has a computer-intensive approach. This 
method is a general approach to statistical inference based on building a sampling distribution 
for a statistic by re-sampling from the original data. 
There are some studies that use bootstrapping methods (Heller, Venkatraman, 1996) to 
compare four classes of test procedures and two survival distributions. Two of these tests use 
bootstrap methods, and they recommend using them when the log-rank test statistic is 
employed. M. Schumacher et al (Schumacher, Hollander, Sauerbrei, 1997) also has explored 
at what extended the result bias of the cut-points can be reduced using bootstrap re-sampling 
and cross-validation techniques, applied to a model with one factor, where an optimal cut-off 
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value in this factor is selected to define a low-risk group and a high-risk group. This single 
factor can be a prognostic index, which is a weighted sum of several covariates. Their results 
have shown that the bootstrapping approach they studied is capable of correcting the 
overestimation of the cut-off point. 
However, there are some concerns about using the log-rank statistic at all, as a means of 
identifying patient cohorts, since thresholding by a prognostic index does not necessarily 
separate patients into groups with different clinical characteristics. This can result in mixed 
populations within single risk groups, which the application of an automatic rule extraction 
method has to be used to obtain coherent rules of variables for each identified risk group. 
Therefore, some statisticians prefer the use of a clustering method, based on the patients 
variables and not only in the prognostic indices obtained, as regression trees or K-means 
clustering, which results in a stratification with coherent patient groups but with relatively 
poor specificity for outcome, as measured by the separation between the group means of the 
overall mortality rates. This section, first presents the log-rank statistic, followed by the 
minimum p-value methodology description, robust log-rank bootstrap methodology, 
regression tree methodology, a clustering methodology and a clustering methodology based 
on learning metrics. Regressing the distribution of prognostic scores with rule-based trees 
(CART) succeeds in separating patient groups with statistically different mean survival but 
coherent membership in each group. 
Many clinicians refer the important issue of explaining individual inferences by the 
modeling and stratification used. This is a key stage in evaluating the clinical plausibility of 
inferences made by analytical models to enable clinicians to apply these inferences with 
confidence. When the stratification methodology used is the regression tree, the tree itself 
explains the rules. However, when another stratification methodology, among the ones 
mentioned previously, is used a rule extraction algorithm is required. A previously published 
methodology designed to extract low-order Boolean rules from data, the orthogonal search 
rule extraction (OSRE) algorithm (Etchells, Lisboa, 2006) will be after explained.  
2.3.1. Log-rank Test 
Two groups of survival data can be compared looking at the survivor function of both 
groups. Plotting these survivor functions some information can be obtained. For example, if 
the survivor function of one group (Group I) is always greater than the survivor function of 
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the other group (Group II), it can be concluded that at any time t, the estimated survival 
probability of group I is greater than group II. 
However, there are two explanations for this conclusion. First is that there is a real 
difference between the survival times of the two groups of individuals. The other reason for 
this is that there is no difference between the survival times in each group. The difference that 
has been observed is due to chance variation. To distinguish between these two explanations, 
the hypothesis testing is used. There is a non-parametric procedure, which is used to compare 
between two groups of survival data, namely Log-rank test (Collet, 2003). 
The log-rank method is used to compare the survival of groups, which takes the whole 
follow up period into account. It is not required to know about the shape of the survival curve 
or the distribution of survival times. This test summarizes the extent to which the observed 
survival times in two groups of data deviate from those expected under the null hypothesis of 
no group differences. This means that the null hypothesis here is that there is no difference 
between the populations in the probability of an event (e.g. death due to breast cancer or death 
by any cause) at any time point. The larger the value of the statistic, the greater the evidence 
against the null hypothesis, because this statistic approximates the χ2 distribution with one 
degree of freedom. The p-value associated with the test statistics can be obtained from the 
distribution function of a chi-square random variable. This statistic is obtained by calculating 
the UL value, which is the difference between the total observed and expected number of 
deaths in Group 1, and the VL value, variance of UL. 
 
UL = (d1 j − e1 j )
j=1
r∑  (54)
where  
e1 j = n1 j d jn j
 (55)
 
VL = var(UL ) = V1 j
j=1
r∑  (56)
where  
v1 j = n1 j n2 j d j (n j − d j )n j2 (n j − 1)
 (57)
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e1j represents the expected number of individuals who died at time t(j) in group 1. Under the 
null hypothesis, the probability of dying at time t(j) does not depend on the group that an 
individual is. As the probability of death is dj/nj, multiplying this value by n1j (number at risk 
before t(j)), gives e1j, which is the expected number of deaths in Group I at t(j). 
The variance of UL is the sum of the variances of d1j, which are represented by v1j, because 
the statistic UL has a zero mean, and the death times are independent one from another. 
Moreover, the UL value has a normal distribution when the number of death times is not too 
small. Then, the valueU L / V L  has a normal distribution with zero mean and unit variance. As 
the square of a standard random variable has a chi-square distribution on one degree of 
freedom, we can have: 
U L
2
VL
= χ 2  (58)
2.3.2. Minimum p-value methodology 
The minimum p-value methodology is an accepted strategy and was implemented in SAS 
(Williams, Mandrekar, Mandrekar, Cha, Furth, 2006). It starts by sorting all the records by 
the value of the prognostic index. Next, the total data are divided into two groups at a 
threshold value that sweeps the full range of prognostic indices from minimum to maximum. 
For each threshold, the log-rank statistic is calculated and hence a p-value results. The 
maximum of the log-rank statistic determines the first cut-off point. The same method is then 
repeated in each of the separated cohorts until no further partitioning exceeds a pre-set 
confidence level which, for this study, is as p-value of 0.01 (99% of confidence), 
corresponding to a test statistic value of around seven. 
In practice, the test statistic very much exceeds this value across a wide range of thresholds 
with the associated p-values forming a plateau indicating that there are a wide range of 
candidate cutpoints in addition to the maximum log rank statistic that has been selected as can 
be seen in Figure 2.9 . Here, the significance of data partitions in the top-down approach that 
is generally applied to stratify patient data in medical statistics detects the global maximum as 
it can be observed in the left picture of Figure 2.9 , but this does not take into account that the 
statistical significance is high for a wider range of possible cut-off thresholds as shown in the 
right picture of Figure 2.9 .  
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Figure 2.9 – Distribution of Risk index versus the log-rank score and p-value. 
The left picture represents the distribution of Risk index versus the log-rank score and the right 
picture represents the distribution of Risk Index versus the p-value. For each risk index there is a log-
rank score as well as a p-value. The higher the log-rank score the lower the p-value. 
2.3.3. Log-rank bootstrap methodology 
The log-rank bootstrap methodology is proposed to make the stratification of risk indices 
more robust (Etchells, Fernandes, Jarman, Fonseca, Lisboa, 2008). The new approach is 
bottom-up according to the following procedure, which involves two nested loops: the inner 
loop and the outer loop. 
 
Inner loop: 
1. Bin the risk indices into discrete intervals each containing a minimum number of cases 
(e.g. minimum number=10). 
2. Calculate the log-rank statistic for each pair of adjacent cells and aggregate together 
the two cells with the smallest value of this test statistic. 
3. Repeat the process until the long-rank statistic is significant for all remaining cell 
pairs. 
 
Outer loop: 
1.  Draw a sample of the risk indices, with replacement, of size equal to the original data 
size – this is a bootstrap re-sample of the data. 
2.  Apply the inner loop to convergence using the re-sampled data. 
3.  Allocate each value in the full range of the risk index to a risk group, from 1..Ngroups 
4. Repeat from i a given number of times (e.g. number samples =3000). 
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5. Identify the distribution of values of Ngroups and discard all group assignments 
different from the mode of this distribution. 
6. For each value in the full range of the risk index, build a distribution of risk group 
allocations – this clearly indicates the cases that fit firmly into a risk group and those 
that are near the boundary between adjacent groups. 
7. Allocate each case in the original sample to the mode of the distribution of risk 
groups. 
 
With this methodology, the training data is bootstrapped a number of times and the group 
allocation algorithm is applied to each bootstrap sample. Different bootstrap samples may 
produce different number of groups. Therefore, the most popular number of groups from all 
the bootstrap samples is chosen. Then, for the risk index value assigned to the training data, a 
distribution of group membership is derived from the bootstrap risk group allocation, as in 
Figure 2.10.  
If the number of bootstrap samples is sufficiently large, then a probability of group 
membership can be assigned to each risk index score. This probability can then be used to 
indicate whether new data presented to the model are clearly in a particular risk group or are 
on or near the borders of two adjacent risk groups. This can be especially useful in the clinical 
context where the inference model allocates a patient to a particular group with a particularly 
aggressive treatment, but the patient may be in the crossover region between this more 
aggressively treated group and in adjacent risk group that is assigned to less aggressive 
treatment. An indication that a patient is in a crossover region of two groups may influence 
the decision of a clinician differently from that of a patient situated firmly in one of the 
groups. 
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Figure 2.10 – Distribution of group membership.  
This was derived from the bootstrap log-rank risk group allocation. Different colours represent each 
risk group. The interception of each risk group should be the cutpoint for risk group belonging. 
2.3.4. Regression Tree Methodology 
There are some algorithms that can be used to build the regression tree methodology. 
However, the algorithm used in this study, to build the tree, was CART. Here it is assumed 
the existence of a single output variable, which is the prognostic index obtained with a 
prognostic model, which was in this study, either with Cox or PLANN-ARD, and one or more 
predictor variables. The output variable is numerical, and the predictor variables may be a 
mixture of continuous and categorical variables. Regression trees are a recursive partitioning 
algorithm, which aim is to determine the optimal cutpoints for predictors. Therefore the 
resultant groups are most homogenous with regard to the outcome (i.e., minimum deviance). 
The terminal nodes of the tree contain the predicted output variable values. The starting level 
(complete dataset) is referred to as the root, each split is referred to as a branch, and the data 
subset resulting from the split is called a node; the terminal or ending nodes are referred to as 
leaves. Regression tree is built through a process known as binary recursive partitioning. This 
is an iterative process of splitting the data into partitions, and then splitting it up further on 
each of the branches. Initially, all the records in the training set are together and the algorithm 
tries breaking up this data, using every possible binary split on every field. The algorithm 
chooses the split that partitions the data into two parts such that it minimizes the sum of the 
squared deviations from the mean of the target in the separate parts.  This splitting or 
partitioning is then applied to each of the new branches.  The process continues until each 
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node reaches a user-specified minimum node size and becomes a terminal node.  (If the sum 
of squared deviations from the mean in a node is zero, then that node is considered a terminal 
node even if it has not reached the minimum size.) 
It is important to refer, while building a tree, that a full tree is complex and can yield an 
overly optimistic goodness of fit. Thus, methods to reduce the tree size have been developed 
so that the model is predictive in other cohorts. Moreover it is essential that the leaves contain 
statistically significant patients, as they need to be compared to each other in order to identify 
the belonging to a risk group. Therefore, it is necessary to define a minimum of records for 
the nodes, a minimum of records for the leaves or both. 
After obtaining the final tree, it was developed a “pruning method”, which aim was to find 
the leaves that have patients with a significantly similar survival of and join them. Therefore, 
leaves must be ordered by their final average and for each pair of leaves the log-rank test 
must be computed. The pair that has the minimum of this statistic, which means that the 
records existing in these leaves are the most similar ones in terms of survival are grouped and 
the new final average is computed, according to new grouped records. After it, all leaves are 
again ordered and the log-rank test is computed for the new grouped leaves with the ones 
which have the closest predictor average value. This algorithm is made until there is no 
significantly difference in terms of survival for the records belonging to each leaf. After the 
“pruning method”, the regression tree remains a classification tree. 
2.3.5. Clustering Methodology 
The clustering method is an orthogonal approach, which aim is to cluster the clinical data 
first, then to produce a cohort tree with the leaves organized in order of mean group survival, 
where the prognostic index is not used at all. It is a k-means algorithm based, with a 
Euclidean metric, which used Monte Carlo methods to overcome the initialization problems. 
However, clustering with a Euclidean metric often provides insufficient discrimination for 
prognostic purposes. 
2.3.6. Clustering methodology based on learning metrics 
The Multivariate Fisher Distance is a metric based on learning metrics that measure local 
distances with respect to the distribution of one or more prognostic indices, which are 
proportional to the risk of mortality. This metric is embedded into a clustering model that can 
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estimate the most likely number of sample partitions within the data, providing a stratification 
of patients intro groups characterized by different survival curves. The Learning Metrics 
model (Kaski, Sinkkonen, Peltonen, 2001) provides a mean for estimating the distance 
function directly from the data, exploiting prior information concerning the distribution of the 
samples with respect to some auxiliary information. Such an auxiliary information is typically 
modeled as a random variable c that is bound to the input samples x by a conditional 
distribution ( | )P c x , providing information regarding relevant aspects of the data. The 
scenario used comprises a set of samples (i.e. patient profiles) x X∈ that are associated to a 
multivariate auxiliary variable PI (prognostic index). In principle, what it has to be done is to 
learn a Fisher metric that can solve the variable’s categorical bias problem, while taking into 
consideration the information brought by the distribution of samples with respect to the 
prognostic indices. The learning metrics, then, measures distances in terms of changes in the 
distribution ( | )P c x  as x varies; such changes can be measured by the local Kullback-Leibler 
divergence that is a non-symmetric measure of the difference between two probability 
distributions as: 
D ( P (c x ) P (c x + dx ) ) = dx T J ( x ) dx  (59)
 
where J(x) is the Fisher information matrix, that is  
J(x) = EP (c x ) ∂ log(P(c x))
T
∂x
∂ log(P(c x))
∂x
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟  (60)
 
where EP(c|x) is the expectation over c. The tensor J(x) is a positive semidefinite function 
defining a local scaling of the input space at the point x.  
The Fisher information is a way of measuring the amount of information that an 
observable random variable x carries about an unknown parameter θ upon which the 
likelihood function of θ , ( ) ( ; )L f Xθ θ= , depends. The likelihood function is the joint 
probability of the data, conditional on the value of θ, as a function of θ. The score function is: 
log ( ; )f X θ
θ
∂
∂  (61)
 
Since the expectation of the score is zero, the variance is simply the second moment of the 
score, the derivative of the log of the likelihood function with respect to θ. Hence, the Fisher 
information can be written 
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2log ( ; )( ) |f XL x E ∂ θ θ∂θ
⎛ ⎞= ⎜ ⎟⎝ ⎠  (62)
 
which implies [ ]( ) 0,L x ∈ ∞ . The Fisher information is thus the expectation of the squared 
score. If a random variable is carrying high Fisher information then the absolute value of the 
score is often high. The new metric that is used to cluster the data in place of the Euclidean 
distance is as follows:  
d 2 ( x , m i ) = ( x − m i )T J ( x )( x − m i )  (63)
 
where mi is the prototype of the i-th cluster and J(x) is the Fisher matrix at the point x.  
For the purpose of our study, it was derived the informed metric based on the Fisher 
information matrix of the conditional distribution of the prognostic indices obtained by 
survival analysis. In particular, we will only focus on the prognostic indices obtain with Cox 
and with PLANN-ARD. Therefore it was considered a set of samples (i.e. the patient profiles) 
x X∈ that are associated to two independent auxiliary variables PICox and PIPLANNARD, through 
the respective conditional probabilities P(PICox|x) and P(PIPLANNARD|x). In addition, it was also 
considered the joint conditional probability of the two independent prognostic indices, that is 
P(PICox , PIPLANNARD|x). To obtain an analytical formulation for the Fisher information matrix 
in our survival analysis scenario, we need to compute the derivative ∂log(P(PIx)) ∂x  for each 
of the three distributions of the prognostic indices. To do so, it was considered PICox and 
PIPLANNARD to be Normally distributed as 
 
P(PI x) ~ exp− (CCX
T −1∑ CCX)
2
⎧ 
⎨ ⎪ 
⎩ ⎪ 
⎫ 
⎬ ⎪ 
⎭ ⎪ 
 (64)
 
where CCX is a short form for  
CCX = Bx + β 0 − μ  (65)
 
where B is the 1 × K vector (2 × K matrix for the joint distribution P(PICox,PIPLANNARD|x)) of 
the linear parameters of Cox survival model. The term µ refers to the Normal expectation and 
x is the K × 1 sample vector. To calculate the Fisher matrix with we need to compute 
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∂ log(P(PI x))
∂x =
∂ − (CCX
T −1∑ CCX)
2
⎧ 
⎨ ⎪ 
⎩ ⎪ 
⎫ 
⎬ ⎪ 
⎭ ⎪ 
∂x  
(66)
 
Given the CCX , we can solve the previous equation using the product rule, yielding 
 
∂ log( P (PI x ))
∂x = −(Bx + β 0 − μ)
T −1∑ B  (67)
 
By inserting this result in the equation 2( , )id x m , the Fisher distance for the prognostic 
indices can be obtained. To complete the derivation of the model, we need to fit the linear 
parameters B and β0 to the values of the prognostic indices PI predicted by the Cox and 
PLANN-ARD model for each sample x. This entails solving a linear system with respect to 
[B;β0], which can be straightforwardly done by using the pseudo inverse matrix (see (Bacciu, 
Jarman, Etchells, Lisboa, 2009)  for details).  
Once the Fisher distance has been estimated, it can be embedded within the clustering 
algorithm at the stage where unit activation is computed. Following on the approach in 
(Bacciu, Jarman, Etchells, Lisboa, 2009), we focus on the CoRe clustering model (Bacciu, 
Starita, 2008), an algorithm that performs cluster number identification by exploiting an 
information compression mechanism of the visual cortex, named repetition suppression. 
Starting from an initial overestimation of the actual cluster number, the CoRe algorithm 
iteratively suppresses neurons whenever they fire un-selectively for the input patterns, 
eventually pruning unselective units from the network. The neurons retained at the end of the 
learning phase encode the clusters found by CoRe within the input data. Hence, the estimated 
cluster number is equal to the network size at convergence. The response of CoRe units is 
determined by a multivariate Gaussian: to embed the Fisher metric within such units, we 
consider the following activation function 
ϕ i ( x, m i, i
−1∑ ) = exp − 12 R( x )( x − m i )[ ]T R(x )( x − m i )[ ]i
−1∑i−1
T∑⎧ ⎨ ⎩ ⎫ ⎬ ⎭  (68)
 
where R(x) is the right Cholesky decomposition of the Fisher matrix J(x). Regards learning, 
the original CoRe algorithm updates unit means and variances in the direction given by the 
gradient (∂ϕi/∂mi) and (∂ϕi/∂Σi).  
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Since the Fisher metrics is a Riemannian metrics, such steepest descent can be computed 
by means of the natural gradient (Amari, 1998). The application of this rule to the prototype 
vectors mi yields to the same update rules as for the Euclidean case; on the other hand, the 
learning equations for the scale matrix Σi need to be slightly modified to enclose the 
contribution from the Fisher matrix J(x) ( see (Bacciu, Jarman, Etchells, Lisboa, 2009) for the 
details of the learning equations ). In the experimental phase, the CoRe algorithm with the 
Fisher metrics has been applied to discover clusters within the patient population, by 
exploiting the information from the distribution of the prognostic indices PICox and PIPLANNARD 
in isolation and jointly. The simulation setup is the same described in (Bacciu, Jarman, 
Etchells, Lisboa, 2009): the CoRe network has been initialized with 30 units and the cluster 
number estimates are based on 50 repeated runs of the algorithm, with random initial 
prototype assignments.  
2.3.7. OSRE rule extraction algorithm 
OSRE is an orthogonal search rule extraction (OSRE) algorithm that provides a practical 
and efficient tool to explain the predictions from different prognostic models, after applying a 
stratification methodology. The main goal of OSRE is to produce rules that are 
comprehensible to a human analysis. The OSRE methodology searches for rules using 
multivariate descriptions of data sub-sets, and provides an efficient alternative to methods that 
follow sequences of univariate searches such the well-known method of Classification and 
Regression Trees. The OSRE methodology transcribes the RULENEG algorithm developed 
by Pop. et al (Pop, Hayward, Diederich, 2009)  for binary data, as if there are categorical or 
ordinal variables RULENEG cannot be applied to the data (Etchells, Lisboa, 2006).  
The OSRE algorithm searches through the Boolean space in order to generate rules in 
response to a certain risk group classified previously. The rules’ search is restricted to the data 
predicted to be within class and searching in successive orthogonal directions. The algorithm 
searches the multi-variable space for changes in the networks response, sweeping each 
variable over its possible values whilst keeping all other variables constant. Therefore, if there 
are m variables, each with up to n values, there are at most nm points to evaluate, which is not 
viable to handle. 
A disadvantage of this algorithm is that it can sometimes produce as many rules as there 
are data. This happens because the orthogonal search is performed relative to a data point and 
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the distance from a particular data point to the decision boundary may be unique to that data 
point. Therefore, a rule refinement technique must be applied, which reduces the number of 
rules. This must delete the rules which are covered by other rules and incorporate a single rule 
allocation to a patient by ordering into a hierarchy were a rule’s position depends on how 
accurate it is, analysing the sensitivity and the specificity of the rule. 
Summarising, after obtaining a risk group belonging for each patient in order to obtain a 
set of rules from the training data, a neural network, MLP, is run in turn for each prognostic 
group. For each MLP, the risk group of interest is assigned the target 1 and the remaining risk 
groups are assigned to 0. For each risk group the rules are placed into a rule hierarchy with 
the aim to assign one rule only to a patient. If a patient is assigned to a rule for more than one 
risk group it is placed into the more conservative of these survival groups. It can also be 
flagged as a patient who is in the cusp of decision boundaries. If a patient is not classified by 
any of the obtained rules, than this patient is considered as an outlier of the rule extraction 
survival model.    
2.4 - Clinical Prognostic Indices 
Single items of patient data, such as age or smoking history are widely used in making 
clinical decisions. Prognostic models are more complex tools for helping decision making that 
combine two or more items of patient data to predict clinical outcomes. They are of potential 
value when doctors are making difficult clinical decisions (such as ordering invasive tests, 
selecting which patients should benefit from scarce resources or selecting the most 
appropriate treatment), or selecting uniform groups of patients for clinical trials. Risk 
prediction models can play an important role in decision making and future management of 
individual or groups of patients with a particular medical condition. These models are usually 
designed to predict the risk of a patient developing some future clinical event based on a 
number of patient and disease characteristics. Unfortunately, most of the published indices of 
risk have no clinical impact and disappear into archives. There are however some prognostic 
indexes that are widely used and accepted in clinical practice. Therefore, the new obtained 
indices must be compared with the existent ones and demonstrate that make better predictions 
in order to be potentially accepted in clinical practice. 
As an example, QRISK, a new cardiovascular disease risk has been developed and 
internally validated (Hippisley-Cox, Coupland, Vinogradova, Robson, May, Bringle, 2007). 
Chapter 2 – Analytical Methodologies 
56 
After some critiques of the original papers, other studies have been carried out to validate 
externally this index and compare it with existing ones (Collins, Altman, 2009), (Hippisley-
Cox, Coupland, Vinogradova, Robson, Bringle, 2008), providing evidence to support the use 
of the index in favour to the existing ones. 
In terms of breast cancer disease, there are different prognostic indices that can be derived 
in different risk groups that are widely used, namely NPI, TNM and St. Gallens, which are 
presented in this section. It is very important for both, breast cancer patients and clinicians, to 
provide some form of interpretation of the prognostic groups in terms of clinically relevant 
variables. This would be highly appreciated when predicting more accurately the clinical 
course of the disease at the time of initial treatment. When defining a prognostic group, the 
survival for each group at a certain time scale, can be obtained as well as the more adequate 
treatment.  
2.4.1. NPI (Nottingham Prognostic Index) 
In practice, oncologists frequently use an algorithm commonly referred to as Nottingham 
Prognostic Index (Haybittle, Blamey, Elston, Johnson, Doyle, Campbell, Nicholson, Griffiths, 
1982), which was derived using the proportional hazards modelling, linear in the parameters. 
The model was fitted to explain the variation in survival, lending itself naturally to the 
derivation of a discrimination index that has since undergone extensive multi-centre 
validation (Galea, Blamey, Elston, Ellis, 1992). It was concluded that the use of NPI allows to 
accurately predict the prognosis of patients with breast cancer and carried out surgical and 
systemic adjuvant procedures that are appropriate for the individual patient (D’Eredita, 
Giardina, Martellotta, Natale, Ferrarese, 2001). This identified three factors from nine firstly 
recorded for each patient as being significant indicators of survival prognosis, namely 
Tumour size (in cm), grade of tumour (coded as 1,2 or 2) and number of axillary nodes 
affected (coded as 1 (no nodes involved), 2 (1 to 3 nodes involved) or 3 (more than 3 nodes 
involved)) in the form: 
 
NPI score = 0.2*Tumour size + Grade of tumour + Number of axillary nodes affected (69) 
 
The split of this index in different prognostic groups is at all explained by expert 
knowledge. These values can be splited in 3, 4 or 5 different groups. The division in five 
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different risk groups is as following: excellent prognosis group (NPI ≤ 2.4), good prognosis 
group ( NPI > 2.4 and NPI ≤ 3.4 ), moderately prognosis good group (NPI > 3.4 and NPI ≤ 
4.4), moderately prognosis poor group (NPI > 4.4 and NPI ≤ 5.4) and pour prognosis group 
(NPI  > 5.4). The moderately good prognosis group and the moderately poor prognosis group 
can be combined resulting in four risk groups. If the excellent group is combined with the 
good prognosis group, 3 risk prognostic groups can be obtained. For each risk group it was 
identified the 5, 10 and 15 years survival. 
This index has the advantage of utilising information about histological differentiation, 
which makes it more specific for patients with early-stage disease, which is non-metastatic. 
2.4.2. TNM prognostic index 
TNM is a  widely used staging system in breast cancer patients. TNM is developed and 
maintained by the International Union Against Cancer (UICC). The TNM classification is 
also used by the American Joint Committee on Cancer (AJCC) and the International 
Federation of Gynecology and Obstetrics (FIGO). In 1987, the UICC and AJCC staging 
systems were unified into a single staging system. 
TNM stands for “tumour, nodes, metastasis”. TNM staging takes into account the size of 
the tumour, whether the lymph nodes are affected and whether cancer has spread to other 
parts of the body (metastasis). The size of the tumour can be divided in four stages: stage 1 
represents a tumour with less than 2 cm, stage 2 a tumour with more than 2 cm and less than 5 
cm, stage 3 a tumour bigger than 5 cm, stage 4 when the tumour has spread into the chest 
wall, skin, is fixed to the skin and chest wall or when it is a inflammatory carcinoma. The 
lymph nodes can be divided in 4 different stages: N0 if no cancer cells were found, N1 if 
cancer cells are in nodes in the armpit but the nodes are not stuck to surrounding tissues, N2 if 
there are cancer cells in the lymph nodes in the armpit, which are stuck to each other and to 
other structures or if there are cancer cells in the lymph nodes behind the breast bone (the 
internal mammary nodes), N3 if there are cancer cells in lymph nodes below the collarbone, 
in the armpit and under the breast bone or above the collarbone. The metastases stage can be 
divided in two stages: M0 if there is no sign of cancer spread and M1 if the cancer has spread 
to another part of the body, apart from the breast and lymph nodes under the arm. 
Once the T, N, and M categories have been determined, this information is combined in 
order to obtain a stage grouping, 4 stages were considered from stage I (the least advanced 
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stage) to stage IV (the most advanced stage). Non-invasive cancer is listed as stage 0. Stage I 
incorporates T1N0M0 and T0N1M0. Stage 2 incorporates: T1N1M0, T2N0M0, T2N1M0, 
T3N0M0. Stage 3 incorporates: T0N2M0, T1N2M0, T2N2M0, T3N1M0, T3N2M0, 
T4N0M0, T4N2M0, T1N3M0, T2N3M0, T3N3M0, T4N3M0. Stage 4 incorporates any T, 
any N and M1. According to these group stages the 5-year relative survival rate can be 
obtained. The strength of this index is that it only requires clinical information, which is 
obtained by the clinician without recourse to laboratory tests. However, its discrimination 
power is best for separating severe from early-stage disease. 
2.4.3. St. Gallen Classification 
Another approach for choosing the best treatment options for early breast cancer has been 
proposed by an international panel of experts in a report from the St. Gallen conference. The 
report represents the consensus on early breast cancer treatment that emerged from the 
conference (Harbeck, Jakesz, 2007). The consensus maintains an emphasis on targeting 
adjuvant systemic therapies according to subgroups defined by predictive markers. It further 
refines the treatment algorithm by identifying 'thresholds for indication' of each type of 
systemic treatment modality (endocrine therapy, anti-HER2 therapy, chemotherapy) based on 
criteria specific to each modality. The report emphasises the importance of identifying which 
type of breast cancer a patient has and which treatment, or combination of treatments, are 
most likely to be successful. 
 
Low risk 
Node negative AND all of 
the following: 
pT ≤ 2 cm AND grade=1 AND no extensive PVI AND ER 
AND/OR PgR expression AND neither HER2 over expression 
nor amplification AND Age≥35 years 
Node negative AND at least 
one of the following: 
pT > 2 cm OR grade=2-3 OR extensive PVI OR lack of ER 
AND PgR expression OR HER2 over expression or 
amplification OR Age<35 years 
Intermediate 
risk 
Node positive (1-3 N+) 
AND  
ER AND/OR PgR expression AND neither HER2 over 
expression nor amplification 
Node positive (1-3 N+) 
AND 
Lack of ER and PgR expression OR HER2 over expression or 
amplification High risk 
Node positive (≥ 4 N+) 
Table 2.3 – St. Gallen risk categories 2007. 
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St. Gallen classification defined 3 risk categories—low, intermediate and high—using a 
combination of nodal status, tumour size, histological and nuclear grade, oestrogen receptor, 
progesterone receptors, the status of extensive peritumoural vascular invasion (PVI), human 
epidermal growth factor receptor 2 (HER2) and age.  The definition of risk categories is 
presented in Table 2.3. Recommendations for adjuvant systemic therapy were based on the 
three categories of risk, menopausal status, and steroid hormone receptor status. 
The recommendations of the St. Gallen consensus panel provide a minimal standard for 
up-to-date breast cancer treatment, which are based on expert opinions as well as published 
trial data. 
 
Concluding, in this chapter it has been presented the essential analytical methodologies, 
which are required for the development of this thesis. It has also been shown the improvement 
of some of the existing methodologies that contributed to this thesis’ innovation.  
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Chapter 3 - 
Study Design for Prediction Models 
 
There are several issues in the design of studies for prediction models. These include the 
main subjects such as the selection of patients for a cohort study, choosing predictors and 
outcome variables, the cohort sample size and how to deal with missing values. Finally, an 
appropriate adequacy of the model must be done in order to verify the choices done. All these 
important issues are presented in this chapter, defining at the end of the chapter a section, 
which defines a modelling strategy that was followed in this thesis.  
3.1 - Choice of covariates 
In order to obtain a well-performing prediction model it is mandatory to have strong 
predictors. It is essential therefore, to make a careful model selection which depends on the 
study aim and the responsibility of the analyst. Bradburn et al (Bradburn M.J., Clark, Love, 
Altman, 2003) suggests three possible scenarios as to why a study may use a multivariate 
model and how to deal with each one: 
1. A single factor is under investigation for its association with survival, but several 
other factors exist. 
2. A collection of factors of known relevance is under investigation for their ability to 
predict survival. 
3. Where a collection of factors are under investigation for their potential 
association with survival, possibly with additional known factors.  
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While choosing a significant model as well as the significant covariates it is worthwhile to 
consider the specific question under investigation and the opinion of a non-statistical 
specialist of the study. 
When the aim of the study is to find a set of potential explanatory variables that the hazard 
function depends on and combine them to find the best models, the statistic AIC (Akaike’s 
Information criterion), can be used (Collet, 2003). This statistic measures the extent to which 
the data are fitted by a particular model. 
The AIC of a model can be defined as: 
AIC = -2logL + αq (70)
 
where q is the number of unknown β parameters in the model, α is a predetermined constant 
and L is the optimised log-likelihood function for the proportional hazards. The smaller the 
value of this statistic, the better the model. 
The value of AIC will increase when an unnecessary variable is added to the model. If the 
only difference between the two models is that one includes unnecessary variables, the values 
of AIC of both models will not be very different. 
When the number of variables is relatively large it can be computationally expensive to 
compare all the models that can be derived. To avoid this situation there are some automatic 
routines for variable selection. These are based on forward selection, backward selection or a 
combination of both, frequently called a stepwise procedure. 
In forward selection, variables are added one at a time. At each step the variable added is 
the one that most decreases the value of AIC. The process ends when no other variable 
decreases the AIC value by a statistical value. In backward elimination variables are excluded 
one at a time and the variable that is omitted is the one that increases the value of AIC. The 
process ends when there is no candidate variable for deletion that increases the AIC value 
more than a statistical amount. 
In stepwise procedure, probably the most widely used procedure in medical applications, the 
variables are added to the model one at a time. The variable added is the one that gives the 
largest decrease of the AIC value. The process ends when the next candidate for inclusion in 
the model doesn’t reduce the AIC value by more than a predefined amount. After selecting 
the best variables, the routine may exclude some of these variables if the variable omitted is 
the one that increases the value of AIC. 
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There are some advantages and disadvantages about using these procedures. The 
advantages reside on the following: they are straightforward to apply in modern statistical 
packages; they are relatively objective and usually reach their goal of making a model smaller 
(this helps to eliminate variables that have no true relationship to the outcome as noise 
variables). Unfortunately, these automatic procedures have some disadvantages as they 
identify solely one model instead of a set of statistical significant models. They depend on the 
variable selection process (forward selection, backward selection, stepwise selection) and they 
depend on the stopping rule used. There are also other problems derived from automated 
selection techniques such as the best model is derived solely on statistical grounds, the 
regression coefficients are biased and standard errors and p-values are too small, especially if 
the sample sizes are very small and if there are little events (Bradburn, Clark, Love, Altman, 
2003). 
Other selection methods have emerged in order to improve the mentioned ones. However, 
these methods are generally computer intensive and are infrequently encountered in medical 
applications. Some approaches use resampling methods such as the bootstrap bagging and 
boosting and others use principles of Bayesian analysis, such as Bayesian model averaging 
(BMA) (Steyerberg, 2009).   
3.2 - Sample size considerations 
There are several aspects in the design of a model of survival data that must be considered. 
One crucial issue that must be considered is the number of patients that is required to make 
the study. A predictive model based on a small sample of individuals will be less reliable than 
one based on a larger number of individuals. However, it is unethical to waste resources in 
studies that are unnecessarily large. The automatic selection procedures described previously 
have some problems when dealing with small data sets, as well as with large data sets, as can 
lead to overoptimistic results. 
Although it is necessary to give a very high relevance to the number of individuals in the 
study, the number of events per variable (EPV) is a bigger measure of power or even validity 
of a survival analysis study. Some work has been made to conclude about the effects of 
changing the EPV in multivariable analysis, as the effect of overfitting or underfitting. The 
overfitting may be caused by unimportant variables being predictively important. On the other 
hand the underfitting may be caused by the reverse effect, which is rejecting a variable that 
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have a significant impact in survival. Some simulation studies (Concato, Peduzzi, Holford, 
Feinstein, 1995), (Concato John, Peduzzi, Holford, Feinstein, 1995), (Concato, Peduzzi, 
Holford, Kemper, Feinstein, 1996) have been made to ensure the number of EPV that can lead 
to fewer problems while designing a predictive model. These studies suggested that an EPV 
or 10 is the minimum value that can obtain good predictions. For example, as the EPV value 
decreases the regression coefficients increases, producing overestimation as well as 
underestimation of the true effect. Also while the EPV decreases, the power to detect 
significant effects also decreases, resulting in problems of underfitting and significant effects 
could be identified in the wrong direction. Other problems such as the low coverage of 
confidence intervals, the lack of validity of the test statistics for the model and the increasing 
of the frequency paradoxical associations may result when the EPV is lower than 10. 
3.3 - Missing Covariate Data 
Missing data is a common problem when developing survival models. Unfortunately, it is 
often neglected or not properly handled during analytic procedures, and this may substantially 
bias the results of the study, reduce study power, and lead to invalid conclusions. While bias 
may be introduced into research through several other mechanisms (e.g., study design, patient 
sampling, data collection, and or other aspects of data analyses), naïve methods of handling 
missing data may substantially bias estimates while reducing their precision and overall study 
power, any of which may lead to invalid study conclusions. 
The usually method to overcome this problem is excluding the individuals whose 
prognostic factors are missing from the study. This method not only wastes valuable data, but 
also can lead to invalid results, if the excluded group is a non-random sub-sample of the entire 
data. Here, the completely observed cases that remain will be unrepresentative of the 
population for which the inference is usually intended: the population for all cases, rather than 
the population of cases with no missing data. In addition, the statistical power of the analyses 
decreases (Greenland, Finkle, 1995) as well as the number of events per variable, which can 
result in less stable results (Bradburn, Clark, Love, Altman, 2003). 
There are several reasons why the data may be missing. Depending on these reasons, 
missing data can be classified as MCAR (Missing completely at random), MAR (Missing at 
random) and MNAR (Missing not at random). It is important to consider these, since 
approaches to handle missing data in statistical analysis rely on the assumption on the 
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mechanism. Missing data is called to be missing completely at random when the probability 
of an observation X missing is unrelated to the value of X or to the value of any other 
variables. Equipment malfunctioned, the data were not correctly entered and spilling of 
material are some examples of MCAR data. The analysis of this kind of data remains 
unbiased, that is some power can be lost, but the estimated parameters are not biased in the 
absence of data. 
If the data meet the requirement that missingness depends on values of variables that were 
actually measured, then the missing data is classified as MAR. In other words, in a given data 
set (Y) consisting of observed values (Yobs) and missing values (Ymis), MAR is present if the 
probability that a value is censored is dependent only on Yobs and not on Ymis. MAR examples 
include more missing values in older subjects, subjects from a certain region or from an 
earlier calendar time. This missing data is a problem, although there are ways of dealing with 
the issue in order to produce meaningful and relatively unbiased estimate. Assuming a MAR 
mechanism exists it is less restrictive and more tenable than assuming that an MCAR 
mechanism exists.  
When the missing data is not at random, the only way to obtain an unbiased estimate of 
parameters is to model missingness. The MNAR mechanism is present when the pattern of 
censoring is related to variables that were not collected and are not related to Yobs, or to Ymis 
rather than to Yobs. As such, it is impossible to estimate the missing values that are censored 
from other known values in the data set. This underlying mechanism of missing is often 
referred to as ‘‘nonignorable’’ because the probability that a value is missing depends on 
other unknown or missing values. Examples include selective non-response on certain 
questions (sexual orientation, income) or clinical condition (missing if a severe condition is 
present, which is not measured accurately). To identify MNAR as the existing mechanism, 
data must be available to fully explain the pattern of missingness. Unfortunately, this never 
occurs when censoring is beyond the investigator’s control and rarely occurs otherwise. 
Available methods of handling incomplete data with an MNAR mechanism may not produce 
valid results, and there is no universal method for handling incomplete data in this situation. 
However, some methods (e.g., Multiple Imputation) have been shown to produce less biased 
results than other methods, even when data are MNAR.  
While certain naïve methods for handling incomplete data (e.g., complete-case analysis, 
available-case analysis, and the missing indicator method) are likely to generate biased results 
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under a MAR mechanism, because the data would have to be MCAR for these methods to 
work, the MAR assumption is necessary and sufficient to justify handling missing data using 
more sophisticated techniques (e.g., Multiple imputation or maximum likelihood estimation) 
to produce valid estimates. The major distinction between these two sophisticated approaches, 
imputation and likelihood-bases is that imputation methods substitute the missing values with 
plausible values so that the completed data can then be analysed with standard statistical 
techniques, while likelihood-based approaches do not require the missing data to be estimated 
explicitly. The later approach is computationally complex and the software is less readily 
available for survival data.  
Imputation methods can be considered as single or multiple imputation methods. Both can 
be an alternative procedure that can be used; however this thesis will only be focused on 
multiple imputation (Clark, Altman, 2003), because when Multiple Imputation (MI) was 
compared with alternative methods of handling incomplete data it has been shown that MI 
generates less biased estimates with more statistical efficiency (Newgard, Haukoos, 2007). In 
this framework, missing data are imputed or replaced with a set of plausible values. Then, 
several data sets are constructed, each being analysed separately. After, their results are 
combined in order to diminish the uncertainty introduced by the imputation. 
Multiple Imputation: 
Data imputation, which is the practice of  “filling in” missing data with plausible values, is 
an attractive approach to analysing incomplete data sets. This approach solves the missing 
data problem at the beginning of the analysis. However, a naïve or unprincipled imputation 
method can create more problems than it solves. 
The general basis of multiple imputation it to use observed values to generate a range of 
plausible values (imputations), based on existing correlations between variables. In multiple 
imputation, the unknown missing data are replaced by m independent draws from an 
imputation model, and each of the m complete data sets is analyzed by standard complete data 
methods.  
One question that arises with imputation models is that we may want to predict missing 
values for one predictor, using other predictors that also have missing values. This can be 
however solved by an iterative process of an imputation step, which imputes values for the 
missing data and a posterior step, which draws new estimates for the model parameters, based 
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on the previously imputed values. This process continues until convergence. The variation 
among the m imputations reflects the uncertainty with which the missing values can be 
predicted from the observed data. At the end of this step there will be m complete data sets 
that reflect uncertainty about the true values of the missing data. 
After creating m completed data sets, analysis are performed by treating each completed 
data set as a real complete data set and finally the results from the m complete data analyses 
are combined using a set of rules that appropriately account for the variance in the MI 
process. Multiple imputation results in a three-step process: imputation, analysis and pooling 
(see Figure 3.1 ). 
 
Figure 3.1 – This figure represents all the three phases of multiple imputation.  
Here the incomplete data set is imputed 3 times and after its imputation, the 3 complete data sets are 
analysed and finally pooled. 
  
The imputation step imputes the missing entries of the incomplete data set, not once, but m 
times. The imputed values are drawn from a distribution, which can be different for each 
missing entry. The analysis phase is an important step of the imputation method because each 
of the m completed data sets must be analysed. After that the m analysis results into a final 
model. This phase is called the Pooling phase and consists of computing the mean over the m 
repeated analysis, its variance, and its confidence interval.  
Some simulation studies have shown that in multiple imputation a m value of 3 is often 
Imputation Analysis Pooling 
Incomplete data Imputed data Analysis results Final results 
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adequate for data with 20% of missingness (Van Buuren, Boshuizen, Knook, 1999). In his 
work, Rubin (Rubin, 1987) shows that the computational efficiency of an estimate is 
influenced by the number of imputations and by the rate of missing information.   
This fact can be surprising as in other applications of Monte Carlo, hundreds or thousands 
of draws are often needed to achieve an acceptable level of accuracy. There are two 
fundamental reasons that in multiple imputation a small value of m will usually suffice. First, 
multiple imputation relies on simulation to solve only the missing data aspect of the problem. 
This means that one could effectively eliminate Monte Carlo error by choosing m to be large, 
but with multiple imputation the resulting gain in efficiency would typically be unimportant, 
because the Monte Carlo error is a relatively small portion of the overall inferential 
uncertainty. The relative efficiency of a point estimate based in m imputation to one based on 
an infinite number of imputations is approximately 1+ λ
m
⎛ 
⎝ ⎜ 
⎞ 
⎠ ⎟ 
−1
, where λ is the rate of missing 
data. For example, for a λ=0.2 and m=3, the error estimate will be 1.033 times as large as the 
estimate with m=∞. On Table 3.1  it the relative efficiency of multiple imputation can be 
observed.  
Proportion of Missing data (λ) Number of 
imputations (m) 10% 30% 50% 70% 90% 
3 0.97 0.91 0.86 0.81 0.77 
5 0.98 0.94 0.91 0.88 0.85 
10 0.99 0.97 0.95 0.93 0.92 
20 1.00 0.99 0.98 0.97 0.97 
30 1.00 0.99 0.98 0.98 0.97 
Table 3.1 – Relative efficiency of multiple imputation. 
 
So, the additional resources that would be required to create and store more than a few 
imputations would not be worthy. Second the rules for combining the m complete data 
analysis account for Monte Carlo error (Shafer, 1997). 
The specification of the imputation model is the most complex step in multiple imputation, 
as its objective is to approximate the true distributional relationship between the unobserved 
data and the available information. There are two modelling choices that usually have to be 
made: the form of the model (e.g. linear, logistic, polytomous) and the set of variables that 
enter the model. As a general rule, using all available information yields multiple imputations 
that have minimal bias and maximal certainty.  
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The Schafer approach for imputed values (Schafer, 1999), assumes the distribution to be a 
multivariate Normal for continuous data, a log-linear model for categorical data or a general 
location model for a mixture of continuous and categorical data. Under certain circumstances, 
categorical variables can be quite reasonably when it is applied the same distribution. In other 
situations, however, it is desirable to use a model specifically designed for categorical data, as 
a log-linear model. 
There are other multiple algorithms besides the Schafer approach, where it is not assumed 
a particular form for the multivariate distribution of the data, that is no explicit non-response 
model is needed, and only the posterior conditional distributions p(Ymissing/X) needs to be 
specified. It is assumed that a multivariate distribution exists, and that draws from it can be 
generated by iteratively sampling (Gibbs sampling) from the conditional distributions. That is 
each incomplete entry is initialized by filling in a random draw from the marginal distribution 
of Yobs. Then, Y1 is imputed by the elementary procedure conditional on all other data 
(observed and imputed combined), then Y2 conditional on all other data (using the most recent 
imputations for Y1), and so on, until all incomplete variables in Y, Z, U and V have been 
imputed. Subsequently, start a second pass through the data, using all imputations created 
during the first pass, and so on. Therefore, the multivariate problem is split into a series of 
univariate problems.  
First, each incomplete entry is initialized by filling in a random draw from the marginal 
distribution of Yobs. After, Y1 is imputed by the elementary procedure conditional on all other 
data (observed and imputed combined), then Y2 conditional on all other data, using the most 
recent imputations for Y1. The process continues until all incomplete variables have been 
imputed. The whole procedure is executed m times in parallel, thus producing m complete 
data sets. 
The application of Gibbs sampling ensured that the imputation process was not 
deterministic because there was a random variation between the completed data sets, and this 
is the main reason for the approach to be considered as a form of Bayesian simulation. 
The number of iterations needed is much lower than is common in modern Markov chain 
simulation techniques that often require thousands of iterations. In regression switching, the 
posterior distributions of the regression coefficients absorb the uncertainty in the predictors. 
The main question now is whether the number of steps is or not enough to stabilize these 
posteriors. Also, the elementary procedure creates imputations that are already statistically 
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independent, therefore no iterations need to be wasted for achieving independence between 
successive draws, as is typical for MCMC methods. Brand’s simulation study successfully 
used just 5 iterations (Brand, 1998). In our implementation we have used 10 iterations to 
check convergence.  
Multiple imputation requires a selection of specific types of variables, namely the target 
variables and the auxiliary variables. The inclusion of the last ones has been considered to 
reduce bias and variance and improve statistical efficiency (Newgard, Haukoos, 2007).  
3.4 - Predictive accuracy and Validation of predictive models 
The purpose of prognostic models is to provide valid outcome predictions for new patients. 
Essentially, the data set to develop a model is not of interest other than to learn for the future. 
To show that a prognostic model is valuable, however, it is not sufficient to show that it 
successfully predicts outcome in the training data. It is needed evidence that the model 
performs well for other group of patients, that is prognostic models need to be internally and 
externally validated (Altman, Vergouwe, Royston, Moons, 2009). The idea of validating a 
prognostic model generally means that it works satisfactorily for patients other than those 
from whose data was derived.  
A key threat to validity is overfitting, i.e. that the data under study are well described, but 
that predictions are not valid for new subjects. Overfitting causes optimism about a model’s 
performance in new subjects. Overfitted models will show both poor calibration and poor 
discrimination when validated in new patients. A drop in discriminative ability at external 
validation compared with the development setting can be explained by overfitting. 
In this context, the assessment of model performance has to focus on the accuracy of the 
predictions, rather than merely on the covariate effects and their statistical significance. 
Almost all models are developed in order to predict the outcome of future patients. The 
reasons for predict this outcome, are: 
1. Inform treatment or other clinical decisions for individual patients 
2. To inform patients and their families 
3. To create clinical risk groups for informing treatment or for stratifying patients by 
disease severity in clinical trials. 
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A prognostic model in medicine only has clinical value if it has been shown that predict 
outcome with some success. For all types of validation we need performance criteria in line 
with the research question.  
As the purpose of prognostic statistical models is to identify the combination of risk factors 
that might predict patient survival, a model must be able to: 
1. Make unbiased predictions, that is, make the agreement between observed and 
predicted event rates for group of patients – called calibration 
2. Ability to distinguish between patients who experience or not the event of interest, 
called discrimination 
 
If a predictive model has poor discrimination, no adjustment or calibration can correct the 
model. On the other hand, if discrimination is good, the predictor can be calibrated without 
sacrificing the discrimination.  
Measures of discrimination include the c-index and Negelkerkes’s R2 (Harrell, 2001). The 
c-index is a generalisation of the area under the ROC (receiver operating characteristic) curve 
to the case of censored survival data and is the concordance between the observed and 
predicted survival. C index considers the “concordance” between the ranking of the predicted 
failure times and that of the observed times, for pair of subjects. Calibration may be quantified 
using an estimate of slope shrinkage (Harrell, 2001). 
For a model including covariates with time-dependent effects and/or time-dependent 
covariates, the original definition of C would require the prediction of individual failure time. 
The time-dependent discrimination index, Ctd (Antolini, Boracchi, Biganzoli, 2005) uses the 
whole predicted survival function as outcome prediction, and the ability to discriminate 
among subjects having different outcomes is summarized over time. Therefore, the Ctd index 
can be viewed as a novel definition of concordance, which is: a subject who developed the 
event should have less predicted probability of surviving beyond his/her survival time than 
any other subject who survived longer. Ctd ranges from 0.5 (representing absence of 
discrimination) to 1 as maximum discrimination. 
Calibration can be assessed by plotting the observed proportions of events against the 
predicted probabilities for groups defined by ranges of predicted risk. Perfect predictions 
should be on the 45º line. This plot can be accompanied by the Hosmer-Lemeshow goodness 
of fit test (D’Agostino, Nam, 2004). This test has limited statistical power to assess poor 
Chapter 3 – Study Design for Prediction Models 
72 
calibration and is oversensitive for very large samples. In survival context the calibration of a 
model is usually studied at a fixed time point.  
The calibration plot can be extended into a “validation plot” as a central tool to visualize 
model performance. Calibration is shown by observed outcomes being close to prediction, 
while discrimination aspects can be indicated with the distribution of the predicted 
probabilities. 
An important aspect of prediction is to consider whether a model derived from an analysis 
of the original data set is transportable to similar patients in other locations. This concept is 
usually called generalizability or validity and depends on the quality of the prediction model 
as developed for the development setting and on characteristics of the population where the 
model is applied. A model that passes this test is considered to be validated. This concept can 
be considered at two levels: patients coming from the same population where the model was 
developed (reproducibility) and to patients coming from a different plausibly population 
(transportability). There are some features that the development of a successful model in 
medicine depends on: 
1. The potential for accurate prognosis (which is presumably unknown); 
2. The intrinsic prognosis information in the available factors; 
3. The measurement process, which converts the intrinsic information into numbers; 
A model might fail either because is statistically invalid or because the intrinsic 
prognostic information is weak. There is nothing to do about the last reason for fail. 
Regarding these two types of models fails, there can have two types of validating a clinical 
model: 
1. A statistically validated model, which passes all appropriate statistical checks, 
including goodness-of-fit on the original data and unbiased prediction on a new data set. 
2. A clinically validated model, which performs satisfactorily on a new data set 
according to context-dependent statistical criteria, laid down for it. 
According with these both types of validating a model, it can happen that a statistically 
validated model is not a clinically validated model, or the contrary. However, a clinically 
validated model is more useful than a statistically validated one. 
There are several reasons why prognostic models may not perform well. The first is related 
with deficiencies of standard modelling methods. These methods are used to derive prognostic 
models with data-dependent aspects, leading to an overoptimistic assessment of predictive 
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performance. One problem of the standard modelling method is how to choose the models 
variables. The stepwise selection algorithm for example, is a fully automated procedure that 
doesn’t require intellectual input. It is desirable to use clinical criteria or statistical methods to 
reduce the number of candidate variables, reducing the risk of an overoptimistic model. 
The second reason for a prognostic model not performs well is related with the deficiencies 
in the design of the prognostic studies, which can result in misleading findings, creating over 
optimism and/or bias. These include the absence of clear inclusion or exclusion criteria, as 
what to do with missing data, unclear rationale for the choice of treatments, an inadequate 
sample size and the number of events per variable in the data. 
The third reason for a prognostic model not performs well is that models may not be 
transportable. The main problem for this reason is the degree of dissimilarity between the 
settings of patients in different centres, including differences in healthcare systems, methods 
of measurement and patient characteristics. If the model contains all the important prognostic 
variables, then the model should be transportable to a centre with different setting patients. 
However, if other important variables are not present in the model it can lead to different 
model performances in different centres. 
Here arises the question: How could we validate a model? 
Altman and Royston (Altman, Royston, 2000) considers the following considerations in 
validating a model: 
1. Study design - The model validation should include internal validation temporal 
validation and external validation. The first validation can be made using the data 
splitting methods, cross-validation or bootstrapping. The second one can be processed 
by evaluating the performance of a model on subsequent patients within the same 
centre(s). The last validation is related with the generalizability of the model. The goal 
of this validation is to demonstrate satisfactory performance for patients from a 
different population from the original. 
2. Measuring the intrinsic prognostic information - There are some studies about the 
measurement of the prognostic information of a model. The idea of greater or lesser 
separation between prognostic groups as a measure of prognostic information remains 
attractive, as is interpretable and pragmatic. 
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3. Comparing predictions with observations - It can be said that evaluation consists of 
comparing the appropriate observed and predicted measure, an aspect of model 
calibration. 
4. Quantifying the performance of a model - The performance of a model can’t be 
determined by a statistical criteria, it must be considered the clinical aim, as the 
comparison between predicted and observed probabilities for each patient or the 
difference between observed and predicted probabilities in group level. 
5. Pre-specifying adequate performance - It is helpful to pre-specify adequate 
performance of a model. However it should be remembered that one feature of 
validation is to provide an unbiased estimate of the prediction error of the model. 
Consequently, the measures should be focused on quantifying the performance of a 
model, but ensuring that the final assessment requires clinical judgement and is 
context-dependent. 
When evaluating a model with new data, usually only p-values are calculated and 
frequently it is concluded that validation is satisfactory if there is no significant difference 
between observed and predicted event rates. However, p-values do not provide a satisfactory 
answer. Even if the performance is less good, the model may still be clinically useful. The 
assessment of usefulness of a model requires clinical judgment and depends on context. 
3.5 - Modelling strategy 
Generally, prediction models may be inaccurate due to violation of assumptions, omission 
of important predictors, high frequency of missing data and/or improper methods, and 
especially with small data sets, overfitting.  
Therefore, it is necessary to define a modelling strategy in order to consider the model the 
more accurate as possible. The modelling strategy followed in this thesis is based on a 
previous published methodology (Harrell Jr., Lee, Mark, 1996) and has the following steps: 
 
1. The databases used, for training and validating the model were analysed and 
considered to have accurate and pertinent data, as large as possible. There were 
enough events captured, which are consistent with the minimum considered in 
(Concato John, Peduzzi, Holford, Feinstein, 1995). 
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2. The relevant predictors were found and to enhance the accuracy of the model, the 
number of variables was reduced. Some previously studies demonstrated (Harrell Jr., 
Lee, Mark, 1996) that the number of predictors’ degrees of freedom to fit a prediction 
model must be less than m/10, where m represents the number of event times in the 
training sample. The number of predictors chosen was consistent with this number. It 
was used backward, forward and stepwise variable selection, using also bootstrapping 
techniques. 
3. The relevant predictors were compared with the clinical relevant published predictors, 
in order to verify its consistency. 
4. The missing data in both databases, one to train the model and another one to validate 
the model, was analysed and it was considered that imputation was the best 
methodology to apply. The imputed databases were also studied to verify the variables 
coherency. 
5. The entire sample was used in the model development, using Cox Proportional 
Hazards and PLANN-ARD. Methods such as bootstrap and cross-validation were used 
to test the data set. 
6. The final model developed for both methodologies (Cox Proportional Hazards and 
PLANA-ARD), was validated for discrimination and calibration ability.  
7. An external data set was used were the model was applied and it was also studied its 
ability for discrimination and calibration, in order to validate it. 
8. To both models Cox Proportional Hazards and PLANN-ARD, it was applied different 
stratification methodologies with the objective to separate the risk scores into distinct 
prognostic risk groups. The model was also validated plotting the observed survival 
for each risk group, using KM estimated survival.  
9. The stratification methodologies were applied to the external data set and it was 
validated its ability to separate the risk scores into distinct prognostic risk groups. 
10. The obtained risk groups were compared with the known breast cancer prognostic risk 
groups (NPI, St. Gallen and TNM) with the aim of verifying which stratification 
methodologies are more coherent. 
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Chapter 4 - 
Results 
This chapter reports all results obtained while developing the study of this thesis. First this 
chapter gives a description of the two datasets used for training and external validation, 
respectively, including also the analysis of the missing data and the imputation results. After it 
describes the semi-parametric linear and neural network prognostic modelling methodologies 
and how multiple imputation of missing data is integrated into the non-linear modelling 
methodologies. It is also presented the evaluation of the predictive performance for the two 
alternative models, applied to an external validation data set and both methodologies are 
compared. 
The results for the different proposed stratification methodologies are reported and 
compared in this chapter. In addition the two alternative models followed by the chosen 
stratification methodology results are compared with the existent breast cancer classification 
schemes. An evaluation of the results is also presented, followed by a methodology to provide 
confidence intervals to the individual prognostic predictions. 
4.1 - Databases 
There were used three data sets for this study. They comprise a retrospective longitudinal 
cohort study of post-operative breast cancer female patients. Two of the data sets were 
recruited at Christie Hospital in Wilmslow, near Manchester, where there are patients across 
the range from requiring no adjuvant therapy to receiving aggressive treatment. The first 
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cohort was recruited between 1983-1989 with a total of 917 patients and the second one 
between 1990-1994 with a total of 931 patients. The third data set consists of 4083 females 
from the British Columbia Cancer Agency (BCCA), Vancouver, during 1989-1993. It is 
important to mention that the last mentioned cohort is the same which was used to validate the 
very widely used prognostic model Adjuvant!. The existing patients have early, or operable 
breast cancer, and were selected using the standard TNM (Tumour, Nodes, Metastasis) 
staging system as tumour with maximum diameter less than 5 cm, node stage less than 2 (no 
nodes affected in the axilla or mobile nodes) and without clinical symptoms of metastatic 
spread. The remaining patients were therefore excluded from the study.  
For Christie Hospital data sets there are 16 explanatory variables in each patient record, in 
addition to codes for therapy received and outcome, as we are only interested in the variables 
available after surgery and those that are not related with the treatment. Those related to the 
treatment are of no interest as they contain implicit information about the mortality risk 
analysed by the doctor. Consequently, these variables were not included on the model: 
radiotherapy, adjuvant treatment and surgery. The clinical stage variable derives from 
variables recorded in the dataset, so there would be some collinearity problems if we use it. 
Therefore, this variable has to be also excluded from the study. 
The BCCA data set contains 10 explanatory variables in each patient record, as well as the 
outcome variables. Among the two sets of covariates there are 9 that match with identical 
categorization in both data sets. 
The Christie Hospital data set has one record with a value of Nodes involved recorded in 
category 4. An analysis was carried out to found the sensitivity of the model selection to this 
record and it was found that aggregating this record into category 3 impacted on the statistical 
significance of more than one covariate following stepwise forward model selection with Cox 
regression. It was considered that this might be due to excessive leverage of this case, which 
were therefore treated as outlier and removed from the study. 
The data from Christie Hospital contains a catch-all category labelled ‘others’ for the 
variable Histological Type, which includes also patients with “in situ” tumour. These records 
were excluded from the study because this category of patients has a different disease 
dynamic (Silverstein, Buchanan, 2003), focusing only on the histological types lobular and 
ductal carcinoma. The sample sizes for training and validation data sets were 743 and 4016. 
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Time-to-event (death by any cause) was measured in months from surgery for the Christie 
data set and from date of diagnosis for BCCA. There is an assumption that surgery for BBCA 
data set took place soon after diagnosis.  
The timescale for the study is 5 years of follow-up for the Christie data set and 10 years of 
follow up at the end of which all surviving patients are administratively censored. The 
proportion of cases who were lost to follow-up before the 5 year period elapsed is around 
9.8% for the Christie Hospital data set and 0.1% for the BCCA data set. 
The marginal distributions are represented in tables Table 4.1, Table 4.2 and Table 4.3. 
 
Variable 
description Categories 
Frequency 
Christie 
Hospital 83-
89 
% Freq. BCCA % 
Frequency 
Christie 
Hospital 90-
94  
% 
1 20-39 81 9 278 7 62 7 
2 40-59 430 47 1676 42 345 48 Age category 3 60+ 406 44 2062 51 336 45 
1 Invasive ductal 724 79 3688 92 632 85 
2 Invasive lobular/lobular in situ 95 10 328 8 111 15 Histological 
type 
3 
In situ/ mixed/ 
medullary/ ucoid/ 
papillary/ tubular/ 
other mixed in situ 
98 11 - - - - 
1 Pre-Menopausal 289 31 1141 28 203 27 
2 Peri-Menopausal 47 5 5 0 27 4 
3 Post-menopausal 581 63 2758 69 513 69 
Menopausal 
Status 
9 Missing 0 0 112 3 0 0 
1 Well differentiated 33 4 388 10 106 14 
2 Moderately differentiated 118 13 1772 44 298 40 
3 Poorly differentiated 89 10 1464 36 194 26 
Histological 
Grade 
9 Missing 677 74 392 10 145 20 
1 
Positive status of 
lymphatics, veins and 
nerves 
  1461 36   
2 
Negative status of 
lymphatics, veins and 
nerves 
- - 2323 58 - - 
8 Not applicable   21 1   
Ivn 
9 Missing   211 5   
1 0 194 21 2622 65 377 51 
2 1-3 167 18 999 25 184 25 
3 4+ 50 6 389 10 97 13 
4 98 (too many to 
count) 1 0 - - - - 
Nodes 
involved 
9 Missing 505 55 6 0 85 11 
Table 4.1 – Variables’ description and marginal distributions. 
These are for Christie Hospital and BCCA data set. 
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Variable 
description 
Categories Frequency 
Christie 
Hospital 83-
89 
% Freq. BCCA % 
Frequency 
Christie 
Hospital 90-
94 
% 
1 0-9 725 79 1719 43 233 31 
2 10-19 111 12 1891 47 356 48 
3 20+ 59 6 292 7 139 19 
4 98(too many to 
count) 14 2 0 0 12 2 
Nodes 
removed 
9 Missing 8 1 114 3 3 0 
1 0-20% 256 28 3219 80 540 73 
2 20-40% 18 2 320 8 28 4 
3 40-60% 40 4 163 4 50 7 
4 60+% 98 11 200 5 39 5 
Nodes Ratio 
9 Missing 505 55 114 3 86 11 
1 <2 cm 383 42 2170 54 413 56 Pathological 
Size 2 2-5 cm 534 58 1846 46 330 44 
1 0-10 242 26 892 22 145 20 
2 10+ 434 47 2352 59 262 35 Oestrogen 
9 Missing 241 26 772 19 336 45 
1 0 734 80 634 85 Clinical 
stage 2 1 183 20 - 109 15 
1 Upper outer 442 48 376 51 
2 Lower outer 102 11 90 12 
3 Upper inner 231 25 104 14 
4 Lower inner 77 8 59 8 
5 Subareolar 56 6 43 6 
Predominant 
site 
9 Missing 0 1 
- 
71 9 
1 Right 427 47 361 49 Side 2 Left 490 43 - 382 51 
1 <2 cm 206 23 207 28 
2 2-5 cm 683 75 381 51 
3 5+ cm 2 0 1 0 
Maximum 
diameter of 
tumour 
 9 Missing 26 3 
- 
154 21 
1 T1(tumour <2 cm) 213 23 357 48 Clinical 
stage tumour 2 T2(2-5 cm) 704 77 - 386 52 
1 
N0 (no nodes found 
clinically, or node 
negative by 
histological type) 
734 80 627 84 
Clinical 
stage nodes 
2 
N1(ipsilateral and 
mobile axillary 
nodes) 
183 20 
- 
116 16 
1 BCS + RT 2086 52 
2 BCS, no RT 0 0 
3 Total mastectomy+RT 380 9 
Local 
treatment 
4 Total mastectomy,no RT 
- 
1550 39 
- - 
 
Table 4.2 – Continuation of variables’ description and marginal distributions. 
These are for Christie Hospital and BCCA data sets. 
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Variable 
description Categories 
Frequency 
Christie 
Hospital 83-
89 
% Freq. BCCA % 
Frequency 
Christie 
Hospital 90-
94 
% 
0 None 736 80 1812 45 306 42 
1 Hormone alone 137 15 1232 31 345 46 
2 Chemo alone 44 5 607 15 91 12 
Sys 2 
(Adjuvant 
Systemic 
treatment) 3 
Combined hormone 
and 
Chemo treatment 
0 0 365 9 1 0 
1 None 0 0 1 0 
2 Incision Biopsy 0 0 0 0 
3 Excision Biopsy 349 38 98 13 
4 Simple Mastectomy 383 42 18 3 
5 Radical Mastectomy 157 17 9 1 
6 Wide local excision + axillary clearance 4 0 269 36 
7 Radical Mastectomy + axillary clearance 24 3 304 41 
8 
Surgery after neo 
adjuvant 
chemotherapy 
0 0 43 6 
Surgery 
9 Missing 0 0 
- 
1 0 
1 No 572 62 361 49 
2 Yes 345 38 379 51 Adjuvant Radiation 3 Missing 0 0 
- 
3 0 
Events at 5 years follow up 
(Overall mortality) 
377 41 555 14 115 16 
Total of records 917 4016 743 
Table 4.3 – Continuation of variables’ description and marginal distributions. 
These are for Christie Hospital and BCCA data set. 
 
The missing values in the data sets are an important issue to consider and should be 
analysed and explained, specially the changes from Christie Hospital 1983-1989 data set to 
Christie Hospital 1990-1994 data set.  
Looking at the marginal distributions of Christie Hospital data set, acquired from 1983-
1989, it can be analysed that there is a high number of missingness for Histological grade and 
Nodes involved variables, because it wasn’t usual to acquire these variables. The proportion of 
Christie Hospital missing data increased in time for Oestrogen (19%), Predominant Site (8%) 
and Maximum tumour diameter (18%). On the other hand, the proportion of Christie Hospital 
missing data of Histological grade (54%), Nodes involved (44%) and Nodes ratio (44%) has 
decreased in time (comparing both Christie Hospital data bases).  
Nodes ratio missingness have a similarity of 99,4% with Nodes involved missingness. This 
missingness is related with the category 1 of Nodes removed variable. Nodes involved missing 
can potentially be explained by the fact that there were so few nodes to measure for each 
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patient that it wasn’t really measured. The category 1 of nodes removed can also represent 
that no nodes were actually removed. 
As one of the main objectives of this study is to make a predictive model using the Christie 
Hospital 1990-94 data set and validate it using the BCCA data set, the marginal distribution 
for each variable and for both data sets should be analysed and compared. Considering that 
there is not a similarity on variables’ marginal distribution for differences higher than 10%, 
the variables that can be considered less similar are Histological grade, Nodes involved, 
Nodes removed and Oestrogen. The higher difference is observed for Oestrogen category 2 
and 9, with differences of 24 and 26% respectively. Analysing the Oestrogen survival curves 
for Christie 1990-94 data set, it can be observed that the missing values are related with a 
good outcome, and with a similar survival curve to category 2. With that assumption, the 
Oestrogen marginal distribution in both data sets would be very similar. 
Analysing the missing values for both data sets it can be observed that for Nodes involved 
and Histological grade variables, there is respectively 11% and 10% more missing in Christie 
Hospital 1990-94 data set than on the BCCA data set. Nodes involved and Nodes ratio 
missingness is related with a good outcome (as category 1). Therefore, these records could be 
considered on category 1. Substituting the missing records as proposed, the marginal 
distribution between both data sets for these variables will be more similar.  
Histological grade has 10% more of missing in Christie Hospital 1990-94 data set than for 
the BCCA data set. Looking at survival curves, this missingness is related with categories 2 
and 3 of histological grade, which means that if these values were distributed between both 
histological grade categories, there is a higher frequency similarity between both data sets. 
Concluding, the marginal distributions for each covariate in both data sets, Christie 
Hospital 1990-94 and BCCA are remarkably consistent, except for the occurrence of missing 
values. Therefore, the patients in both data sets have potentially the same profile, which is 
good for the purpose of this study. 
Moreover, the KM curves from both data sets, Christie Hospital 1990-1994 and BCCA 
were analysed in order to verify the consistency of clinical profiles. It was observed that the 
Nodes ratio, Oestrogen, Histological Grade KM curves are very similar for both data sets, but 
almost all the categories have a lower survival in Christie Hospital data set. For Nodes 
involved and Nodes removed the main difference between both KM curves lies in the missing 
category. Analysing both data sets’ Histological type and Pathological size KM curves, it can 
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be concluded that they are very similar. Looking at Age and Menopausal status KM curves it 
can be observed that there are some differences on their shape, for both data sets. With all 
these evidences it can be suggested that patients survival from both data sets, over the 5 years 
follow-up are highly related. 
4.2 - Analysis of variables’ missingness  
Frequently, data on prognostic factors are missing for some patients. There are three main 
strategies for managing incomplete data: a new attribute may be created to denote missing, the 
missing values can be imputed, or the cases with missing values can be removed from the 
study. The latest strategy is the most widely used when modeling clinical data.  
The BCCA data has a total of 4016 subjects. Excluding all missing records it will remain 
2685 (411 deaths) of them, which is 67% of the entire data set. Excluding all missing records 
from Christie Hospital data set, from 1990-1994, which has 743 patients it would remain 265 
(44 deaths) records, which is 36% of the whole data set and. If all of these missing records 
were excluded, valuable data would be wasted and modelling could lead to invalid results if 
the excluded group is a selective subset from the entire sample in respect to prognosis.  
It exists several approaches for dealing with incomplete covariates in survival analysis. 
However, these methods all rely on the assumption that non-response probabilities do not 
depend on any unobserved information, that is, the data are missing at random (MAR). This 
property was looked for evidence in both data sets. Assessing associations between missing 
data and observed variables within our data sets made this evidence. While the relation 
between missing data and the outcome was explored using the Kaplan-Meier curves for each 
explanatory variable, the relationship between missing and other variables was measured 
using univariate and multivariate logistic regressions. KM curves were analysed, using the 
event of interest death attributed to any cause other than breast cancer and a follow up of 5 
years. 
4.2.1. Christie Hospital data set Missingness 
For Christie Hospital 1990-94 data set, the variables that have missing values are 
Maximum Tumour Diameter, Nodes ratio, Nodes involved and Oestrogen, Histological grade, 
Nodes removed and Predominant site, and its KM curves are represented in Figure 4.1. These 
variables were analysed and it was concluded that the missing values for Maximum Tumour 
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Diameter, Nodes ratio, Nodes involved and Oestrogen are related with a better prognosis, 
suggesting that eliminating the patients with these missing values would lead to an 
underestimate of the true survival of the cohort. The opposite effect was seen for Predominant 
site. 
 
 
 
 
 
Figure 4.1 – KM curves for Christie Hospital 1990-94 data set variables’.  
The top pictures represent the KM curves for Maximum Tumour Diameter, Nodes ratio and Nodes 
involved variables, respectively from left to right. The bottom pictures represent the KM curves for 
Oestrogen, Histological grade and Predominant site variables, respectively from left to right. Missing 
is labeled as number 9 for all variables. 
 
In addition, the values of the potential prognostic factors for Christie Hospital data set can 
be related with the missingness of those factors. Looking at the cross-tabulations between the 
prognostic variables it can be seen that the missingness of Oestrogen is highly correlated with 
Nodestage categorized as 1, and the missingness of Maximum Tumour Diameter is highly 
correlated with Pathological Size equals caterorized as 1. It is known by the KM curves that 
the category 1 of Nodestage and Maximum Tumour Diameter variables’ are related with a 
good survival. Consequently, once again it is concluded that the missingness of Oestrogen 
and Maximum Tumour Diameter variables’ are both related with a good survival. 
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  Nodestage 
  1 2 Total 
1 112 33 145 
2 212 50 262 
O
es
tr
og
en
 
Missing 303 33 336 
 Total 627 116 743 
 
Table 4.4 – Cross tabulations between some Christie Hospital variables. 
The left table represents Nodestage and Oestrogen variables and the right table Maximum Tumour 
Diameter and Pathological Size. 
 
The same analysis was made, for comparing Nodes ratio with Oestrogen, Node ratio with 
Histological grade and Node ratio with Maximum Tumour Diameter. It was concluded that 
the missingness of Oestrogen, Histological grade and Maximum Tumour Diameter are all 
related with both category 1 and missing of Node ratio. Despite this fact, it was concluded 
that these patients are not the same, as it can be observed in the following figure, where the 
missing values for Oestrogen and Histological Grade are split into the diverse categories of 
Maximum Tumour Diameter variable (Figure 4.2 ). 
 
  
Figure 4.2 – Bar chart comparing the frequency of the categories for different variables. 
These variables are Oestrogen, Histological grade, Maximum tumour diameter and Nodesratio  from 
the Chrisite Hospital data set. 
 
Univariate and multivariate logistic models were performed for Christie Hospital 1990-
1994 data set, considering the outcome missing or non-missing of a variable, with the purpose 
of demonstrate if the missingness of potential prognostic factors are associated with other 
potential prognostic factors and auxiliary variables. 
  Pathological size 
  1 2 Total 
1 168 39 207 
2 115 266 381 
3 0 1 1 
M
ax
im
um
 
T
um
ou
r 
D
ia
m
et
er
 
Missing 130 24 154 
 Total 413 330 743 
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There are a number of additional variables that were not considered as factors in prognostic 
studies, but were potentially associated with missing data, such as surgery, adjuvant radiation 
and adjuvant treatment. Table 4.5 reflects the associations between missingness and other 
potential prognostic factors and auxiliary variable. In Table 4.5  it can be seen that tumour 
stage and surgery are associated with the missingness of all but one prognostic variables, 
looking at the p-values (p-value < 0.05) and to the regression coefficients of each univariate 
logistic regression. The missingness of Oestrogen is associated with almost all variables.  
With this it can be concluded that there is evidence that missingness in Christie Hospital 
data set is missing at random. The associations found with the multivariate logistic 
regressions were expected, and there is no evidence to exclude the MAR assumption. 
  Missingness of 
  Histological Grade Oestrogen Nodes ratio 
Maximum 
Tumour Diam 
Predominant 
Site Nodes Involved
Adjuvant 
Treatment p-value: 0.9944 
2.068;0.957;1.533
;1.347;-12.36; 
16.080.88;-12.36 
p-value: 0.0012 
p-value: 0.3636 p-value: 0.0737  
3.408;5.339;4.797; 
-6.209;-6.728;     
-6.728; 5.815; -
6.49 
p-value: 0.0003 
p-value: 0.3911
Adjuvant 
Radiation 
4.462; 3.755 
p-value: 0.0010 
-0.161;0.488 
p-value: <0.0001 p-value: 0.0769 
3.793;4.435 
p-value: 0.0027 p-value: 0.0546 p-value: 0.0930
Surgery 
11.22;-3.44;-2.977; -
3.218; -4.425; -
3.287;-4.553 
p-value: 0.0072 
-13.21;1.5;         
-0.22;0.23;-0.17;   
-0.634;-0.723 
p-value: <0.0001 
-4.844;10.791; 
8.673;-5.086;-
5.14;3.653;-5.13 
p-value:<0.0001 
-9.288;4.347; 
2.349;3.176; 
2.952;2.652; 3.099
p-value:<0.0001 
p-value: 0.7389 
-4.841;10.741;  
8.687;-5.093;    
-5.143;3.666;-
5.132 
p-value:<0.0001
Histological 
Grade - 
0.489;-0.042 
p-value: 0.0007 
1.498;0.132 
p-value:<0.0001 
0.669;-0.0039 
p-value:<0.0001 p-value: 0.1601 
1.466;0.149 
p-value:<0.0001
Age p-value: 0.1843 p-value: 0.1769 p-value: 0.1179 p-value: 0.2561 p-value: 0.0751 p-value: 0.1247
Histological 
Type 
-3.0179 
p-value: <0.0001 p-value: 0.3211 p-value: 0.1839 p-value: 0.4477 
0.5772 
p-value: 0.0280 p-value: 0.1648
Max. Tum. 
Diameter p-value: 0.9992 
4.308;3.588 
p-value: 0.0003 
3.959;2.836 
p-value: 0.0012 - p-value: 0.0782 
3.96;2.825 
p-value: 0.0012
Menopausal 
status p-value: 0.5264 
-0.3702;0.345 
p-value: 0.0368 
-0.542;0.146 
p-value: 0.0148 
-1.0875;0.4271 
p-value:<0.0001 p-value: 0.4265 
-0.54;0.153 
p-value: 0.0165
Manchester 
stage p-value: 0.0797 
0.4494 
p-value: <0.0001 
0.836 
p-value: 0.0051 
1.4128 
p-value:<0.0001 p-value: 0.1258 
0.8337 
p-value: 0.0052
Nodes 
Involved p-value: 0.0678 
0.645;-0.126 
<0.0001 p-value: 0.9962 
0.7096;-0.4155 
p-value:<0.0001 
-0.1026;0.6694 
p-value: 0.0048 - 
Nodes 
Removed p-value: 0.1470 
0.722;-0.228;-0.399
p-value: <0.0001 p-value: 0.9989 
0.379;-0.434;-0.118
p-value: 0.0012 p-value: 0.1618 p-value: 0.9989
Node ratio -0.512;0.2634;0.1337 p-value: 0.0488 
0.641;-0.419;-0.166
p-value: 0.0041 - 0.0775 p-value: 0.8871 p-value: 1 
Node stage p-value: 0.0617 0.423 p-value: 0.0001 
0.7191 
p-value: 0.0059 
1.0873 
p-value:<0.0001 p-value: 0.2919 
0.7165 
p-value: 0.0061
Oestrogen p-value: 0.1430 - p-value: 0.4797 p-value: 0.3585 p-value: 0.3405 p-value: 0.4797
Side p-value: 0.0514 p-value: 0.285 p-value: 0.2732 p-value: 0.1393 p-value: 0.5323 p-value: 0.3286
Site p-value: 0.9202 p-value: 0.3189 p-value: 0.7555 p-value: 0.1051 - p-value: 0.7052
Pathological
Size p-value: 0.9111 
0.6464 
p-value: <0.0001 
0.8277 
p-value:<0.0001 
0.8838 
p-value:<0.0001 p-value: 0.8934 
0.8209 
p-value:<0.0001
A
ss
oc
ia
tio
n 
w
ith
 
Tumour 
stage p-value: 0.8053 
0.6352 
p-value: <0.0001 
0.7854 
p-value:<0.0001 
1.8174 
p-value:<0.0001 
0.3127 
p-value: 0.0147 
0.7776 
p-value:<0.0001
Table 4.5 – Missingness associations for Christie Hospital data set. 
These associations are between missingness and other potential prognostic factors and auxiliary 
variables for Christie Hospital 1990-94 data set. The values represent the regression coefficients and 
the p-values based on a log-rank test for survival distributions in missing and non-missing groups. 
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4.2.2. BCCA data set Missingness 
It is also essential to conclude about the type of missing mechanism in BCCA data set. In 
BCCA data set, an analysis of the KM curves of each prognostic variable (Figure 4.3 ) with 
missing data has shown that those patients missing Menopausal status, Nodes removed, Node 
ratio and Oestrogen had a better prognosis, suggesting that eliminating the patients with 
missing values would lead to an underestimate of the true survival of the cohort. The opposite 
effect was seen for Nodes involved. An analysis of the survival distributions of non-missing 
and missing data within Ivn and Histological grade factors, showed no visual of significant 
differences. 
 
  
 
   
Figure 4.3 – KM curves BCCA data set variables’.  
The top pictures represent the KM curves for Menopausal status, Histological grade and Nodes ratio, 
respectively from left to right. The bottom pictures represent the KM curves for Oestrogen, Nodes 
involved and Nodes removed, respectively from left to right. Missing is labeled as number 9 for all 
variables. 
 
Cross-tabulations were used to conclude about the relation between the existing missing of 
the variables with the other variables. The patients, who have missing values on Nodes 
Involved and Nodes Removed variables, have also on Nodes ratio variables, as this was 
computed from the previous two referred variables. The missing values at Oestrogen, Ivn and 
Menopausal Status are related with categories 1 and 2 of Nodes Removed variable. However, 
as can be observed on the following figures (Figure 4.4), these patients are not the same. 
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Figure 4.4 – Bar chart comparing the frequency of the categories for different variables.  
These variables are Oestrogen, Menopausal status, Ivn and Nodes removed from BCCA data set. 
 
  Missingness of 
  Menopausal status 
Nodes ratio Histological 
Grade Ivn 
Nodes 
involved 
Nodes 
removed Oestrogen 
Sys2 
-0.2839;        
   -0.898;0.545 
p-value:<0.0001
0.478;0.129; 
-0.5621 
p-value: 0.0222 
0.104;0.484;   
 -0.3562 
p-value:<0.0001
-0.058;0.474;-
0.388 
p-value:0.0004
p-value:0.1795
0.478;0.129;    
 -0.562 
p-value:0.0222 
0.748;-0.185; -0.22
p-value:<0.0001
Local p-value:0.9732 0.399;-0.274 p-value: 0.0202 
-0.387;0.119 
p-value:<0.0001
-0.55;0.36 
p-value:<0.0001
-1.266;1.542 
p-value: 0.0230
0.399;-0.234 
p-value: 0.0202 
0.28;-0.386 
p-value: 0.0001 
Age category 0.2745;1.1188 p-value:<0.0001 p-value: 0.1273 
-0.714;0.124 
p-value:<0.0001
-0.317;-0.114 
0.0005 p-value: 0.5814 p-value: 0.1273 
-0.431;0.288 
p-value: 0.0008 
Histological 
type p-value: 0.7655 
p-value: 0.3514 -0.3474 
p-value:<0.0001 p-value: 0.9523 p-value: 0.9747 p-value: 0.3514 p-value: 0.2456 
Menopausal 
status - 
 
p-value: 0.8424 
-0.986;1.3365 
p-value:<0.0001
-0.909;1.129 
0.0005 p-value: 0.8021 p-value: 0.8424 p-value: 0.7501 
Histological 
Grade p-value: 0.3209 
p-value: 0.2020 - p-value: 0.0905 p-value: 0.3686 0.2020 0.445;-0.0224 <0.0001 
Ivn p-value: 0.7123 p-value: 0.0779 -0.3824;-0.523p-value: 0.016 - p-value: 0.6350 p-value: 0.0779 
-0.378;0.314 
p-value:<0.0001
Nodes 
involved p-value: 0.1123 
0.902;-0.518 
p-value:<0.0001 p-value: 0.9987
-0.421;0.116 
0.0001 - 
0.902;-0.518 
p-value:<0.0001 
0.549;-0.169 
p-value:<0.0001
Nodes 
removed p-value: 0.5268 
 
p-value: 1 p-value: 0.2028
1.058;0.854 
0.0061 p-value: 1 - p-value: 0.3123 
Nodes Ratio p-value: 0.5226 
- 
p-value: 0.4626
-0.534;0.207; 
0.067 
p-value:<0.0001
p-value: 1 p-value: 1 
0.503;-0.089;  -
0.23 
<0.0001 
Pathological 
size p-value: 0.4990 
p-value: 0.2233 p-value: 0.3825 p-value: 0.6715 p-value: 0.1056 p-value: 0.2233 0.5322 p-value:<0.0001
A
ss
oc
ia
tio
n 
w
ith
 
Oestrogen p-value: 0.3442 p-value: 0.1337 0.2882 p-value:<0.0001 p-value: 0.2123 p-value: 0.5363 p-value: 0.1337 - 
Table 4.6 – Missingness associations for the BCCA data set. 
These associations are between missingness and other potential prognostic factors and auxiliary 
variables for BCCA data set. The values represent the regression coefficients and the p-values based 
on a log-rank test for survival distributions in missing and non-missing groups. 
  
Table 4.6 reflects the associations between the missingness of some variables with other 
potential prognostic factors and auxiliary variable for BCCA data set. The dependent variable 
is, in this analysis, the presence or absence of missing and for each prognostic factor, it can be 
observed if it is associated with other potential prognostic factors and auxiliary variables. 
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Table 4.6 shows that Sys2 (Adjuvant systemic treatment) and Local (local treatment) are 
associated with missingness of all but one prognostic variable, looking at the p-values (p-
value < 0.05) and to the regression coefficients of each univariate logistic regression. This 
relation is expected, because these are auxillary variables related with patients’ treatment, 
which must be related with patients’ covariates. It can be seen in this table that there is at least 
one variable that is related with the missing of a prognostic factor. As a conclusion, there is 
evidence that missing mechanism in BCCA data set is missing at random (MAR). The 
associations found with the multivariate logistic regressions were expected and there is no 
evidence to exclude the MAR assumption. 
4.3 - Imputation results 
Whereas creating an attribute for ‘missing’ can be effective and has been successfully used 
in earlier studies with the Christie data set e.g. (Lisboa, Wong, Harris, Swindell, 2003), the 
structure of ‘missingness’ may be different in the external validation data from that in the 
modelling data. This is partly indicated by the markedly different prevalence of missing in the 
two data sets. Moreover, inferences made for individual patient cases in the future cannot 
make assumptions relating to the distribution of ‘missingness’ in the original modelling data.  
For these reasons, as well as the assumption of MAR evidence in the presented databases, 
missing data were imputed following the practice indicated in Chapter 3. Simulations studies 
have shown that the required number of repeated imputations m can be as low as three for 
data with 20% percent of missing data (Van Buuren, Boshuizen, Knook, 1999).  
In this study, the variables which have the higher values of missing, are Oestrogen (with 
19% for BCCA data set and 45% for Christie Hospital data set) and Histological Grade (with 
10% for BCCA data set and 20% for Christie Hospital data set).  Therefore, 10 different 
imputations were applied, which is a conservative choice, because unless rates of missing 
information are unusually high, there is little or no practical benefit to use more than 10 
imputations (Schafer, 1999). It has been found that in the presence of large amounts of 
missing data, convergence can be obtained in as few as 10 iterations, which was the number 
of iterations used in this study (Van Buuren, Boshuizen, Knook, 1999). In fact, the marginal 
distributions following imputation with 10 and 20 iterations matched very well, with a 
difference by category generally less than 1% and never greater than 2% of the population for 
Christie Hospital data set, as it can be observed in Table 4.7. The complete summary statistics 
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for the datasets with imputed data for Christie Hospital 1990-94 and BCCA data sets are 
shown in Table 4.8. 
For both data sets, the prevalence (%) of prognostic factors in the original data sets 
(ignoring missing data) were consistent with those from the 10 imputations. The BCCA 
ranges of imputation values for each potential prognostic variable are very narrow, which 
suggests that the distributions for each of the potential prognostic factors in the 10 imputed 
data sets are very similar. The Christie Hospital, has higher ranges of imputation values, 
which is the result of a very high missing values for some covariates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7 – Results of the missing data imputation with 10 and 20 iterations. 
 
 
 
 
  Christie Hospital 1990-94 completed 
data set (10 iterations) 
Christie Hospital 1990-94 completed 
data set (20 iterations) 
Differences 
Variables Mean # Median Range % Mean # Median Range % % 
1 151 144 119-219 20 147 139 114-200 20 0 
2 387 393 318-416 52 390 397 341-422 52 0 
3 205 206 197-208 28 206 205 202-210 28 0 
Hist. 
Grade 
9 - - - - - - - - - 
1 572 579 540-616 77 560 557 540-593 75 2 
2 60 55 28-110 8 61 45 28-110 9 1 
3 59 53 50-89 8 67 54 50-116 9 1 
4 52 43 39-98 7 56 42 39-123 7 0 
Nodes 
ratio 
9 - - - - - - - - - 
1 428 433 377-462 58 429 450 379-459 58 0 
2 210 227 184-237 28 212 212 186-266 28 0 
3 105 99 97-130 14 102 99 97-137 14 0 
Nodes 
involved 
9 - - - - - - - - - 
1 233 233 233-234 31 233 233 233-234 31 0 
2 357 357 356-358 48 357 357 356-358 48 0 
3 140 140 139-142 19 140 140 139-142 19 0 
4 12 12 12-13 2 13 13 12-14 2 0 
Nodes 
removed 
9 - - - - - - - - - 
1 240 247 226-275 33 253 255 234-274 34 1 
2 495 496 467-517 67 490 489 469-509 66 1 Oestrog. 
9 - - - - - - - -  
1 423 425 411-430 57 417 423 396-429 56 1 
2 99 97 93-114 13 99 97 91-112 13 0 
3 111 110 106-125 15 114 111 105-132 15 0 
4 65 66 60-68 9 65 67 59-69 9 0 
5 45 45 43-47 6 48 47 43-65 6 0 
Site 
9 - - - - - - - - - 
1 271 265 222-345 36 261 260 235-287 35 1 
2 428 424 388-470 58 429 424 407-479 58 0 
3 44 40 2-112 6 53 60 10-82 7 1 
Max. 
Tumour 
Diam. 
9 - - - - - - - - - 
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 BCCA 
Original 
data set 
BCCA Completed data set Christie 
Hospital 
1990-94 
original 
data set 
Christie Hospital 1990-94 
completed data set 
Variables # % Mean 
# 
Median Range % # % Mean 
# 
Median Range % 
1 1141 29 1204 1205 1197-1209 30 - - - - - - 
2 5 0 5 5 5-5 0 - - - - - - 
3 2758 71 2808 2807 2802-2814 70 - - - - - - 
Menop. 
status 
9 112 0 - - - - - - - - - - 
1 1461 38 1547 1546 1541-1555 38 - - - - - - 
2 2323 61 2443 2445 2437-2451 61 - - - - - - 
8 21 1 36 26 23-29 1 - - - - - - Ivn 
9 211 0 - - - - - - - - - - 
1 388 11 461 460 445-485 12 106 18 151 144 119-219 20
2 1772 49 1944 1945 1926-1958 48 298 50 387 393 318-416 52
3 1464 40 1611 1613 1596-1624 40 194 32 205 206 197-208 28
Hist. 
Grade 
9 392 0 - - - - 145 0 - - - - 
1 3219 83 3248 3239 3219-3323 81 540 82 572 579 540-616 77
2 320 8 369 366 320-430 9 28 4 60 55 28-110 8 
3 163 4 168 165 163-195 4 50 8 59 53 50-89 8 
4 200 5 231 203 200-306 6 39 6 52 43 39-98 7 
Nodes 
ratio 
9 114 0 - - - - 86 0 - - - - 
1 2622 65 2623 2623 2622-2624 65 377 57 428 433 377-462 58
2 999 25 1004 1004 1003-1005 25 184 28 210 227 184-237 28
3 389 10 389 389 389-389 10 97 15 105 99 97-130 14
Nodes 
involved 
9 6 0 - - - - 85 0 - - - - 
1 1719 44 1803 1807 1771-1814 45 233 39 233 233 233-234 31
2 1891 49 1907 1904 1895-1946 48 356 43 357 357 356-358 48
3 292 7 306 307 299-310 7 139 16 140 140 139-142 19
4 0 0 0 - 0 0 12 2 12 12 12-13 2 
Nodes 
removed 
9 114 0 - - - - 3 0 - - - - 
1 892 27 1098 1093 1080-1128 27 145 36 240 247 226-275 33
2 2352 73 2918 2923 2888-2936 73 262 64 495 496 467-517 67Oestrog. 
9 772 0 - - - - 336 0 - - - - 
1 - - - - - - 376 56 423 425 411-430 57
2 - - - - - - 90 13 99 97 93-114 13
3 - - - - - - 104 16 111 110 106-125 15
4 - - - - - - 59 9 65 66 60-68 9 
5 - - - - - - 43 6 45 45 43-47 6 
Site 
9 - - - - - - 71 0 - - - - 
1 - - - - - - 207 35 271 265 222-345 36
2 - - - - - - 381 65 428 424 388-470 58
3 - - - - - - 1 0 44 40 2-112 6 
Max. 
Tumour 
Diam. 
9 - - - - - - 154 0 - - - - 
Table 4.8 –  Missing data imputated compared with original data for both data sets.  
Modelling using Cox proportional hazards and its validation 
An analysis was carried out to verify if the prognostic factors survival distributions were 
consistent for each imputed data set. It was concluded that all the distributions were very 
similar between them and with the original data set (ignoring the missing data), which means 
that the imputation methodology was successfully applied. It can therefore be concluded that 
the survival curves for imputed data are very well defined for all 10 imputations. 
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The purpose of this modelling is to identify a model, which predicts the overall survival for 
the Christie Hospital 1990-94 data set and validate this model using the BCCA data set. As 
previously identified there are 9 explanatory variables with identical categorization that match 
in both data sets. Consequently, there is a subset of 9 variables that can be used to predict 
survival. These variables are Age, Histological type, Menopausal status, Histological Grade, 
Nodes Involved, Nodes Removed, Nodes Ratio, Pathological Size and Oestrogen.  
All the analysis were performed and implemented in SAS software (SAS software).  
4.3.1. Modelling breast cancer overall mortality using Cox proportional hazards 
The event of interest used in this model was death attributed to any cause, with 5 years of 
follow-up. It is firstly necessary to identify the variables that predict better the breast cancer 
overall mortality for Christie Hospital, in order to simplify the prognostic model and enhance 
its accuracy. 
Firstly the analysis was developed using the missing values as a different attribute. A 
preliminary model selection with a proportional hazards model was fitted, following a 
forward selection stepwise procedure, applying Akaike’s information criterion (using a 95% 
significance level to enter in the model and 99% significance level to leave the model). This 
model has selected 6 explanatory variables: Age category, Histological type, Histological 
grade, Nodes ratio, Oestrogen and Pathological size.  
The same model selection methodology was applied to the 10 imputed data sets, and the 
above six variable model were selected 6 times out of 10. This means that, not only the 
imputation is consistent, but also these variables predict survival well. 
The event of interest, death attributed to any cause, can be divided in death caused by 
breast cancer and caused by other causes, where two models can be fitted, using the same 
parameters as before, in order to identify which variables are related with which events of 
interest. These two models were fitted using the same procedure as before and considering 
missing as a different attribute. It was found that for the model which event of interest is death 
due to breast cancer specificity, 5 explanatory variables were selected: Nodes ratio, 
Oestrogen, Histological grade, Histological type and Pathological size. The model with the 
events related with other causes of dead it was selected Age category variable as the only 
variable that predicts survival. Therefore, it can be concluded that the variables selected with 
stepwise procedure for overall mortality are the same if the two previous models are joined. 
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This result can suggest that the other causes of death are related with very high age and 
with the treatments as well. As it can be seen in Table 4.9  these events are related with the 
higher age category; with adjuvant radiation equals to 1 and adjuvant treatment equals to 1 
and 3. With these results it can be concluded that other causes of death is related with elderly 
people, as the treatments are not existent or are the less aggressive ones. This means that these 
patients are not dying due to the applied treatment. 
Variables Categories 
Number of deaths 
attributed to other 
than breast cancer 
1 20-39 1 
2 40-59 4 Age 
3 60+ 17 
1 No 19 
2 Yes 3 Adjuvant radiation 3 Missing 0 
0 None 9 
1 Hormone alone 11 
2 Chemo alone 2 Adjuvant treatment 
3 Combined hormone and Chemo treatment 0 
Table 4.9 – Relation between the event other causes of death and some variables.  
The automatic routines have a number of disadvantages as they lead to the identification of 
a one particular subset and they depend on the stopping rule to determine whether a term 
should be included in or excluded from a model. The chosen variables must be carefully 
analysed in order to substitute, remove or introduce any variable. Therefore, there are some 
methods that help to obtain nearly unbiased models, such as data-splitting, cross-validation 
and bootstrapping. The last method used the entire dataset for model development. 1000 
bootstrap re-samples were applied to the Christie Hospital 1990-94 data set with missing 
coded as a separate attribute and a 100 bootstraps were applied to each of the 10 imputed 
missing data set. Variable selection was repeated for each sample using the same stopping 
rule as previously, following a forward selection stepwise procedure and applying Akaike’s 
information criterion (using a 95% significance level to enter in the model and 99% 
significance level to leave the model). The 10 most chosen models examples are shown in 
Table 4.10  
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Most chosen 
model 
Nm. of times 
chosen 
Missing coded as a 
different attribute 
Nm. of times 
chosen 
Imputed data 
sets 
1 95 1,2,3,4,7,8,9 62 1,2,3,4,7,8,9 
2 85 1,2,3,4,6,8,9 60 1,2,3,4,7,8 
3 71 1,2,3,4,6,7,8,9 42 1,2,3,4,6,7,8,9 
4 65 1,2,3,4,7,8 39 1,3,4,6,7,8,9 
5 61 1,2,3,4,6,8 31 2,3,4,6,7,8,9 
6 55 1,2,3,4,5,6,8,9 30 2,3,4,7,8 
7 47 1,2,3,4,6,7,8 30 2,3,4,6,7,8 
8 46 1,2,3,4,8,9 29 
1,2,3,4,5,6,7,8
,9 
9 40 1,2,3,4,8 28 1,3,4,7,8 
10 31 1,2,3,4,5,6,7,8,9 28 1,3,4,6,7,8 
Table 4.10 – Models chosen using the bootstrapping ordered by their frequency.  
The model characterized in green represents the model chosen with missing as a different attribute 
with the stepwise procedure. 
Legend: 1-Oestrogen; 2- Histological grade; 3- Histological type; 4 - Node ratio; 5- Nodes removed; 
6 – Nodes involved; 7 - Pathological size; 8 – Age category; 9- Menopausal status. 
  
In this bootstrap analysis there are five variables that are almost always selected, namely 
Nodes ratio, Histological grade, Histological type, Oestrogen and Age. There are other 3 
variables, Pathological size, Nodes involved and Menopausal status, that there is some doubt 
if they should enter in the model. However, when the variables Nodes Involved and Nodes 
Ratio are both in the same model, considering missing as a different attribute and the baseline 
model, the beta values and the standard deviation, applying Cox proportional model, are very 
high, as it can be observed in Table 4.11. These values mean that these two variables are very 
correlated, which suggests that they shouldn’t be together in the model. 
 
Nodes ratio Nodes involved 
Categories Beta values Standard error Beta values 
Standard 
error 
1 10.48401 569.444 -11.55989 569.444 
2 11.25590 569.444 -10.84243 569.444 
3 10.49255 569.444 -10.52854 569.444 
4 11.52662 569.444 - - 
Table 4.11 – Beta values for Cox proportional modelling 
Cox proportional hazards model was fitted with variables Oestrogen, Pathological size, Histological 
type, Age, Histological grade, Nodes ratio and Nodes involved. 
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Moreover, in order to better identify which variables are really significant in predicting 
survival, the -2LogL statistic was compared for different predictive models, using missing as 
a different attribute. The results are in the following table: 
 
   -2logL statistic d.f. p-value 
differences from 
5 variables 
model 
AIC value 
1 Without variables 1495,275 - - 1495,275 
2 1,2,3,4,5 1376,203 12 - 1400,203 
3 1,2,3,4,5,6 1370,867 13 0.05 1396,867 
4 1,2,3,4,5,7 1370,483 14 <0.05 1398,483 
5 1,2,3,5,6,8 1373,907 12 - 1397,907 M
od
el
s 
6 1,2,3,4,5,6,7 1364,597 15 <0.05 1394,597 
Table 4.12 – -2LogL statistic for different fitted models.  
Legend: 1-Oestrogen; 2- Histological grade; 3- Histological type; 4 - Node ratio; 5-Age category ; 6 
– Pathological size; 7 – Menopausal status; 8-Nodes involved. 
 
Analysing both AIC values and the -2LogL values, there is evidence that adding the 
Pathological size variable to the model with the five variables, there is a significant reduction 
on their values and it can be concluded that this is also a significant model. On another hand, 
with the bootstrapping method, the most chosen model was the one with the five most 
predictive variables, adding the Pathological size and Menopausal status variables. However, 
from the model number 3 to model number 6 there is not a significant reduction on the AIC 
values that justifies adding another variable (diminution of 2,2 on 2 degrees of freedom). 
Even model 5 that has never been selected on the bootstrapping analysis also shows good 
prediction values, looking at the AIC values. Consequently, some analysis should be done for 
the models when missing imputation is applied. 
There are therefore 4 different models that can be considered to predict this data set. Its 
beta parameters are listed in Table 4.13 for the imputed data set and in Table 4.14 for the non-
imputed data set, where the baseline population was chosen as the one with the higher 
frequencies, excluding the missing categories. It can be concluded firstly that the effect of 
removing menopausal status and after pathological size, all betas retain the same sign. 
Secondly, there is not a significantly difference in their values, with the exception of Age 
category, for both imputed and non-imputed data set. Moreover, the prognostic index ranges 
for the four models are also very similar.  
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Concluding, the influence of more 1 or more 2 variables in the 5 variables model is the 
same for imputed and not imputed missing data. Comparing the models, one with Nodes ratio 
variable and the other with Nodes involved variable, the beta values are very similar, and there 
is not an evidence that one model predicts better than the other. 
Furthermore, a comparison of the beta values for the model with missing as a different 
attribute and the model with missing imputed showed comparable values for the observed 
covariates, which increases our expectations that the imputed data is consistent. 
 
Variables Category 
Betas for model: Age 
+ Histological grade 
+ Histological type + 
Oestrogen + Nodes 
ratio 
Betas for model: 
Age + Histological 
grade + 
Histological type + 
Oestrogen + Nodes 
involved + 
Pathological size 
Betas for model: Age 
+ Histological grade 
+ Histological type + 
Oestrogen + Nodes 
ratio + Pathological 
size model 
Betas for model: Age 
+ Histological grade + 
Histological type + 
Oestrogen + Nodes 
ratio + Pathological 
size model + 
Menopausal status 
1 Baseline Baseline Baseline Baseline 
2 1.254700391 - 1.221011 1.25291764 
3 0.831657469 - 0.685276 0.738188991 
Node ratio 
4 1.776765282 - 1.652103 1.714117099 
1 Baseline Baseline Baseline Baseline Histological 
type 2 -0.759140605 -0.784716 -0.779706 -0.741725142 
1 -0.630550611 -0.368312 -0.494438 -0.530857271 
2 Baseline Baseline Baseline Baseline 
Histological 
grade 
3 0.562734991 0.402875 0.516832 0.535875904 
1 0.610158793 0.636483 0.607958 0.627812087 Oestrogen 
2 Baseline Baseline Baseline Baseline 
1 0.700142796 0.789706 0.617202 0.94465774 
2 Baseline Baseline Baseline Baseline Age category 
3 0.479431844 0.567988 0.461044 0.215964939 
1 - Baseline Baseline Baseline 
Path size 
2 - 0.441709 0.613669 0.650141205 
1 - - - -0.599008159 
2 - - - 0.252118407 
Menopausal 
status 
3 - - - Baseline 
1 - Baseline - - 
2 - 0.755296 - - 
Nodes 
involved 
3 - 1.493828 - - 
Table 4.13 – Models parameters for the imputed data sets. 
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Variables Category 
Betas for model: 
Age + Histological 
grade + Histological 
type + Oestrogen + 
Nodes ratio 
Betas for model: Age 
+ Histological grade 
+ Histological type + 
Oestrogen + Nodes 
involved + 
Pathological size 
Betas for model: Age 
+ Histological grade 
+ Histological type + 
Oestrogen + Nodes 
ratio + Pathological 
size 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes ratio 
+ Pathological size + 
Menopausal status 
1 Baseline - Baseline Baseline 
2 1.41611 - 1.28206 1.34598 
3 0.73434 - 0.63693 0.74416 
4 1.83346 - 1.72628 1.82309 
Nodes ratio 
9 0.72183 - 0.82950 0.88682 
1 Baseline Baseline Baseline Baseline Histological 
type 2 -2.03423 -2.03095 -1.99489 -2.00017 
1 -0.63418 -0.50111 -0.55602 -0.60004 
2 Baseline Baseline Baseline Baseline 
3 0.59909 0.53407 0.58127 0.61641 
Histological 
grade 
9 1.26132 1.32421 1.22102 1.26599 
1 0.82096 0.83302 0.83004 0.87434 
2 Baseline Baseline Baseline Baseline Oestrogen 
9 -0.01113 0.17255 0.09281 0.09722 
1 0.71009 0.85100 0.64269 1.01620 
2 Baseline Baseline Baseline Baseline Age category 
3 0.45329 0.57738 0.44559 0.12114 
1 - Baseline Baseline Baseline 
Path size 
2 - 0.43317 0.49708 0.52278 
1 - - - -0.73444 
2 - - - 0.21092 
Menopausal 
status 
3 - - - Baseline 
1 - Baseline - - 
2 - 0.82883 - - 
3 - 1.58428 - - 
Nodes 
involved 
9 - 1.05793 - - 
Table 4.14 – Models parameters for the not imputed data sets. 
Comparing the imputed and not imputed models betas, for the different used variables, it 
can be observed that they are very similar, as the sign for all of them is the same and there is 
no significant difference between them, with the exception of Histological Type variable. 
With this fact it can be concluded that the “missingness” influences the significance of the 
Histological Type in the model. The narrow ranges of beta values for each prognostic variable 
suggests that distributions for each of the potential prognostic factors in the 10 imputed data 
sets were similar, as it can be observed in Table 4.15. There is a very high correlation between 
prognostic indices for the imputed and not imputed data, as it is shown in Figure 4.5 , which 
suggests that the imputations make sense and are not completely at random. This analysis was 
developed for all previous models and the conclusions obtained were the same. 
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Figure 4.5 – Scatter plot between the imputed and not imputed model. 
It uses Histological Grade, Histological type, Oestrogen, Age category, Pathological size and Nodes 
ratio as predictor variables. 
 
To conclude about the model to use to predict breast cancer overall mortality it is 
necessary to verify if an addition of a variable makes a significantly better model and it is not 
over-fitted to the data set. Therefore, it is necessary a more carefully analysis of the identified 
models with an internal and external validation. However ,with the results obtained so far 
there is an evidence that the model that predicts better is the one with the following six 
variables: Pathological size, Histological grade, Histological type, Oestrogen and Nodes 
ratio. Considering this model as the most predictive one, an important requirement must be 
assessed, that is the ratio of events per variable. Any model based on a small number of 
individuals will be less reliable than one based on a larger number. However, the power of a 
survival analysis model is related to the number of events rather than the number of 
participants and simulation work has suggested that at least 10 events need to be observed for 
each covariate considered (Bradburn M.J., Clark, Love, Altman, 2003), (Concato John, 
Peduzzi, Holford, Feinstein, 1995). In our analysis there are on the training data set 115 
events and 10 covariates for the 6 prognostic variables, implying 11 events per covariate, 
which means that the regression coefficients are possibly not biased. The confidence intervals 
may have the proper coverage and the test statistics might be valid for the model. Moreover, 
Harrell et al. (Harrel, Lee, Califf, Pryor, Rosati, 1984) suggests a rough rule of thumb that in 
order to have predictive discrimination that validates on a new sample, the number of 
covariates or degrees of freedom shouldn’t be more than the number of events/10. In our 
analysis this rule is very approximate, as the number is 11, therefore it can be considered to 
have predictive discrimination. 
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  Missing as a different attribute Imputed missing data 
 
Varia
bles 
Cate
gory Betas 
Std 
error 
Wald 
Chi-
square 
Significa
nce Betas 
95% 
confidence 
limits 
Std 
error Min beta Max beta 
Beta 
Differences 
   46.6 <0.0001       
1 Baseline - - - Baseline - - - -  
2 1.28206 0.35 13.3 0.0003 1.221011 (0.59488; 1.847143) 0.32 1.096674 1.388680 0.06105 
3 0.63693 0.33 3.8 0.0513 0.685276 (0.03403; 1.336522) 0.33 0.490181 0.835719 0.04835 
4 1.72628 0.27 40.8 <0.0001 1.652103 (1.07537; 2.228833) 0.29 1.384110 1.827760 0.07418 
Nodes 
ratio 
9 0.82950 0.34 6.1 0.0239 - - - - - - 
   21.2 <0.0001       
1 Baseline  - - Baseline - - - - - Hist. 
type 
2 -1.99489 0.43 21.2 <0.0001 -0.779706 (-1.63886; 0.079448) 0.44 -0.981595 -0.333998 1.2152 
   23.5 <0.0001       
1 -0.55602 0.45 1.5 0.2186 -0.494438 (-1.43704; 0.448162) 0.47 -0.835856 -0.112374 0.06158 
2 Baseline - - - Baseline - - - - - 
3 0.58127 0.24 6.1 0.0135 0.516832 (0.04618; 0.987483) 0.24 0.324459 0.651287 0.06444 
Hist. 
grade 
9 1.22102 0.30 16.7 <0.0001 - - - - - - 
   13.6 0.0011       
1 0.83004 0.25 11.4 0.0007 0.607958 (0.09949; 1.116421) 0.26 0.394441 0.917643 0.22208 
2 Baseline - - - Baseline - - - - - 
Oest. 
9 0.09281 0.25 0.14 0.7067 - - - - - - 
   6.7 0.0346       
1 0.64269 0.29 5.1 0.0246 0.617202 (0.05059; 1.183818) 0.29 0.544848 0.693451 0.02549 
2 Baseline - - - Baseline - - - - - 
Age 
3 0.44559 0.21 4.4 0.0366 0.461044 (0.03031;0.891774) 0.22 0.366594 0.531312 0.01545 
   5.2 0.0231       
1 Baseline - - - Baseline - - - - - Path. 
size 
2 0.49708 0.22 5.2 0.0231 0.613669 (0.17458;1.052756) 0.22 0.504409 0.784853 0.11659 
Table 4.15 – Beta values comparison for imputed and not imputed model. 
The model was fitted with variables Histological Grade, Histological type, Oestrogen, Age category, 
Pathological size and Nodes ratio. 
 
  
Furthermore, the three chosen variables Pathological size, Nodes ratio and Histological 
grade reflect the known Nottingham Prognostic Index (NPI), where the node status is 
replaced by Nodes ratio. Histological type and Oestrogen relate to a coarse sub-typing of the 
disease and response to therapy, respectively. Age category was selected because it is related 
with the event of interest, death attributed to any cause other than breast cancer. 
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4.3.2. Sensitivity analysis of Nodes involved variable 
The original data set, removing category 3 from histological type, comprised for 1 record 
for category 4 of Nodes involved variable, for Christie Hospital data set and therefore it was 
carried out a study in order to analyse the sensitivity of this category to the data set and to the 
model. The strategy to deal with this record must be one of the following: remove this record 
and category from the data set; recode this record as category 3 or leave this record and 
category as it is in the original data set.  
The imputation methodology was also performed leaving this record on category 4, and it 
was concluded that the imputation methodology was successfully applied, with the exception 
of Nodes involved variable. This is a consequence of the fact that there exists only 1 record for 
category 4 of this variable. When the missing is imputed, this category can have from 1 to 51 
subjects which compromises the survival curves, being very different from each other and 
from the survival curves without imputing. These results suggest that the category 4 of Nodes 
Involved variable should be recoded or eliminated, because it can compromise the analysis. 
The survival curves for the 10 imputations were compared in order to verify the convergence 
of imputation and the impact of category 4 of Nodes involved. Removing the record form the 
data set, it was concluded that there were significant differences on the survival curves for 
Nodes involved and Nodes ratio variable. However, if this record is removed, these survival 
curves become more consistent for all the 10 different imputations. Generally it can be 
concluded that the survival curves for imputed data are very well defined for all imputations, 
when the 2 records are removed from the data set.  
Ahead there are the analysis of the model without these two subjects and coding them as 
Nodes involved equals to 3 in order to conclude about what to use in this modelling selection. 
The bootstrap methodology applied previously in order to detect the most predictive 
model, was also applied coding the record being analysed as category 3 and leaving it as 
category 4, for both imputed and not imputed data sets.    
1000 bootstrap re-samples were applied to the Christie Hospital 1990-94 data set, coding 
missing as a separate attribute and a 100 bootstraps were applied to each of the 10 imputed 
missing data set. Variable selection was repeated for each sample, using the same stopping 
rule, with a proportional hazards model, following a forward selection stepwise procedure and 
applying Akaike’s information criterion (using a 95% significance level to enter in the model 
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and 99% significance level to leave the model). The first 10 most chosen models are shown in 
Table 4.17  and Table 4.18. 
Table 4.16 – Imputation results comparison. 
This analysis was performed removing category 4 from Nodes involved variable and leaving the 
variable as it is in the original data set. 
 
Most chosen 
model 
Nm. of times 
chosen 
Nodes involved 
coded as 4 
Nm. of times 
chosen 
Nodes involved 
coded as 3 
Nm. of times 
chosen 
Nodes involved 
removed 
1 101 1,2,3,4,6,8,9 83 1,2,3,4,7,8,9 95 1,2,3,4,7,8,9 
2 89 1,2,3,4,6,7,8,9 65 1,2,3,4,6,8,9 85 1,2,3,4,6,8,9 
3 67 1,2,3,4,6,8 62 1,2,3,4,5,6,8,9 71 1,2,3,4,6,7,8,9 
4 65 1,2,3,4,7,8,9 61 1,2,3,4,6,7,8,9 65 1,2,3,4,7,8 
5 58 1,2,3,4,5,6,8,9 53 1,2,3,4,6,8 61 1,2,3,4,6,8 
6 46 1,2,3,4,6,7,8 52 1,2,3,4,7,8 55 1,2,3,4,5,6,8,9 
7 45 1,2,3,4,8 42 1,2,3,4,8,9 47 1,2,3,4,6,7,8 
8 34 1,2,3,4,5,6,7,8,9 39 1,2,3,4,5,6,8 46 1,2,3,4,8,9 
9 33 1,2,3,4,8,9 39 1,2,3,4,5,6,7,8,9 40 1,2,3,4,8 
10 29 1,2,3,4,7,8 35 1,2,3,4,8 31 1,2,3,4,5,6,7,8,9 
Table 4.17 – Models chosen using bootstrapping, coding missing as a different attribute.  
The model characterized in green represents the first model chosen with missing as a different 
attribute. Legend: 1-Oestrogen; 2- Histological grade; 3- Histological type; 4 - Node ratio; 5- Nodes 
removed; 6 – Nodes involved; 7 - Pathological size; 8 – Age category; 9- Menopausal status. 
 
Although it appears that the coding of Nodes involved variable does not interfere in model 
selection, the obtained results show a different perspective. Actually, with the obtained results 
it can be concluded that the model selection is more consistent when the category 4 of Nodes 
involved variable is deleted from the data set, because there is less noise in the data set and in 
model selection. Furthermore, using the imputed data sets in model selection, there is more 
consistency in variables selection when this category is deleted, as the variables selected 
without the bootstrapping are in the second place when there is a ranking of all models. This 
  Christie Hospital 1990-94 removing  
category 4 from Nodes involved 
variable 
Christie Hospital 
1990-94 original 
data set 
Christie Hospital 1990-94 
completed data set 
Variable Mean 
# 
Median Range % # % Mean # Median Range % 
1 428 433 377-462 58 377 57 415 421 378-453 56 
2 210 227 184-237 28 184 28 204 206 184-248 27 
3 105 99 97-130 14 97 15 100 98 97-112 13 
4 - - - - 1 0 24 15 1-51 4 
N
od
es
 in
vo
lv
ed
 
9 - - - - 85 0 - - - - 
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indicates a high sensitivity of the models to this record and category; therefore the record was 
removed from the modelling data, as outlier. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.18 – Models chosen using bootstrapping applied to the imputed data sets.  
The model characterized in green represents the first model chosen with missing as a different 
attribute. Legend: 1-Oestrogen; 2- Histological grade; 3- Histological type; 4 - Node ratio; 5- Nodes 
removed; 6 – Nodes involved; 7 - Pathological size; 8 – Age category; 9- Menopausal status. 
 
4.3.3. Cox Proportional hazards model validation 
There are a few ways to assess or validate the performance of a prognostic model, that can 
be divided in internal and external validation. Firstly, the Cox proportional hazards underwent 
an internal validation, that is model was developed in a portion of a data set and it was applied 
to the other portion of the data set. The model was developed with missing as a different 
attribute, and it a 10 fold cross validation of the data was used. A random 74 subjects was left 
out each time and 10 models were developed, with the variables already found as significant, 
Histological type, Histological grade, Pathological size, Node ratio, Oestrogen and Age 
category, on the 669 subjects. The prognostic index (βx) was calculated for the leaving out 
random subjects, with the beta values modelled with the remaining subjects. Figure 4.6 
represents a scatterplot between the prognostic indices calculated with the model developed 
for the entire subjects and the prognostic indices calculated using cross-validation.  
This figure shows that both prognostic indices for the same records have a high correlation, 
concluding that the model is very well fitted. It can be observed that there are some outliers, 
mainly for the Prognostic indices upper 4, for the cross validation. However, these outliers are 
Most 
chosen 
model 
Nm. of 
times 
chosen 
Nodes involved coded 
as 4 - Imputed 
Nm. of 
times 
chosen 
Nodes involved 
coded as 3 - Imputed 
Nm. of 
times 
chosen 
Nodes involved 
removed - Imputed 
1 57 1,2,3,4,6,8,9 67 1,3,4,6,7,8 62 1,2,3,4,7,8,9 
2 51 1,2,3,4,5,6,8,9 56 1,3,4,5,6,7,8 60 1,2,3,4,7,8 
3 47 1,2,3,4,6,8 53 1,3,4,5,6,7,8,9 42 1,2,3,4,6,7,8,9 
4 47 1,2,3,4,6,7,8,9 50 1,2,3,4,5,6,7,8,9 39 1,3,4,6,7,8,9 
5 44 1,2,3,4,5,6,7,8,9 44 1,2,3,4,6,7,8,9 31 2,3,4,6,7,8,9 
6 36 1,2,3,4,6,7,8 40 1,2,3,4,7,8,9 30 2,3,4,7,8 
7 32 1,3,4,6,7,8,9 39 1,2,3,4,7,8 30 2,3,4,6,7,8 
8 31 1,2,3,4,7,8 36 1,2,3,4,5,6,8,9 29 1,2,3,4,5,6,7,8,9 
9 30 2,3,4,6,7,8 35 1,2,3,4,6,8,9 28 1,3,4,7,8 
10 29 2,3,4,6,7,8,9 34 1,2,3,4,6,8 28 1,3,4,6,7,8 
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due to the fact that some beta values of the 10 produced models are very high or low, resulting 
on the few records for each training model. It can also be observed that the higher correlation 
is for the 6 variables model trained using Nodes Ratio variable. 
 
 
 
Figure 4.6 – Scatter plot between the cross-validated PI and the PI not cross-validated. 
The upper left picture represents the 5 variables model and the upper right picture represents the 7 
variables model. The bottom left picture represents the 6 variable model developed with Nodes ratio 
and the bottom right picture represents the 6 variables model developed with Nodes involved. 
 
Other analysis was produced using the imputed training data sets and cross-validation 
methodology. For each imputed data set a different model was built. However, instead of 
building a model for the 10 imputed data sets, it was built one for each 9 imputed data sets. 
This model was then applied to the remaining imputed data set. At the end, all the imputed 
data sets were applied to these different produced models. A prognostic index was obtained 
for each patient and compared with the prognostic index obtained with the model constructed 
with all the imputed data sets, as it can be observed on Figure 4.7.  This figure shows that 
both prognostic indices for the same records have a high correlation for the different 4 
models, concluding that all models are very well fitted.  
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Figure 4.7 – Scatter plot between different prognostic indexes.  
These are the final prognostic index developed with the 10 imputed data sets and the prognostic index 
obtained by cross-validating the imputed data sets. The upper left picture represents the 5 variables 
model and the upper right picture represents the 7 variables model. The bottom left picture represents 
the 6 variables model developed with Nodes ratio and the bottom right picture represents the 6 
variables model developed with Nodes involved. 
 
The consistency of the imputed data has already been demonstrated. Therefore, it is 
important to validate the performance of the prognostic model with the imputed data, 
assessing its calibration and discrimination. Calibration compares the observed and predicted 
event rates for group of patients and discrimination, quantifies the model’s ability to 
distinguish between patients who do or do not experience the event of interest. The Ctd values 
and the Hosmer-Lemeshow statistic were obtained for the 4 models in discussion, in order to 
assess the discrimination and calibration of the models, respectively.  
Ctd values as well as the standard deviation in square brackets, for each discrete time, are 
represented in the first line of Table 4.19. The Hosmer-Lemeshow χ2 statistic is also 
represented in Table 4.19 , next to the Ctd index, with associated p-values in square brackets. 
For the calculation of Hosmer-Lemeshow statistic, the patients were grouped in 10 classes. It 
must be regarded that large values of χ2 statistic and small p-values indicate a lack of fit of the 
model. The calibration plots evaluated by grouping subjects according to the predicted 
survival, S(t), at t=1,2,3,4 and 5 years are shown in Figure 4.8 .  
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  Years 
  1 2 3 4 5 
Age + Histological grade 
+ Histological type + 
Oestrogen + Nodes ratio 
0.75(0.144); 
0.11[1] 
0.78(0.085); 
0.49[1] 
0.81(0.057); 
1.68[0.996] 
0.78(0.049); 
2.67[0.976] 
0.75(0.046); 
2.50[0.981] 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes 
involved + Pathological 
size 
0.83(0.117); 
0.1[1] 
0.82(0.059); 
0.2[1] 
0.83(0.044); 
0.9[1] 
0.83(0.037); 
1.21[0.999] 
0.80(0.039); 
1.5 [0.997] 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes ratio 
+ Pathological size 
0.86(0.091); 
0.06[1] 
0.85(0.06); 
0.26[1] 
0.85(0.046); 
0.95 [1] 
0.83(0.041); 
1.31[0.998] 
0.81(0.041); 
2.81 [0.973] 
M
od
el
s 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes ratio 
+ Pathological size model 
+ Menopausal status 
0.80(0.125); 
0.01[1] 
0.82(0.076); 
0.49[1] 
0.82(0.055); 
2.04[0.991] 
0.79(0.048); 
1.05[0.999] 
0.77(0.045); 
0.94[1] 
Table 4.19 – Models Calibration and discrimination assessment. 
It was performed for the 4 different models, using the training data set and imputation methodology. 
 
 
 
  
    
Figure 4.8 – Calibration plots for the 4 different models for the training data set.  
From left to right calibration is at t=1,2,3,4,5 years. The x axis is the observed survival and the y axis 
is the predicted survival. The upper pictures represent the calibration plots for the 5 variables model, 
the second upper pictures represent the calibration plots for the 6 variables model developed using 
Nodes involved variable, the third upper pictures represent the calibration plots for the 6 variables 
model developed using Nodes ratio variable and the bottom pictures represent the calibration plots for 
the 7 variables model. 
 
 
Chapter 4 – Results 
106 
From the Ctd values for all models, it can be seen that generally, a satisfactory performance 
with values of about 0.8 was reached. However, the discrimination of both 6 variables model 
is much better than the other two models. In adittion, the model which includes the Node 
Ratio variable has better discrimination than the one that includes the Nodes Involved 
variable, that increases our expectation that the model comprised by Histological Grade, Age 
category, Histological type, Oestrogen, Pathological size and Nodes Tatio is the one that 
predicts better. From the graphical inspection of the calibration plots, none of the models 
showed any major tendency to systematic over/under estimation of the observed survival in 
groups. Moreover, calibration is better in groups with high-predicted survival, for all models. 
It can be inspected that all models have a very good calibration performance. 
Even internal validation is essential and produces a conclusion about the model validation; 
external validation a more efficient approach. In order to demonstrate the prognostic model is 
valuable, it is not sufficient to show that it successfully predicts outcome in the initial 
development data. It is necessary to prove that the model performs well for other group of 
patients. The external validation examines the generalisability of the model, for which it is 
required a new data collected from an appropriate (similar) patient population in a different 
centre. Therefore, the BCCA data set was used to validate externally all the models developed 
and considered previously. All the 4 different models were subjected to validation, with the 
purpose of verifying the conclusions obtained with the training data set.  Once obtained the 
betas and the prognostic indexes for the derivation data set, the 5-year estimated prognostic 
index was calculated for each patient in the imputed validation data sets. The final computed 
beta values were applied to each imputed data set (from the validation cohort), obtaining 10 
prognostic indexes for each patient, which were then averaged in order to obtain a single 
prognostic risk.  The discrimination and calibration were assessed for the validated model, 
using the Ctd values and the Hosmer-Lemeshow statistic, respectively for the different 4 
models in discussion. The Ctd values, as well as the standard deviation in brackets, for each 
discrete time, are represented in the first line of Table 4.20, as it was represented for the 
training data set. The Hosmer-Lemesow statistic is presented on Table 4.20 , next to the Ctd 
index, with the χ2 value and the p-value in square brackets. The calibration plots evaluated by 
grouping subjects according to the predicted survival, S(t), at t=1,2,3,4 and 5 years are shown 
in Figure 4.9 .  
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  Years 
  1 2 3 4 5 
Age + Histological grade + 
Histological type + 
Oestrogen + Nodes ratio 
0.72(0.09); 
0.35[1] 
0.73(0.039); 
0.83[1] 
0.74(0.028); 
1.98[0.992] 
0.71(0.024); 
4.91[0.842] 
0.70(0.022); 
8[0.534] 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes involved 
+ Pathological size 
0.74(0.090); 
0.04[1] 
0.74(0.040); 
0.36[1] 
0.73(0.028); 
1.18[0.999] 
0.71(0.024); 
2.09[0.990] 
0.69(0.022); 
2.84[0.970] 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes ratio + 
Pathological size 
0.74(0.090); 
0.38 [1] 
0.75(0.039); 
0.79[1] 
0.75(0.027); 
2.09 [0.99] 
0.74(0.023); 
5.28[0.808] 
0.72(0.021); 
8.39[0.495] M
od
el
s 
Betas for model: Age + 
Histological grade + 
Histological type + 
Oestrogen + Nodes ratio + 
Pathological size model + 
Menopausal status 
0.75(0.087); 
0.42[1] 
0.76(0.038); 
0.99[0.999] 
0.75(0.027); 
2.32[0.985] 
0.74(0.023); 
5.66[0.773] 
0.72(0.021); 
8.65[0.471] 
Table 4.20 – Models Calibration and discrimination assessment. 
It was performed for the 4 different models, using the validation data set and imputation methodology. 
 
 
From the Ctd, it was reached a satisfactory performance of about 0.7, for all models, which 
slightly lower than the one obtained with the training data set (0.8). However, this lowering 
was already been expected. The 6 variables model, fitted with Nodes Ratio and the 7 
variables model have a slightly better discrimination performance than both the 5 variables 
model and the 5 variables model fitted with Nodes Involved. Analysing the Chi-square 
values, as well as the p-values, it can be verified that all models have a very good calibration 
performance and, as it was expected, the calibration performance is lower than the trained 
models. From the graphical inspection of the calibration plots it can be concluded that for all 
models, with the exception of the 6 variables models fitted with Nodes Involved, there is an 
underestimation of the observed survival in the groups, more accentuated in groups with low 
predicted survival and for time equals to 3, 4 and 5 years. Moreover, calibration is better in 
groups with high-predicted survival, for all models.  
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Figure 4.9 – Calibration plots for the 4 different models, for the validation data set.  
From left to right calibration is at t=1,2,3,4,5 years. The x axis is the observed survival and the y axis 
is the predicted survival. The upper pictures represent the calibration plots for the 5 variables model, 
the second upper pictures represent the calibration plots for the 6 variables model developed using 
Nodes involved variable, the third upper pictures represent the calibration plots for the 6 variables 
model developed using Nodes ratio variable and the bottom pictures represent the calibration plots for 
the 7 variables model. 
4.4 - PLANN-ARD Modelling and its validation 
Partial Logistic Artificial Neural network with Automatic Relevance Determination 
(PLANN-ARD) model accounts implicitly for non-linear and non proportional covariate 
effects. The neural network does not seek merely to explain the observed variation in 
survival, as a function of covariate effects. Instead, it fits the hazard function directly, without 
resort to proportionality assumptions about the covariate effects.  In this way, it is suited to 
making individual predictions of the event rate. The event of interest and the follow up time 
is the same as it was used in Cox Proportional hazards modelling.  
As a consequence of imputation, PLANN-ARD was run 10 times, one for each imputed 
data set, resulting in 10 different trained networks. PLANN-ARD was trained using the 
variables previously selected. Using the PLANN-ARD, the mean of the hazard of the 10 
imputed data sets can be computed as in equation 53.  
According to the discrete time perspective, a prognostic index can be defined to enable 
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each patient to be allocated into a risk group, using the 5-year survival as the stratification 
index.  This was defined using the identity identified in equation 52.  
Similarly to Cox proportional hazards modelling, a careful validation was carried out for 
the PLANN-ARD modelling, also divided in internal and external validation.  Calibration and 
discrimination performance was assessed for all the 4 different models. Both training and 
validation data sets were used to carry out this validation. Table 4.21, Table 4.22, Figure 4.10 
and Figure 4.11 represent all the obtained values for the training and validation data set , 
respectively.  
PLANN-ARD discrimination was measured through the Ctd values. A satisfactory 
performance was reached, for all models, with values of about 0.8 for the training data set, 
with the exception of the 5 variables model, reaching that performance only at 3 years. The 
validation data set reached a value approximately of 0.7.  For the training data set, it can be 
analysed, not only that the discrimination for both 6 variables models is much better than for 
the other 2 models, but also that the model which includes the Node Ratio variable has better 
discrimination than the one that includes the Nodes Involved variable. This increases our 
expectation that the model comprised by Histological Grade, Age category, Histological 
type, Oestrogen, Pathological size and Nodes Ratio is the one that predicts better. 
 Years 
 1 2 3 4 5 
Age + Histological grade + 
Histological type + Oestrogen 
+ Nodes ratio 
0.77(0.138); 
0.14[1] 
0.79(0.081); 
0.33[1] 
0.81(0.055); 
2.56[0.979] 
0.79(0.048); 
2.65[0.977] 
0.76(0.046); 
2.15[0.989] 
Betas for model: Age + 
Histological grade + 
Histological type + Oestrogen 
+ Nodes ratio + Pathological 
size 
0.86 (0.093); 
0.05[1] 
0.85 (0.062); 
0.26[1] 
0.85(0.046); 
1.65[0.996] 
0.83(0.041); 
1.28[0.998] 
0.81(0.041); 
1.49[0.997] 
Betas for model: Age + 
Histological grade + 
Histological type + Oestrogen 
+ Nodes involved + 
Pathological size 
0.83(0.117); 
0.05[1] 
0.84(0.055); 
0.28[1] 
0.84(0.042); 
0.67[1] 
0.83(0.037); 
1.68[0.996] 
0.80(0.038); 
1.94[0.992] 
Betas for model: Age + 
Histological grade + 
Histological type + Oestrogen 
+ Nodes ratio + Pathological 
size model + Menopausal 
status 
0.81(0.114); 
0.14[1] 
0.83(0.067); 
0.74[1] 
0.83(0.050); 
2.69[0.975] 
0.80(0.045); 
2.78[0.972] 
0.77(0.043); 
1.88[0.993] 
Table 4.21– Models Calibration and discrimination assessment. 
It was performed for the 4 different models, using the training data set and imputation methodology. 
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Figure 4.10 – Calibration plots for the 4 different models, for the training data set.  
From left to right calibration is at t=1,2,3,4,5 years. The x axis is the observed survival and the y axis 
is the predicted survival. The upper pictures represent the calibration plots for the 5 variables model, 
the second upper pictures represent the calibration plots for the 6 variables model developed using 
Nodes involved variable, the third upper pictures represent the calibration plots for the 6 variables 
model developed using Nodes ratio variable and the bottom pictures represent the calibration plots for 
the 7 variables model. 
 
  Years 
  1 2 3 4 5 
Age + Histological grade + 
Histological type + Oestrogen + 
Nodes ratio 
0.73 (0.089); 
0.2 [1] 
0.73 (0.040); 
0.68 [1] 
0.73 (0.028); 
1.29 [0.998] 
0.72 (0.024); 
1.96 [0.992] 
0.70 (0.022); 
3.56 [0.938] 
Betas for model: Age + 
Histological grade + 
Histological type + Oestrogen + 
Nodes ratio + Pathological size 
0.75 (0.086); 
0.08 [1] 
0.75(0.039); 
0.22 [1] 
0.75(0.028); 
0.53 [1] 
0.74(0.023); 
0.73 [1] 
0.72(0.021); 
1.23 [0.999] 
Betas for model: Age + 
Histological grade + 
Histological type + Oestrogen + 
Nodes involved + Pathological 
size 
0.77 (0.091); 
0.05 [1] 
0.78 (0.038); 
0.12 [1] 
0.77 (0.027); 
0.21 [1] 
0.75 (0.022); 
0.31[1] 
0.74 (0.020); 
0.36[1] M
od
el
s 
Betas for model: Age + 
Histological grade + 
Histological type + Oestrogen + 
Nodes ratio + Pathological size 
model + Menopausal status 
0.77(0.080); 
0.20 [1] 
0.76 (0.038); 
0.36 [1] 
0.76 (0.027); 
0.63[1] 
0.74 (0.023); 
1.27[0.999] 
0.73 (0.021); 
1.96 [0.992] 
Table 4.22 – Models Calibration and discrimination assessment. 
It was performed for the 4 different models, using the validation data set and imputation methodology. 
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Figure 4.11 – Calibration plots for the 4 different models, for the validation data set. 
From left to right calibration is at t=1,2,3,4,5 years. The x axis is the observed survival and the y axis 
is the predicted survival. The upper pictures represent the calibration plots for the 5 variables model, 
the second upper pictures represent the calibration plots for the 6 variables model developed using 
Nodes involved variable, the third upper pictures represent the calibration plots for the 6 variables 
model developed using Nodes ratio variable and the bottom pictures represent the calibration plots for 
the 7 variables model. 
 
 PLANN-ARD calibration was achieved using the Hosmer-Lemeshow statistic and the 
calibration plots at t=1,2,3,4 and 5 years. From the Hosmer-Lemeshow statistic all models 
show an excellent calibration, for the training and validation data set. From the graphical 
inspection of the calibration plots, none of the models showed any major tendency to 
systematic over/under estimation of the observed survival in groups, for the training data set. 
Observing the calibration plots for the validation data set it can be concluded that for all 
models there is an underestimation of the observed survival in the groups, with the exception 
of the 6 variables model with Nodes Involved. Moreover, calibration is better in groups with 
high-predicted survival, for all models, and for the training and validation data set. Therefore, 
it can be concluded that all models have a very good calibration performance.  
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4.5 - Comparison between Cox and PLANN-ARD modelling 
The performance of the models developed with Cox proportional hazards can be compared 
with the performance of the models developed with PLANN-ARD, for both training and 
validation data set.  
  
 
 
  
Figure 4.12 – Comparison between Cox and PLANN-ARD PI for the training data set. 
The top figures represent the models developed with 5 and 7 variables, from left to right respectively. 
The bottom pictures represent the model developed for the 6 variables models, with Nodes involved 
and Nodes ratio, from left to right respectively. 
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 Figure 4.13 – Comparison between Cox and PLANN-ARD PI for the validation data set.  
The top figures represent the models developed with 5 and 7 variables, from left to right respectively. 
The bottom pictures represent the model developed for the 6 variables models, with Nodes involved 
and Nodes ratio, from left to right respectively. 
  
For the training data set, comparing the Cox regression models values with PLANN-ARD 
values, overlapping performances are evident. Analysing the Chi-square values, as well as the 
p-values, it can be concluded that all models have a very good calibration performance, with 
the PLANN-ARD model slightly better than the Cox model. 
For the validation data set the discrimination values are better for the PLANN-ARD model 
than for the Cox proportional hazards for all the models and for all the time intervals. 
Analysing the Chi-square values, as well as the p-values, it can be concluded that the 
PLANN-ARD models are better calibrated than the Cox models. Observing the calibration 
plots for the validation data set it can be noticed that for all models with the exception of the 6 
variables model built with Nodes Involved, there is an underestimation of the observed 
survival in the groups, more accentuated on Cox model. The prognostic index obtained for 
each patient with Cox and PLANN-ARD can also be compared (Figure 4.12  and Figure 
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4.13), for training and validation data set respectively. Comparing the obtained Cox 
prognostic index with the PLANN-ARD prognostic index it can be verified that they are non-
linear related, for all models and for both training and validation. Nevertheless there is a very 
high correlation between them, from 0.95551(6 variables model with Nodes Involved) to 
0.97877(5 variables model) for the training data set, and 0.79994 (6 variables model with 
Nodes Involved) to 0.97905 (6 variables model with Nodes Ratio), measured by the Pearson 
correlation. Particularly it seems that the PLANN-ARD model compresses the PI values in the 
extreme sectors but extends the dynamic range for the middle sector for all models with the 
exception of the 6 variables model developed with Nodes Involved. This compression and 
extension can be caused by the non-linear algorithm, which implicitly models interactions 
between covariates.  
4.6 - Stratification methodologies 
Stratification of patients by risk of adverse outcome is central to clinical practice. In 
clinical environment, stratification of patients by risk, based on survival models is frequently 
used in the evaluation of treatments or on the impact of prognostic factors on survival.  This 
begins with modelling empirical data either with a classifier or a failure time model, 
depending on whether the data represents a snapshot in time of the patient’s condition at 
diagnosis, or evolution of the disease over time in a longitudinal cohort study.  Either way, the 
equivalent of the linear argument β.x in a Generalised Linear Model defines a prognostic 
index that ranks patient data by severity of the illness. In the case of breast cancer, typically a 
piecewise linear model is used (Cox, 1972) from which the prognostic index can be derived. 
After defined a prognostic index, this may be used to stratify patients into risk groups with 
statisticy significant grouped outcomes.  A good example of this is the Nottingham Prognostic 
Index (NPI) which is widely used in clinical practice (Haybittle, Blamey, Elston, Johnson, 
Doyle, Campbell, Nicholson, Griffiths, 1982). The same principles apply when flexible 
models are used, such as generic non-linear algorithms including artificial neural networks. 
First, the results from two stratification methodologies are presented and compared, 
namely the log-rank bootstrapping methodology and the minimum p-value methodology. 
Secondly, the results obtained with the regression tree methodology, the k-means clustering 
methodology and the clustering methodology based on learning metrics are presented 
followed by a comparison between all the presented methodologies of stratification. 
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4.6.1. Log-rank bootstrapping methodology and minimum p-value methodologies 
The log-rank bootstrapping stratification methodology, as well as the minimum p-value 
methodology, were applied to both prognostic indices, one obtained through the Generalised 
Linear model, Cox regression and other obtained with the PLANN-ARD model.  
The log-rank bootstrap methodology and the minimum p-value methodology stratify the 
prognostic index directly, obtained for each patient. Both methodologies were applied to a 
previous published model where a new attribute was created to denote the missing values of 
the model (Jarman et al, 2008), using the Christie data set 1983-89 to train the model. The 
robustness of the bootstrapping log-rank approach to risk group identification is illustrated in 
Figure 4.14. The bootstrap log-rank methodology has found 4 different risk groups for both 
prognostic indexes whereas the minimum p-value methodology has found 6 different risk 
groups for both prognostic indexes. The small size sample causing the unexpected outcome 
profiles in the solution with 6 risk groups may be an indication that this methodology is over-
fitted to the training data, for both prognostic index calculations. 
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Figure 4.14 – Actuarial estimates of survival obtained with KM for the training data set. 
The number of cases is 917, stratified using the log-rank test over a 60 month period. The top row uses 
the minimum p-value method and the bottom row uses the proposed method for increasing robustness 
in the risk stratification. The left column uses Cox regression modelling and the right column the 
PLANN-ARD neural network. 
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An out-of sample or temporal validation for the log-rank bootstrapping methodology and 
minimum p-value methodology was developed using a second data set from the same centre, 
which was collected between 1990 and 1993. Analysing the “Kaplan Meier” curves, as well 
as the log-rank pairwise comparisons for the validation data set, the performance of the new 
methodology for stratification of illness indices can be evaluated. The robustness of the new 
approach to risk group identification applied to an out-of-sample data set is illustrated in 
Figure 4.15 and Table 4.23. Although the standard methodology applied to the training data 
set stratifies the patients with a significant difference in survival, the same does not happen 
when it is applied to the validation data set.  
 
 
 
Figure 4.15 – Actuarial estimates of survival obtained with KM for the validation data set. 
There are 931 cases, stratified using the cut-off points found in the training data set, over a 60 month 
period. The top row uses the minimum p-value method and the bottom row uses the proposed method 
for increasing robustness in risk stratification. The left column uses Cox regression modelling and the 
right column the PLANN-ARD neural network. 
 
The minimum p-value methodology’s lack of robustness can be observed in the Kaplan 
Meier curves using the PLANN-ARD for modelling (Figure 4.15), where there is no 
significant survival difference between risk groups 1 and 2 and risk groups 3 and 4. The same 
evidence can be observed in the log-rank pairwise comparisons (Table 4.23), where there is 
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no significant difference between the referred groups. On the other hand, analysing both 
Kaplan Meier curves and log-rank pairwise comparisons, it can be observed that there is a 
significant survival difference in patient stratification using the methodology proposed. 
While analyzing the out-of-sample validation of both stratification methodologies, it can be 
concluded, as it was suggested before, that the minimum p-value methodology is overfited to 
the training data set, resulting in not so good patient stratification when it is applied to a 
different data set. The new proposed methodology has however a very good performance 
when it is applied to an out-of-sample data set, as the difference in group-risk survival is 
highly significant. 
 
1 2 3 4 5 
 Risk Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 0.0006 (0.9803) - - - - 
3 6.31 (0.0120) 
3.84 
(0.05) - - - 
4 12.29 (0.0050) 
4.37 
(0.0365) 
0.1010 
(0.7507) - - 
5 32.78 (0.0000) 
12.97 
(0.0003) 
1.0443 
(0.3068) 
8.4239 
(0.0037) - 
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
6 134.66 (0.0000) 
50.14 
(0.0000) 
10.9272 
(0.0009) 
91.59 
(0.0000) 
15.36 
(0.0000) 
 
 
1 2 3 
 Risk Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 7.9833 (0.0047) - - 
3 69.59 (0.000) 
39.71 
(0.0000) - 
L
og
 R
an
k 
(M
an
te
l-C
ox
) 
4 125.99 (0.000) 
73.50 
(0.000) 
7.23 
(0.0072) 
 
Table 4.23 – Log rank pairwise comparisons for the validation data set. 
Both tables represent the validation modelling with PLANN-ARD. The top table represents the 
minimum p-value methodology and the bottom table represents the log-rank bootstrap methodology 
for increasing robustness in the risk stratification. 
 
The log-rank bootstrapping methodology was applied to both prognostic models, Cox 
proportional hazards and PLANN, developed in chapter 2 for overall mortality using the 
Christie data set 1990-93, the six most predictive variables (Histological grade, Histological 
type, Age, Oestrogen, Pathological size and Nodes Ratio) and the missing imputation 
methodology. The log-rank bootstrapping methodology was validated on the BCCA data set 
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also using the missing imputation methodology previously explained, also applied to both 
model Cox proportional hazards and PLANN. This stratification methodology obtained 4 
different risk survival groups for both prognostic models, where the risk group allocation 
retains very good separation between the observed survival in each group, measured by the 
actuarial estimates (Kaplan-Meier) for both training and validation data set, see Figure 4.16. 
This separation is quantified using the log-rank test, which gives strong statistical significance 
for all pairwise tests, for both training and validation data sets, reflecting the separation 
between the confidence intervals shown in Table 4.24 and Table 4.25.   
 
 
Figure 4.16 – KM curves using the log-rank bootstrapping methodology for both PI. 
The left pictures represents the KM curves using the PLANN-ARD index and the right pictures 
represents the KM curves using the Cox model. The top pictures were obtained for the training data 
set while the bottom pictures were obtained for the validation data set. 
 
A concern of many clinicians is the ‘black box’ nature of artificial neural networks (ANN) 
(Lisboa, 2002) which raises the important issue of explaining individual inferences by the 
network. This is a key stage in evaluating the clinical plausibility of inferences made by 
analytical models to enable clinicians to apply these inferences with confidence. A previously 
published methodology designed to extract low-order Boolean rules from data will be used. 
The orthogonal search rule extraction (OSRE) algorithm (Etchells, Lisboa, 2006) provides a 
practical and efficient tool to explain the otherwise black box predictions from artificial neural 
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models. The OSRE methodology searches for rules using multivariate descriptions of data 
sub-sets and therefore can be applied to the bootstrap log-rank stratification methodology in 
order to define each risk group in terms of clinical rules. Table 4.26  represents the rules for 
the prognostic index obtained with Cox proportional hazards modelling and Table 4.27  
represents the rules for the prognostic index obtained with PLANN-ARD. 
 
1 2 3 
 Risk Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 10.90 (0.0010) - - 
3 62.27 (0.000) 
15.11 
(0.0001) - 
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
4 135.58 (0.000) 
61.02 
(0.000) 
47.79 
(0.000) 
Table 4.24 – Log-rank pairwise values for the different risk groups.  
These were obtained using the log-rank bootstrapping methodology for both prognostic indices 
obtained. The left table represents the log-rank pairwise values using the PLANN-ARD index and the 
right table represents the log-rank values pairwise using the Cox model, for the training data set. 
 
 
 
 
 
 
 
 
Table 4.25 – Log-rank pairwise values for the different risk groups. 
These were obtained using the log-rank bootstrapping methodology for both prognostic indices 
previously obtained. The left table represents the log-rank pairwise values using the PLANN-ARD 
index and the right table represents the log-rank values pairwise using the Cox model, for the 
validation data set. 
 
It is interesting to verify that the differences from the training to the validation data set on 
the mean survival KM curves are very similar for both Cox and PLANN modelling. For both 
modelling there is a decreasing on the mean survival value from training and validation, for 
risk group 1 and 2, with a difference of approximately 3 % and 2%, respectively. However, 
there is an increasing on the mean survival values for the 4th risk group from training and 
validation. The training and validation survival values for risk group 3 are very similar, for 
both modelling. 
 
 1 2 3 
 
Risk 
Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 18.26 (0.000)   
3 77.47 (0.000) 
13.31 
(0.0003)  
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
4 218.31 (0.000) 
61.64 
(0.000) 
18.71 
(0.000) 
 1 2 3 
 
Risk 
Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 57.20 (0.000) - - 
3 193.80 (0.000) 
25.85 
(0.000)  
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
4 403.70 (0.000) 
104.63 
(0.000) 
31.93 
(0.0000) 
 1 2 3 
 
Risk 
Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 57.21 (0.000) - - 
3 230.24 (0.000) 
37.96 
(0.000) - 
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
4 406.73 (0.000) 
113.53 
(0.000) 
32.43 
(0.000) 
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Rule 1 Pathsize=1 and Noderatio=1 and Histgrade =1 or 2 
Rule 2 Age=2 and Noderatio=1 and Oestrogen=2 and Histgrade =1 or 2 
Rule 3 Noderatio=1 and Histype=2  
Rule 4 Pathsize=1 and Noderatio=1 or 2 or 3 and Histgrade = 1  
Rule 5 Pathsize=1 and Histype=2  
Rule 6 Pathsize=1 and Noderatio=1 and Oestrogen=2 and Age= 2 R
isk
 G
ro
up
 1
 
Rule 7 Oestrogen=2 and Noderatio=1 and Histgrade=1  
Rule 1 Histgrade=2 and Histype=1 and Noderatio=1 and Oestrogen=2 and Age= 1 or 3 and 
Pathsize=2 
Rule 2 Histgrade=3 and Noderatio=1 and Oestrogen=1 and Age= 2 and Pathsize=1 
Rule 3 Histgrade=3 and Noderatio=1 and Oestrogen=2 and Age= 1 or 3 and Pathsize=1 
Rule 4 Histgrade=2 and Histype=1 and Noderatio=2 and Age= 2 or 3 and Pathsize=1 
Rule 5 Histgrade=2 and Histype=1 and Noderatio=1 and Oestrogen=1 and Age=2 and Pathsize=2 
Rule 6 Histgrade=3 and Noderatio=1 and Oestrogen=2 and Age= 2 and Pathsize=2 
Rule 7 Histgrade=2 and Histype=1 and Noderatio=3 and Oestrogen=2 and Age=2 and Pathsize=2 
R
isk
 G
ro
up
 2
 
Rule 8 Histgrade=2 and Histype=1 and Noderatio=2 or 3 and Age=2 and Pathsize=1 
Rule 1 Histgrade=3 and Noderatio=1 or 3 and Oestrogen=1 and Pathsize=2 
Rule 2 Histgrade=1 or 2 and Noderatio=2 or 3 and Oestrogen=2 and Age= 2 or 3 and Pathsize=2 
Rule 3 Histgrade=3 and Noderatio=1 or 3 and Age= 1 or 3 and Pathsize=2 
Rule 4 Histype=1 and Noderatio=1 or 2 and Oestrogen=1 and Age= 1 or 3 and Pathsize=2 
Rule 5 Histgrade=3 and Noderatio=1 or 2 and Oestrogen=1 and Age= 1  
Rule 6 Histype=2 and Noderatio=2 or 4 and Pathsize=2 
Rule 7 Histgrade=2 and Histype=1 and Noderatio=4 and Pathsize=1 
R
is
k 
G
ru
p 
3 
Rule 8 Histgrade=3 and Noderatio=2 or 3 and Oestrogen=1 and Pathsize=1 
Rule 1 Histgrade=2 or 3 and Histype=1 and Noderatio=2 or 4 and Pathsize=2 
Rule 2 Histype=1 and Noderatio=4 and Oestrogen=1  
Rule 3 Histgrade=3 and Noderatio=2 or 3 or 4  and Age= 1  
Rule 4 Noderatio=2 or 3 or 4 and Oestrogen=1 and Age= 1 and Pathsize=2 R
is
k 
G
ro
up
 4
 
Rule 5 Histgrade=3 and Noderatio=2 or 3 or 4 and Oestrogen=1 and Age= 1 or 3 and Pathsize=2 
Table 4.26 – Rules obtained with OSRE. 
OSRE was applied to bootstrap log-rank stratification methodology using the Cox proportional 
hazards prognostic index. 
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Rule 1 Pathsize=1 and Noderatio=1 and Histgrade =1 or 2 and Oestrogen=2 
Rule 2 Histgrade=1 or 2 and Noderatio=1 and Oestrogen=2 and Age= 2  
Rule 3 Histype=2 and Pathsize=1 
Rule 4 Histype=2 and Noderatio=1 and Oestrogen=2 and Age= 2 or 3  
Rule 5 Histgrade=1 and Noderatio=1 or 2 or 3 and Age= 2 and Pathsize=1 
Rule 6 Histgrade=1 or 2 and Noderatio=1 and Age= 2 and Pathsize=1 R
isk
 G
ro
up
 1
 
Rule 7 Noderatio=1 and Oestrogen=2 and Age= 2 and Pathsize=1 
Rule 1 Histgrade=1 or 2 and Histype=1 and Noderatio=1 and Oestrogen=2 and Age= 3 and 
Pathsize=2 
Rule 2 Histgrade=3 and Noderatio=1 and Oestrogen=1 and Age=2 and Pathsize=1 
Rule 3 Histgrade=1 or 2 and Histype=1 and Noderatio=2 or 3 and Age= 3 and Pathsize=1 
Rule 4 Histgrade=3 and Noderatio=1 and Oestrogen=2 and Age= 3 and Pathsize=1 
Rule 5 Histgrade=3 and Noderatio=1 and Oestrogen=2 and Age= 2 and Pathsize=2 
Rule 6 Histgrade=2 or 3 and Histype=1 and Noderatio=2 and Oestrogen=2 and Age= 2 or 3 and 
Pathsize=1 
Rule 7 Histgrade=1 or 2 and Histype=1 and Noderatio=3 and Oestrogen=2 and Age=2 and 
Pathsize=2 
Rule 8 Histgrade=2 and Noderatio=1 and Oestrogen=2 and Age= 1 and Pathsize=1 
Rule 9 Histgrade=2 and Histype=1 and Noderatio=3 and Oestrogen=1 and Pathsize=1 
R
isk
 G
ro
up
 2
 
Rule 10 Histype=2 and Noderatio=1 and Oestrogen=1 and Age= 3 and Pathsize=2 
Rule 1 Histgrade=2 or 3 and Histype=1 and Noderatio=1 and Oestrogen=1 and Age=2 and 
Pathsize=2 
Rule 2 Histgrade=2 and Noderatio=2 or 3 and Oestrogen=2 and Age= 2 or 3 and Pathsize=2 
Rule 3 Histgrade=3 and Noderatio=1 or 3 and Oestrogen=1 and Age= 1 or 3 and Pathsize=1 
Rule 4 Histgrade=3 and Noderatio=1 and Oestrogen=2 and Age= 1 or 3 and Pathsize=2 
Rule 5 Histgrade=1 or 2 and Histype=1 and Noderatio=1 and Oestrogen=1 and Age= 2 or 3 and 
Pathsize=2 
Rule 6 Histype=1 and Noderatio=1 and Oestrogen=2 and Age= 1 and Pathsize=2 
Rule 7 Noderatio=4 and Age=2 and Pathsize=1 
Rule 8 Histgrade=1 or 2 and Histype=1 and Noderatio=2 or 3 and Oestrogen=1 and Age=2 and 
Pathsize=2 
Rule 9 Histgrade=3 and Noderatio=2 or 3 and Oestrogen=1 and Age= 2 or 3 and Pathsize=1 
R
is
k 
G
ru
p 
3 
Rule 10 Histype=1 and Noderatio=1 and Oestrogen=1 and Age= 1 and Pathsize=1 
Rule 1 Histgrade=3 and Oestrogen=1 and Age= 1 or 3 and Pathsize=2 
Rule 2 Histype=1 and Noderatio=4 and Pathsize=2 
Rule 3 Histype=1 and Noderatio=2 or 3 or 4 and Oestrogen=1 and Pathsize=2 
Rule 4 Histgrade=3 and Noderatio=2 or 3 or 4 and Age= 1 or 3 and Pathsize=2 
Rule 5 Histype=1 and Noderatio=4 and Age= 1 or 3  
Rule 6 Noderatio=4 and Age= 1 or 3 and Pathsize=2 
Rule 7 Oestrogen=1 and Age=1 and Pathsize=2 
Rule 8 Noderatio=2 or 3 or 4 and Oestrogen=1 and Age= 1  
Rule 9 Histype=1 and Noderatio=2 or 4 and Age= 1 and Pathsize=2 
R
isk
 G
ro
up
 4
 
Rule 10 Noderatio=4 and Oestrogen=1 
Table 4.27 – Rules obtained with OSRE. 
OSRE was applied to bootstrap log-rank stratification methodology using PLANN-ARD prognostic 
index. 
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Mean KM 
survival 
Cox 
Training 
Mean KM 
survival for 
Cox 
Validation 
Differences 
Mean KM 
survival 
PLANN –ARD 
Training 
Mean KM 
survival 
PLANN-ARD 
Validation 
Differences 
1 97,53 95,26 2,27 97,85 95,26 2,59 
2 89,02 87,33 1,69 91,71 87,23 4,48 
3 74,10 76,68 -2,58 76,51 78,21 -1,7 R
is
k 
G
ro
up
s 
4 43,59 60,37 -16,78 59,09 64,55 -5,46 
Table 4.28 – Mean KM survival values at the end of follow up (5 years). 
This was computed for the Cox Proportional hazards modelling and PLANN-ARD modelling, for the 
training and validation data set. 
4.6.2. Regression tree stratification methodology 
Regression tree decision methodology was performed using CART algorithm (Breiman, 
Friedman, Olsen, Stone, 1984) where there were 6 predictor categorical variables 
(Histological grade, Histological type, Nodes Ratio, Oestrogen, Pathological size and Age) 
and one continuous target variable, which was the prognostic index already obtained. One tree 
was developed using the prognostic index obtained with Cox Proportional Hazards and 
another tree was developed using the PLANN-ARD Modeling. Missing values were 
incorporated in the modelling, using the multiple imputation methodology previously 
mentioned. It is important to mention that the predictor variables used in CART are the mode 
of the 10 imputed data sets obtained previously, both for training and validation data set. It is 
important to mention, that a full tree is complex and can yield an overly optimistic goodness 
of fit. Thus, methods to reduce the tree size have been developed so that the model is 
predictive in other cohorts. Moreover, it is essential that the leaves contain statistically 
significant patients, as they need to be compared to each other in order to identify the 
belonging to a risk group. Therefore, it was defined that the minimum number of records for 
each node tree was 20, and the minimum number of records for each leaf was 10, in order to 
define a significance level of populations to be compared. At the maximum grow of the tree, 
both trees, one with the prognostic index calculated with Cox regression and another with the 
prognostic index calculated with PLANN-ARD, finalized with 41(N) and 47 (N) leaves, 
respectively. The “Cox regression tree” has an error of 0,079 and the “PLANN-ARD” 
regression tree has an error of 0,089, both calculated using a 10 fold cross-validation. After 
the development of the “pruning method” both trees finalized with 4 different groups, which 
means the regression tree, after the “pruning method” ended as a classification tree, as it can 
be observed in the following figures.  
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Figure 4.17 – Final classification tree using the PI obtained with PLANN-ARD. 
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Figure 4.18 – Final classification tree using the PI obtained with Cox regression. 
Chapter 4 – Results 
125 
Figure 4.19 represents the box plots identified for the different risk groups as well as for 
both prognostic indices. It can be observed that the confidence intervals for the different risk 
groups are very low and as long as the risk group goes higher the prognostic index also goes 
higher, showing that the risk groups are consistent with the prognostic index.  
 
Figure 4.19 – Box-plots for the different risk groups. 
The risk groups were obtained using the regression tree stratification method for both prognostic 
indices previously obtained, for the training data set. The left picture represents the box plots using 
the PLANN-ARD prognostic index and the left picture represents the box plot using the Cox 
prognostic index. 
 
Kaplan-Meier curves, as well as the log-rank pairwise comparisons were obtained, for both 
obtained trees, and for the training data set, where it can be sustained that group allocation 
retains very good separation between the observed survival in each group, measured by the 
actuarial estimates (Kaplan-Meier). This separation is quantified using the log-rank test, 
which gives strong statistical significance for all pairwise tests. The weakest separation is 
between groups 2 and 3 using PLANN-ARD, for which the p-value is 0.0048. 
 
 
Figure 4.20 – KM curves using the regression tree stratification method for both PI.  
The left picture represents the KM curves using the PLANN-ARD index and the right picture 
represents the KM curves using the Cox model, using the training data set. 
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1 2 3 
 Risk Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 17.50 (0.000)   
3 46.86 (0.000) 
7.96 
(0.0048)  
Lo
g 
R
an
k 
(M
an
te
l-
C
ox
) 
4 141.53 (0.000) 
61.02 
(0.000) 
13.27 
(0.0003) 
 
Table 4.29 – Log-rank pairwise values for the different risk groups. 
These were obtained using the regression tree stratification method for both prognostic indices 
previously obtained. The left table represents the log-rank pairwise values using the PLANN-ARD 
index and the right table represents the log-rank values pairwise using the Cox model, using the 
training data set. 
 
One of the main advantages of this stratification methodology is its simplicity and 
transparency of group composition, using the rules that are obtained at the final built tree. The 
rules for the previously showed trees are on Table 4.30 and Table 4.31 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 
 Risk Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 27.96 (0.000)   
3 80.14 (0.000) 
16.32 
(0.000)  
Lo
g 
R
an
k 
(M
an
te
l-
C
ox
) 
4 207.01 (0.000) 
73.09 
(0.000) 
9.44 
(0.0021) 
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Table 4.30 – Rules obtained with regression tree using the Cox proportional hazards PI. 
 
 
 
 
 
 
 
 
 
 
 
Rule 1 Pathsize=1 and Noderatio=1 and Histype=2 and Histgrade =1 or 2 
Rule 2 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade =1 
Rule 3 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade = 2 and Age =2 
Rule 4 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade = 2 and Age =3 and Oestrogen 
=2 
Rule 5 Pathsize=1 and Noderatio≠1 and Histype=2 and Histgrade =1 or 2 and Age=1 or 2 
Rule 6 Pathsize=1 and Noderatio≠1 and Histype=1 and Histgrade =1 and Age=1 or 2 
Rule 7 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=2 and Age =2 
Rule 8 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=2 and Age =1 or 3 and 
Oestrogen=2 
R
isk
 G
ro
up
 1
 
Rule 9 Pathsize=2 and Noderatio=1 and Histgrade=1 and Histype=1 and Oestrogen=2 
Rule 1 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade = 2 and Age =1 and Oestrogen 
=2 
Rule 2 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade=2 and Age =1 or 3 and 
Oestrogen =1 
Rule 3 Pathsize=1 and Noderatio≠1 and Histype=2 and Histgrade =1 or 2 and Age=3 
Rule 4 Pathsize=1 and Noderatio≠1 and Histype=1 and Histgrade =1 and Age=3 
Rule 5 Pathsize=1 and Histgrade=3 and Noderatio=1 
Rule 6 Pathsize=1 and Histgrade=2 and Noderatio≠1 and Histype=1 and Age=1 or 3  
Rule 7 Pathsize=1 and Histgrade=2 and Noderatio=2 or 3 and Histype=1 and Age=2 
Rule 8 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=2 and Age =1 or 3 and 
Oestrogen=1 
Rule 9 Pathsize=2 and Noderatio=1 and Histgrade=1 and Histype=1 and Oestrogen=1 
Rule 10 Pathsize=2 and Noderatio=1 and Histgrade=2 and Histype=1 
Rule 11 Pathsize=2 and Noderatio =1 and Histgrade=3 and Age=2 
Rule 12 Pathsize=2 and Noderatio =1 and Histgrade=3 and Age=1 or 3 and Oestrogen=2 
Rule 13 Pathsize=2 and Noderatio = 2 or 3 and Histgrade=1 or 2 and Histype=2 
R
isk
 G
ro
up
 2
 
Rule 14 Pathsize=2 and Noderatio = 2 or 3 and Histgrade=1 or 2 and Histype=1 and Age=2 
Rule 1 Pathsize=1 and Histgrade=3 and Noderatio≠1 
Rule 2 Pathsize=1 and Histgrade=2 and Noderatio=4 and Histype=1 and Age=2 
Rule 3 Pathsize=2 and Noderatio=1 and Histgrade=3 and Age=1 or 3 and Oestrogen=1 
Rule 4 Pathsize=2 and Noderatio=4 and Histype=2 
Rule 5 Pathsize=2 and Noderatio=3 and Histgrade=3 
R
isk
 G
ro
up
 3
 
Rule 6 Pathsize=2 and Noderatio=2 or 3 and Histgrade=1 or 2 and Histype=1 and Age=1 or 3 and 
Oestrogen=2 
Rule 1 Pathsize=2 and Noderatio=2 or 3 and Histgrade=1 or 2 and Histype=1 and Age=1 or 3 and 
Oestrogen=1 
Rule 2 Pathsize=2 and Noderatio=2 and Histgrade=3 R
is
k 
G
ro
up
 
4 
Rule 3 Pathsize=2 and Noderatio=4 and Histype=1 
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Rule 1 Pathsize=1 and Noderatio=1 and Age=2 and Histgrade =1 or 2 
Rule 2 Pathsize=1 and Noderatio=1 and Histype=2 and Histgrade =1 or 2 and Age=3 
Rule 3 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade = 1 and Age =3 and Oestrogen =2 
Rule 4 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade = 2 and Age =3 
Rule 5 Pathsize=1 and Noderatio=2 or 3 and Histype=2 and Histgrade = 1 or 2 and Age =2 
Rule 6 Pathsize=1 and Noderatio=2 or 3 and Histype=1 and Histgrade =1 and Age=2 
Rule 7 Pathsize=1 and Noderatio=1 and Histgrade=3 and Oestrogen=2 and Age =2 
Rule 8 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=2 and Age =2 
Rule 9 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=2 and Age =1 or 3 and 
Oestrogen=2 
R
isk
 G
ro
up
 1
 
Rule 10 Pathsize=2 and Noderatio=1 and Histgrade=1 and Oestrogen=2 and Age=2 and Histype=1 
Rule 1 Pathsize=1 and Noderatio=1 and Histgrade = 1 or 2 and Age =1 
Rule 2 Pathsize=1 and Noderatio=1 and Histype=1 and Histgrade = 1 and Age =3 and Oestrogen =1 
Rule 3 Pathsize=1 and Noderatio= 2 or 3 and Histype=2 and Histgrade =1 or 2 and Age=1 or 3 
Rule 4 Pathsize=1 and Noderatio=2 or 3 and Histype=1 and Histgrade =1 and Age=1 or 3 
Rule 5 Pathsize=1 and Noderatio=2 or 3 and Histype=1 and Histgrade =2  
Rule 6 Pathsize=1 and Histgrade=3 and Noderatio=1 and Age=2 and Oestrogen=1  
Rule 7 Pathsize=1 and Histgrade=3 and Noderatio=1 and Age=3 
Rule 8 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=2 and Age =1 or 3 and 
Oestrogen=1 
Rule 9 Pathsize=2 and Noderatio=1 and Histgrade=1 or 2 and Histype=1 and Oestrogen=1 and 
Age=2 
Rule 10 Pathsize=2 and Noderatio=1 and Histgrade=2 and Histype=1 and Age=2 and Oestrogen=2 
Rule 11 Pathsize=2 and Noderatio =1 and Histgrade=3 and Age=2 and Oestrogen=2 
Rule 12 Pathsize=2 and Noderatio =1 and Histgrade=1 or 2 and Age=3 and Oestrogen=2 and 
Histype=1 
R
isk
 G
ro
up
 2
 
Rule 13 Pathsize=2 and Noderatio = 2 or 3 and Histgrade=1 or 2 and Histype=2 
Rule 1 Pathsize=1 and Histgrade=3 and Noderatio=1 and Age=1 
Rule 2 Pathsize=2 and Histgrade=1 or 2 and Noderatio=1 and Histype=1 and Age=1 or 3 and 
Oestrogen=1 
Rule 3 Pathsize=2 and Histgrade=3 and Noderatio=1 and Age=1 or 3 and Oestrogen=2 
Rule 4 Pathsize=2 and Histgrade=1 or 2 and Noderatio=1 and Histype=1 and Age=1 and 
Oestrogen=2 
Rule 5 Pathsize=2 and Noderatio=1 and Histgrade=3 and Age=2 and Oestrogen=1 
Rule 6 Pathsize=2 and Noderatio=2 or 3 and Histgrade=1 or 2 and Age=2 and Histype=1 R
isk
 G
ro
up
 3
 
Rule 7 Pathsize=2 and Noderatio=2 or 3 and Histgrade=1 or 2 and Age= 3 and Oestrogen=2 and 
Histype=1 
Rule 1 Pathsize=1 and Histgrade=1 or 2 and Noderatio=4 
Rule 2 Pathsize=1 and Noderatio=2 or 3 or 4 and Histgrade=3 
Rule 3 Pathsize=2 and Noderatio=4  
Rule 4 Pathsize=2 and Noderatio=2 or 3 and Histgrade=3 
Rule 5 Pathsize=2 and Noderatio=2 or 3 and Histgrade=1 or 2 and Histtype=1 and Age=1 or 3 and 
Oestrogen=1 
Rule 6 Pathsize=2 and Noderatio=2 or 3 and Histgrade=1 or 2 and Histtype=1 and Age=1 and 
Oestrogen=2 
R
isk
 G
ro
up
 4
 
Rule 7 Pathsize=2 and Noderatio=1 and Histgrade=3 and Age=1 or 3 and Ostrogen=1 
Table 4.31 – Rules obtained with regression tree using the PLANN-ARD PI. 
 
An out-of sample or temporal validation for the regression tree methodology was 
performed using the BCCA data set. As in the development of both trees, it was also used the 
missing imputation methodology and it was used also the mode of the covariates, considering 
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the 10 imputed data sets. The obtained rules from the final trees were applied for each patient 
on the validation data set identifying which ones belong to each risk group. 
Figure 4.21 represents the box plots identified for the different risk groups, for both 
prognostic indices obtained with PLANN-ARD and Cox proportional hazards. It can be 
observed that the confidence intervals for the different risk groups are very low as in the 
training data set. As long as the risk group goes higher the prognostic index also goes higher, 
showing that the risk groups are consistent with the prognostic index.  
  
Figure 4.21 – Box-plots for the different groups. 
These were obtained using the regression tree stratification method for both prognostic indices 
previously obtained, for the validation data set. The left picture represents the box plots using the 
PLANN-ARD prognostic index and the left picture represents the box plot using the Cox prognostic 
index. 
 
Analysing the “Kaplan Meier” curves as well as log rank pairwise comparisons for the 
validation data set, the performance of the regression tree methodology for stratification of 
illness indices, can be evaluated. The robustness of this approach to risk group identification 
applied to an out-of-sample data set is illustrated in Figure 4.22 Table 4.33 . 
  
Mean KM 
survival 
Cox 
Training 
Mean KM 
survival for 
Cox 
Validation 
Differences 
Mean KM 
survival 
PLANN –ARD 
Training 
Mean KM 
survival 
PLANN-ARD 
Validation 
Differences 
1 98.29 95.49 2.8 98.29 95.10 3.19 
2 87.20 86.14 1.06 90.28 88.73 1.55 
3 70.13 70.37 -0.24 79.81 79.27 0.54 R
is
k 
G
ro
up
s 
4 40.54 63.30 -22.76 56.57 67.63 -11.06 
Table 4.32 – Mean KM survival values at the end of follow up (5 years).  
These were obtained for Cox Proportional hazards modelling and PLANN-ARD modelling, for the 
training and validation data set. 
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Figure 4.22 – KM curves using the regression tree stratification method for both PI. 
The left picture represents the KM curves using the PLANN-ARD index and the right picture 
represents the KM curves using the Cox model, using the validation data set. 
 
Kaplan-Meier curves, as well as the log-rank pairwise comparisons were obtained, for both 
trees, where it can be confirmed that group allocation retains very good separation between 
the observed survival in each group, measured by the actuarial estimates (Kaplan-Meier). This 
separation is quantified using the log-rank test, which gives strong statistical significance for 
all pairwise tests. The weakest separation is for groups 3 and 4 using Cox prognostic index, 
the same obtained with the training data set, for which the p-value is 0.0526. The Kaplan 
Meier curves as well as the log-rank pairwise values obtained increase our expectation that 
this is a very good method to allocate the patients in different risk groups, even when there are 
some differences of the mean survival from the training to the validation data set as it can be 
observed on table Table 4.32 , which represents the KM survival values at the end of follow 
up. It is interesting to verify that the differences from the training to validation data set on the 
mean survival KM curves are very similar for both Cox and PLANN modelling. For both 
modelling there is a decreasing on the mean survival value from training and validation, for 
risk group 1 and 2, with a difference of approximately 3 % and 1%, respectively. However, 
there is an increasing on the mean survival values for the 4th risk group from training and 
validation. The training and validation survival values for risk group 3 are very similar for 
both modelling. 
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Table 4.33 – Log-rank pairwise values for the different risk groups. 
These were obtained using the regression tree stratification method for both prognostic indices 
previously obtained. The left table represents the log-rank pairwise values using the PLANN-ARD 
index and the right table represents the log-rank values pairwise using the Cox model, using the 
validation data set. 
4.6.3.  Unsupervised clustering stratification methodology 
The clustering method is an orthogonal, unsupervised, approach where the clinical data is 
first clustered without reference to the PI, then organised in order of mean group survival. It is 
an iterative k-means algorithm, which uses Monte Carlo methods to overcome initialization 
problems. The algorithm was applied to the training data set and all variables were normalized 
using the metric (value-min_variable)/ (max_variable- min_variable). As it was employed the 
imputation methodology, it was used the mode of variables obtained from the 10 imputed data 
sets. Moreover, only the variables previously reasoned as the most predictive ones to the 
prognostic model were considered (Histological grade, Histological Type, Oestrogen, Age, 
Pathological size and Nodes Ratio). 
Two indices were used in order to verify the consistency of this method. The first one is 
the Fisher separation index for each cluster partition, invariant J value, and the second one is 
the Cramer V-index. For each individual partition, the Cramer V-index is measured for every 
pairing with the remaining cluster partitions of a given cluster number, and the median value 
is recorded. The Cramer V-index is a measure of concordance, which quantifies the extent of 
consistency between many cluster partitions with the same number of clusters but with 
random initializations. A value equal to one means that the mean of the patients are always 
assigned to the same cluster, even with different initializations. Thus, the more the values are 
close to 1, the clustering is more consistent for each initialization. For a given cluster number, 
the methodology starts with N initializations of the clustering algorithm. The results are not 
particularly sensitive to either the value of N or the proportion of clustering kept, as long as 
these numbers are large enough to show the structure of the cluster solution space.  
 1 2 3 
 
Risk 
Groups 
 
X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 38.6166 (0.000) - - 
3 135.6330 (0.000) 
31.2572 
(0.000) - 
Lo
g 
R
an
k 
(M
an
te
l-
C
ox
) 
 
4 327.8023 (0.000) 
133.6450 
(0.000) 
22.5478 
(0.0000) 
 1 2 3 
 
Risk 
Groups 
 
X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 79.0760 (0.000) - - 
3 244.9665 (0.000) 
68.3584 
(0.000) - 
Lo
g 
R
an
k 
(M
an
te
l-
C
ox
) 
4 308.6466 (0.000) 
100.0789 
(0.000) 
3.7561 
(0.0526) 
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Several cluster solutions were considered, from 2 to 10 cluster centres. Figure 4.23 
presents the box plots considering the Cramer V values, showing the concordance for the 
different solutions. From this figure it can be concluded that the 4 cluster solution has the 
higher concordance values as it is the solution that the median and the mean Cramer V values 
are closer to 1. Mapping the space of cluster partitions, a Separation-Concordance plot, Figure 
4.24 there will be visible an indication of the most suitable cluster number to use for a 
particular data set, since a match between the assumed and actual cluster number is likely to 
result in more stable solutions, i.e. those scoring highest under the Cramer V-index.  Figure 
4.25 represents the cumulative Cramer V Concordance values for the different cluster 
solutions and its area under the curve, where the smaller the area the better cluster solution. 
Therefore, the most likely cluster number is 4. 
 
Figure 4.23 – Concordance plot for different number of clustering. 
 
Chapter 4 – Results 
133 
 
Figure 4.24 – Separation measure (y axis) versus concordance measure (x axis) plot. 
 
 
Figure 4.25 – Cramer Area plot. 
The top figure represents the cumulative Cramer-V scores, for each cluster solution, where the smaller 
the area the better the solution. The bottom figure represents the area under the curve for each 
number of clusters. 
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The box plots related to the two prognostic indices, the Cox and the PLANN-ARD are 
presented on Figure 4.26. It can be observed that the mean of the prognostic indexes are well 
separated for each cluster, showing that the risk groups are consistent with the prognostic 
index, for both Cox and PLANN-ARD. It can also be concluded with that the patients profile 
is consistent with each patient prognostic index for the one obtained with PLANN-ARD and 
Cox proportional hazards modelling. Risk groups displayed distinct observed survival, 
measured by Kaplan-Meier actuarial estimates and log-rank pairwise values, observed in 
Figure 4.27 and Table 4.34. However, it can be observed that the separation between the 3nd 
and the 4th risk group, which are the ones with the higher survival, is not significantly 
different as the p-value is equal to 0.2309.  
 
  
Figure 4.26 – Box plots for the 3 (top figures) and 4 (bottom figures) cluster solution.  
The left pictures represent the graphic using the prognostic index obtained with Cox while the right 
pictures represent the prognostic index obtained with PLANN-ARD. 
 
 
Figure 4.27 – KM curves the 4 cluster solution. 
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Table 4.34 – Log-rank pairwise values for 4 cluster solution. 
 
At the end of the clustering algorithm, these can be converted into rules of variables, which 
determine the characterization of the patient cohorts using the OSRE algorithm, offering 
transparency of group composition, as it can be observed in Table 4.35 .  
 
 Group 1 Group 2 Group 3 Group 4 
Rule 1 
Histgrade =2 or 3 and 
Histype = 1 and 
Noderatio =1 and  
Age =1 or 2 
Noderatio = 3 or 4 
Histgrade = 1 or 2 and 
Histtype = 1 and 
Noderatio = 1 or 2 and 
Age = 3 
 
Histtype = 2 and 
Noderatio = 1 or 2 
 
Rule 2 Histgrade = 3 and Noderatio=1 or 2  - 
Histgrade = 1 and 
Histtype = 1 and 
Noderatio = 1 or 2 
 
- 
Rule 3 
Histgrade =2 or 3 and 
Histype = 1 and 
Noderatio =1 or 2 and 
Oestrogen = 1 and 
Age =1 or 2 
- 
Histgrade = 1 or 2 and 
Histtype = 1 and 
Noderatio = 2 and 
Oestrogen = 2 and   
Age = 2 or 3 
 
- 
Rule 4 
Histgrade = 2 or 3 
and Histtype = 1 and 
Noderatio = 1 or 2 
and Age = 1 
 
- - - 
 
Table 4.35 – Rule-based characterization of the patient cohorts. 
These rules were found using the clustering method followed by the OSRE algorithm. 
 
This stratification methodology was validated in an out-of sample data set, on the BCCA 
data set. The method for validate the clustering algorithm can be one of the three: 
1. Using the centres obtained for each cluster 
2. Using the rules obtained for each centre 
 1 2 3 
 
Risk 
Groups 
 
X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 16.57 (0.0000) - - 
3 9.73 (0.0018) 
43.81 
(0.0000) - 
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
  
4 9.09 (0.0026) 
29.15 
(0.0000) 
1.43 
(0.2309) 
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3. Defining the k records closer to each record to validate. The class is represented as the 
mode of the class for all the k records. (it was used a k = 9)  
The first method was not a good validation approach as it is demonstrated by applying the 
obtained centres to the training data set (the records which were first characterized as 
belonging to a risk group were now characterized as belonging to another risk group). There 
was an error of 79% using the centres of each cluster as a validation method.  
Using the second method, there are some new records that may not be fitted to any of the 
rules obtained with the training data set and can be overlapped in different classes. If this 
happens, these records can be considered as outliers and should be flagged as special cases 
with an explanation of how they differ from the nearest rules. 
The last method finds the nearest records between the training data set and the validation 
data set (euclidean distance) and the existing mode for the 9 nearest records is the class 
labelled for the new record in the validation data set. 
This stratification methodology validation was carried out through the mentioned last two 
ways of doing it, and the patient risk group allocation was compared. Using the rules, 82 
patients were classified as belonging to both risk group 1 and 4. Therefore, they were 
excluded as outliers. Using the k closer records, 47 of these 82 patients were considered to 
belong to risk group 4 and 35 to risk group 1. Analysing the cross-tabulation on Table 4.36 it 
can be observed that both validations are very similar as there were only 26 patients classified 
to different risk groups.  
 
  Clustering rules 
  Group1 Group2 Group3 Group4 Total 
Group1 2014 10 1 0 2025 
Group2 0 385 0 0 385 
Group3 0 0 1320 15 1335 
Group4 0 0 0 189 189 
C
lu
st
er
in
g 
9 
cl
os
er
 
Total 2014 395 1321 204 3934 
 
Table 4.36 – Patients’ cross tabulation using the application of nearest records and rules. 
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Using the k closer records methodology, different risk groups for the validation data set 
were obtained. They displayed distinct observed survival, measured by Kaplan-Meier 
actuarial estimates and log-rank pairwise values, with the exception of risk group 3 and 4 (the 
highest survival risk groups), as it can be observed in Figure 4.28 and Table 4.37 . It can be 
noticed that the survival curves obtained for the training data set are very similar to the ones 
obtained for the validation data set.  
 
Figure 4.28 – KM curves for the 4 cluster solution, using the validation data set. 
 
 
 
 
 
 
Table 4.37 – Log-rank pairwise values for the 4 cluster solution and validation data set. 
4.6.4. Clustering methodology based on learning metrics 
The clustering methodology based on learning metrics approach was applied to 3 
distributions of auxiliary information, i.e. using PICox alone, using PIPLANNARD alone and on 
the joint information from the two independent indices. The first two experiments predicted 
the cluster number to be either 6 or 7. By using the joint information, on the other hand, the 
algorithm stably identifies 5 clusters. Figure 4.29 shows the KM curves for the 5 patient risk 
groups for the training data set, obtained with the joint information, as well as a 2D plot of the 
clustered samples in the space of the prognostic indices. The KM plot clearly shows that 
 1 2 3 
 
Risk 
Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 77.16 (0.0000) - - 
3 13.50 (0.0002) 
122.89 
(0.0000) - 
Lo
g 
R
an
k 
(M
an
te
l-C
ox
) 
4 5.19 (0.0162) 
42.40 
(0.0000) 
0.32 
(0.5711) 
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clusters 2 and 3 denote the same risk profile, while the remaining 3 clusters identify 3 
markedly different survival behaviours.  
On Table 4.38  are the log-rank pairwise values represented on the KM plot, where it can be 
observed that they do not display distinct observed survival, specially for risk groups 1 and 4; 
2 and 3. Figure 4.30 shows the clusters projected onto the 3 principal components of the 
original data (leftmost) and of the dataset subject to the affine transformations induced by the 
Fisher metric (rightmost).  In the original space, cluster 3 is fully contained in a separated 
sample group and such separation in the input space seems to be the cause of the generation of 
a separate cluster with the same survival profile of cluster 2, also in the Fisher space. Overall, 
the clustering analysis seems to confirm that there are 4 risk groups within the data. Clusters 
identify 4 markedly different survival behaviours.  
 
Figure 4.29 – KM curves and cluster in the space of two prognostic indices. 
The left-most picture represents the actuarial estimates of survival obtained with the Kaplan-Meier 
method, stratified over a 60 month period and the right-most picture depicts the clustered samples in 
the space of the two prognostic indices. 
 
 
 
 
 
 
 
Table 4.38 – Log-rank pairwise values for the 5 cluster solution 
 1 2 3 4 
 
Risk 
Groups X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
X ^2 
(sig.) 
2 25.59 (0.0000) - - 
- 
3 22.95 (0.0000) 
0.0684 
(0.7970) - 
- 
4 2.69 (0.1085) 
9.70 
(0.0031) 
9.49 
(0.0027) 
- 
Lo
g 
R
an
k 
(M
an
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l-
C
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) 
5 2.11 (0.1316) 
49.98 
(0.0000) 
42.15 
(0.0000) 
10.63 
(0.0007) 
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Figure 4.30 – Cluster projections on different components.  
The left-most picture shows the clusters projected onto the 3 principal components of the original data 
and the right-most picture shows the affine transformed samples in the Fisher-induced space. 
 
Accordingly, informed clustering with the Fisher information matrix as a metric, finds two 
different patient subgroups with similar disease progression and stratifies the patient 
population into distinct cohorts showing a progression in survival, also reflected by a 
localised distribution of risk scores estimated by either survival model. This approach has the 
merit of allowing a specific definition of the patient population, from which to forward the 
predict grouped survival, instead of inferring a threshold back from the log-rank separation 
index.   
4.6.5.  Comparison between the different stratification methodologies 
Perhaps surprisingly, the four risk allocation methodologies broadly agree, although they 
are founded on very different principles.  However, at the level of detail there are important 
differences.  In particular, it is generally the case in breast cancer that the population of 
operable patients comprises a very well surviving group and another, thankfully a much 
smaller group, with especially poor survival.  Nevertheless, it is the accurate discrimination 
and grouping of patients in the mid-surviving groups that is of most interest, since these two 
groups of patients are those likely to benefit most from better targeting of therapy. 
The prognostic indices obtained with Cox proportional hazards, PICox and with PLANN-
ARD modelling, PIPLANNARD, as well as the mode of the 6 variables found as the most 
predictive ones, for the 10 imputed data sets were used for the different stratification 
methodologies, for both the training and validation data set.  
Using the bootstrap log-rank aggregation, the regression tree method and the unsupervised 
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clustering approach it were found 4 different risk groups. The clustering methodology based 
on learning metrics found 5 different risk groups. The two clustering methods did not display 
distinct observed survival measured by Kaplan-Meier actuarial estimates unlike the regression 
tree methodology and the log-rank bootstrap aggregation method, for both training and 
validation data sets. Therefore, it can be concluded that group separation is much better for 
regression tree and bootstrap log-rank methodology. These two methodologies have a very 
similar survival, for both prognostic indexes and for both training and validation data sets. 
However, looking at the log-rank pairwise values and KM curves, the bootstrap log-rank 
methodology has better separation between the risk groups. Although survival for both 
methods is similar, group membership is not the same, as it can be observed on Table 4.39 .  
 
  Regression tree Cox 
  1 2 3 4 Total 
1 291 73 1 0 365 
2 2 170 1 0 173 
3 0 92 69 5 166 
4 0 1 6 32 39 Bo
ot
st
ra
p 
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nk
  
C
ox
 
Total 293 336 77 37 743 
 
 
 
 
Table 4.39 – Patients’ cross tabulation between two different stratification methodologies. 
These methodologies are Regression tree and bootstrap log-rank aggregation. The left tables 
represent for the prognostic index obtained with Cox proportional hazards and the right tables 
represent for the prognostic index obtained with PLANN-ARD. The top tables are for the training data 
set and the bottom ones are for the validation data set. 
  
For the training data set, with the exception of the 4th risk group, the bootstrap log-rank 
aggregation is generally more conservative in terms of patients’ risk group allocations than 
the regression tree method. However, this analysis is found more for the prognostic index 
obtained with Cox proportional hazard, as the one obtained with PLANN-ARD, the risk group 
allocation is less sparse. This conclusion is also observed for the validation data set, when the 
  Regression tree PLANN 
  1 2 3 4 Total 
1 284 10 0 1 325 
2 9 166 5 1 181 
3 0 39 93 17 149 
4 0 2 6 80 88 Bo
ot
st
ra
p 
 
L
og
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PL
A
N
N
 
Total 293 247 104 99 743 
  Regression tree Cox 
  1 2 3 4 Total 
1 1371 381 0 0 1752 
2 20 900 18 1 939 
3 7 628 356 64 1055 
4 0 10 58 202 270 Bo
ot
st
ra
p 
 
lo
g-
ra
nk
  
C
ox
 
Total 1398 1919 432 267 4016 
  Regression tree PLANN 
  1 2 3 4 Total 
1 1439 325 6 1 1771 
2 68 744 62 19 893 
3 3 146 554 192 895 
4 0 1 10 446 457 Bo
ot
st
ra
p 
 
L
og
-r
an
k 
 
PL
A
N
N
 
Total 1510 1216 632 658 4016 
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Cox proportional hazard is utilized as the prognostic index. As opposite, with the prognostic 
index obtained with PLANN-ARD, the regression tree is more conservative in terms of 
patient’s allocations than the bootstrap log-rank aggregation method. 
Consequently, the bootstrap log-rank method showed clearly the better discrimination in 
survival between the most and least surviving group, and is more conservative than the use of 
regression trees, compared to which it draws a substantial number of patients from group 2 
into group 3. This effect is more pronounced when the linear survival estimator is used, in 
part reflecting the observation that the non-linear estimator, PLANN-ARD, is itself slightly 
more conservative than Cox regression with respect to these two risk groups. 
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Figure 4.31 – Survival curves obtained for the patients’ cross-tabulation. 
They were obtained with the regression trees stratification methodology and bootstrap log-rank 
stratification methodology for the Cox Proportional Hazards and for the validation data set. 
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In order to verify the patients’ consistency allocated to the different stratification 
methodologies, regression tree and bootstrap log-rank, using prognostic risks, Cox 
proportional hazards and PLANN-ARD, the survival curves for the previously cross-
tabulations are plotted on Figure 4.31 and Figure 4.32 , for the validation data set. Analysing 
the survival curves for both risk indexes, the obtained survival curves with the bootstrap log-
rank stratification methodology are more consistent than the ones for regression trees 
methodology. This finding is more evident for Cox proportional hazards model.   
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Figure 4.32 – Survival curves obtained for the patients’ cross-tabulation. 
They were obtained with the regression trees stratification methodology and bootstrap log-rank 
stratification methodology for the PLANN-ARD and for the validation data set. 
 
Comparing the KM curves for the PICox and PIPLANNARD it can be confirmed that, for both 
algorithms (Bootstrap log-rank aggregation and regression tree), survival is lower for the risk 
groups obtained by using PICox, for both training and validation data set. This conclusion is 
more evident for the training data set. However, the risk groups’ patient allocation obtained 
with PIPLANNARD are more conservative than PICox, for both training and validation data set, 
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because patients are allocated in higher risk groups, as it can be observed in Table 4.40 . This 
finding manifests itself more, using the regression tree stratification methodology. 
 
  Cox 
  1 2 3 4 Total 
1 280 13 0 0 293 
2 12 235 0 0 247 
3 0 85 19 0 104 
4 1 3 58 37 99 
PL
A
N
N
-A
R
D
 
Total 293 336 77 37 743 
 
  Cox 
  1 2 3 4 Total 
1 1329 181 0 0 1510 
2 64 1152 0 0 1216 
3 0 560 72 0 632 
4 5 26 360 267 658 
PL
A
N
N
-A
R
D
 
Total 1398 1919 432 267 4016 
 
Table 4.40 – Risk groups’ cross tabulation between different models.  
The left tables represents patients’ cross tabulation for the regression tree method and the right tables 
represents patient’s cross-tabulation using the Bootstrap log-rank aggregation, using the PI obtained 
with Cox and PLANN-ARD. The top tables are for the training data set and the bottom tables are for 
the validation data set. 
 
In order to verify the patients’ consistency allocated to the different prognostic risks, Cox 
proportional hazards and PLANN-ARD, using both regression tree and bootstrap log-rank 
stratification methodologies, the survival curves are plotted the Figure 4.33 and Figure 4.34. 
Analysing the survival curves it can be concluded that for each risk index, the survival curves 
obtained with the PLANN-ARD prognostic index are more consistent than the ones for Cox 
proportional hazards prognostic index. This finding is more evident for the regression tree 
stratification.   
 
 
 
 
 
  Cox 
  1 2 3 4 Total 
1 322 3 0 0 325 
2 43 137 1 0 181 
3 0 33 116 0 149 
4 0 0 49  39 88 
PL
A
N
N
-A
R
D
 
Total 365 173 166 39 743 
  Cox 
  1 2 3 4 Total 
1 1709 62 0 0 1771 
2 43 813 37 0 893 
3 0 64 824 7 895 
4 0 0 194 263 457 
PL
A
N
N
-A
R
D
 
Total 1742 939 1055 270 4016 
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Figure 4.33 – Survival curves obtained for the patients’ cross-tabulation. 
They were obtained with the regression trees stratification methodology for both indexes, Cox 
Proportional Hazards and PLANN-ARD, for the validation data set. 
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Figure 4.34 – Survival curves obtained for the patients’ cross-tabulation. 
They were obtained with the bootstrap log-rank stratification methodology for both indexes, Cox 
Proportional Hazards and PLANN-ARD, for the validation data set. 
 
Regarding all the risk groups, the most similar figures between the training and validation 
data set were achieved for Log-rank bootstrapping aggregation using PLANN as the 
prognostic model. The next more similar values are for the regression decision tree 
stratification methodology using also the PLANN as the prognostic model. Herewith there is 
a greater survival similarity at 5 years between the training and validation data set using the 
PLANN as a prognostic model. 
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4.7 - OSRE and CART rules comparison 
For each rule extraction methodology, CART and OSRE, and for each model used, Cox 
proportional hazards modelling and PLANN-ARD, different rules can be obtained. These 
rules must be applied to new patients in order to obtain the risk group they belong.  
For a specific model, all the rules obtained with regression trees methodology are mutually 
exclusive as opposed to the rules obtained with OSRE. In OSRE a patient can be classified for 
different rules and these rules can be in the same risk group or not. However, OSRE 
determines a rule hierarchy, which means that for each patient each rule is tested in turn and 
as soon as a rule is met for that patient profile it is not necessary going through the hierarchy. 
Even so, a patient can met the requirements of different rules of different risk groups. Here, it 
was chosen a conservative approach that is the patient must belong to the higher risk group. 
When OSRE rules were applied to the development data set, 22 patients were not classified 
for PLANN modelling and 23 patients were not classified for Cox modelling. When OSRE 
rules were applied to the validation data set, 227 patients were not classified for PLANN 
modelling and 205 patients were not classified for Cox modelling. This means that these 
patients were considered as outliers. 
The rules obtained with both methodologies, OSRE and CART were compared and it was 
analysed that generally the methodologies derive the same number of rules. Therefore it 
cannot be confirmed that one methodology is more parsimonious than another. 
For both rules extraction methodology it was necessary more rules to specify the patients 
belonging using the PLANN-ARD prognostic model than the Cox modelling. There were 
more similar rules between both methodologies when it is used the PLANN-ARD model 
rather than the proportional hazards modelling: 6 rules versus 2 rules for the development data 
set and 5 rules versus 1 rule for the validation data set. 
As it was performed with patients’ group risk membership, the rules’ consistency can be 
also analysed, both for stratification methodologies and for the different prognostic models in 
order to verify more precisely which stratification methodology can perform better, in terms 
of rules.  
The rules obtained with OSRE and CART methodology where compared for both Cox 
modeling and PLANN-ARD modeling, through the KM curves’ analysis and the statistical 
difference between them. This analysis was performed for the development and validation 
data set, where for the second the 5 and 10 years of follow up were used.  
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Using the prognostic index obtained with Cox modelling, the CART rules are more 
consistent than OSRE rules, because there are more KM curves statistically different for the 
same rule for OSRE methodology than for CART methodology. For PLANN-ARD modelling 
this consistency couldn’t be corroborated, as for development and validation there is not an 
evidence of more KM curves statistically different neither for OSRE nor for CART 
methodology.  
The rules obtained with each stratification methodology were also compared in a different 
way, that is, the rules obtained using the Cox model and the rules obtained with PLANN-
ARD model were compared for each OSRE and CART. Here it can be affirmed that the rules 
obtained with CART methodology are very similar between each other, 9 for development 
and 7 for validation data set. However, it was concluded for both, development and validation 
data set (5 and 10 years of follow up) that generally there is more consistency in rules 
obtained with PLANN-ARD than with Cox. The rules obtained with OSRE methodology are 
less similar, 7 for development and 5 for validation data set. Nevertheless the Cox rules are 
more consistent than the PLANN-ARD rules, for the development data set that and the 
contrary is verified for the validation data set, to both 5 and 10 years of follow up. 
4.8 - Interval estimates of individual prognosis 
Following the methodology previously explained on chapter 2 about the Individual 
prognostic predictions with confidence intervals using the PLANN-ARD Model, a survival 
distribution was obtained for the training data set, as it can be observed on Figure 4.35  . With 
this distribution a mean value as well as the 95% confidence intervals for each patient can be 
obtained. 
The median survival estimates across all of the training data at the end of follow up is 
0.8149 and the KM estimated survival is 0.8748. Box plots of personal survival estimates, 
split into the four PLANN-ARD prognostic groups obtained with the CART methodology are 
represented in Figure 4.36. The mean of the individual survival estimates in each group 
predicted by the PLANN-ARD model can be compared with the observed grouped mean 
survival estimated with the Kaplan-Meier method at 5 years of follow-up, shown for each 
risk group in Table 4.41. By the table inspection, model predictions are generally 
conservative, because these are generally lower for the different risk groups than the KM 
estimated values. 
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Figure 4.35 – Survival Distribution for an individual patient.  
It was calculated from 1000 iterations of estimated survival for an individual patient for the training 
data set, where the mean survival and the 95% confidence intervals can be obtained. 
 
 
 
Figure 4.36 – Box plots of individual survival estimates to 5 years. 
These are separated into PLANN-ARD CART risk groups. 
 
 
Risk 
group 
Mean predicted 
survival 
95% Low individual  
survival estimate 
95% High individual 
survival estimate 
KM 
estimate 
95 % Low 
KM estimate 
95 % High 
KM estimate 
1 0,917 0,846 0,949 0,983 0,958 0,99 
2 0,809 0,697 0,883 0,903 0,851 0,93 
3 0,603 0,541 0,732 0,798 0,695 0,857 
4 0,421 0.235 0.65 0,566 0.448 0.646 
Table 4.41 – Mean and 95% confidence intervals. 
These values were computed for the individual PLANN-ARD survival estimate and the Kaplan-Meier 
estimated survival to 5 years, separated into PLANN-ARD CART risk groups. 
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4.9 - Comparison between the existent prognostic groups and the proposed 
ones 
As previously mentioned, there are several clinical prognostic classification schemes 
proposed for breast cancer patients, some of which discriminate between the survival of 
different risk groups defined from the patient characteristics, such as the TNM staging system. 
The most widely used nowadays are the Nottingham prognostic index (NPI) and the 
consensus rules agreed by the St. Gallen group.  
By cross-matching these prognostic classification schemes with the new prognostic 
indexes obtained with the Cox proportional hazards and PLANN-ARD followed by the 
regression tree stratification methodology it is possible to examine survival for patient sub-
groups, using Kaplan Meier estimated survival curves, to uncover heterogeneity among the 
prognostic groups. This can be achieved to both training and validation data sets. 
4.9.1. Comparison between NPI with Cox and PLANN-ARD modelling 
Whereas data collected at Christie Hospital are categorical, descriptive statistics from a 
complementary data set also from Christie Hospital gave a mode for pathological size groups 
1 and 2 as 1.1 and 2 cm, respectively. Therefore, these values were used to calculate the NPI 
score. In order to keep consistency between the Christie and BCCA data set, the NPI was also 
calculated with the same mode used before for the different groups of pathological size. 
Values of the NPI index may be split into as many as five groups from excellent (group1) 
through good (2), moderately good (3a), moderately poor (3b) and poor (4) expected 
outcome. However, in this analysis we analyzed only 4 risk groups, where the moderate 
groups 3a and 3b are combined following common clinical practice resulting in three cut-off 
points at 2.41, 3.41 and 5.41.  
Figure 4.37 represent the KM curves, applying the NPI to Christie and BCCA data sets. 
Comparing the NPI grouped survival with the proportional hazards modeling and PLANN-
ARD modeling for both data sets, it can be verified that they produce almost identical 
grouped survival, with a higher evidence for PLANN modeling. For both data sets it is clear 
that the NPI groups have slightly higher survival to 5 years than the corresponding PLANN-
ARD and Cox groups as well as different population sizes.  
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Figure 4.37 – KM survival curves for the NPI. 
The NPI formula was applied to Christie Hospital and BCCA data sets, left and right picture 
respectively. 
 
To investigate the correlation between the patients selected by the two methodologies, the 
three prognostic indexes were cross-tabulated in Table 4.42 . Inspecting these tables, there are 
a considerable number of patients that do not belong to the same risk group. However, it is 
difficult to define that one stratification methodology is more conservative in terms of patient 
allocation than the other. That conclusion is only valid for risk group 2 and 4, for both 
comparisons, NPI with Cox and NPI with PLANN-ARD, where it can be observed that 
PLANN-ARD is more conservative than NPI. This is observed for both training and 
validation data sets. 
 
  Cox  
  1 2 3 4 Total
1 74  17  0 0 91 
2 168  113  6 1 288 
3 51  205  55  23  334 
4 0 1  16 13  30 
N
PI
 
Total 293 336 77 37 743 
 
  Cox 
  1 2 3 4 Total 
1 274  6 0 1 281 
2 881  254  9 7 1151 
3 243  1494  252  52  2041 
4 0 165  171  207  543 
N
PI
 
Total 1398 1919 432 267 4016 
 
Table 4.42 – Cross-tabulation between different classification schemes. 
These classification schemes are NPI, Cox proportional hazards and PLANN-ARD for the training 
and validation data sets, top and bottom tables respectively. 
 
  PLANN-ARD 
  1 2 3 4 Total
1 65  25  1 0 91 
2 165  101  21  1 288 
3 63  121  81  69  334 
4 0 0 1 29 30 
N
PI
 
Total 293 247 104 99 743 
  PLANN-ARD 
  1 2 3 4 Total 
1 238  37  1 5 281 
2 903  205  25  18 1151 
3 369  921  480  271  2041 
4 0 53  12 364 543 
N
PI
 
Total 1510 1216 632 658 4016 
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In order to discover which of the prognostic models (comparing with NPI) had 
homogeneous groups of patients, indicated by consistent survival curves from one matrix plot 
to the next in either the rows or the columns of the matrix, the patient groups in terms of KM 
estimated survival within each matrix cell was examined, as in Figure 4.38 and Figure 4.39. 
For all three models, the higher and the lower survival groups have homogenous survival 
curves. Analogously for all models risk group 2 and 3 present a more heterogeneous set of 
survival curves with survival decreasing as the risk group in the corresponding prognostic 
index decrease. 
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Figure 4.38 – Matrix of KM curves for NPI vs Cox for the validation data set. 
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Figure 4.39 – Matrix of KM curves for NPI vs PLANN-ARD for the validation data set. 
4.9.2. Comparison between TNM with Cox and PLANN-ARD modelling 
The study developed for the NPI classification scheme was also applied to the TNM 
Classification of Malignant Tumours (TNM). Here three different risk groups were 
considered:  Group 1, characterized by T1N0M0; Group 2 characterized by T2N0M0 and   
Group 3 characterized by T3N0M0 or T1N1M0, T2N1M0, or T3N1M0. Figure 4.40 
represents the KM curves, applying the TNM to Christie data set and Table 4.43 the 
respective log-rank pairwise values. This staging system cannot be applied to the validation 
data set because the regional lymph nodes variable it is necessary to compute these risk 
groups, and it is not available for the BCCA data set. It can be examined that all the KM 
curves have significant distinct survival, existing however an overlap of the risk group 2 and 3 
curves’ from the start of the follow up until the 30th month. Table 4.44  corresponds to the 
cross-tabulation between the TNM risk groups with the ones established for Cox proportional 
hazards and PLANN-ARD modeling using the regression tree stratification methodology. It 
can be noticed that, as it exists less of a risk group, the membership is very sparse, being more 
remarkable for the second risk group, for both modeling.  
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Figure 4.40 – TNM KM survival curves applied to the Christie Hospital data set. 
 
 
 
 
 
 
 
Table 4.43 – Log-rank pairwise values for TNM applied to the training data set. 
 
 
  Cox  
  1 2 3 4 Total
1 229  137  6 0 372 
2 45  144  47 19 255 
3 19 55  24 18  116 
T
N
M
 
Total 293 336 77 37 743 
 
Table 4.44 – Cross-tabulation between different classification schemes. 
These classification schemes are TNM, Cox proportional hazards and PLANN-ARD using the 
regression tree stratification methodology for the training data set. 
 
 
 
 
 
 1 2 
 
Risk 
Groups X ^2 
(sig.) 
X ^2 
(sig.) 
2 20.8866 (0.0000) - 
Lo
g 
R
an
k 
(M
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l
-C
ox
) 
3 67.6241 (0.0000) 
12.0643 
(0.0005) 
  PLANN-ARD 
  1 2 3 4 Total
1 237  118 8 9 372 
2 37  95  71  52 255 
3 19  34  25  38  116 
T
N
M
 
Total 293 247 104 99 743 
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4.9.3. Comparison between St. Gallen with Cox and PLANN-ARD modelling 
In order to achieve consistency between Christie Hospital and BCCA data set in the use of 
the consensus rules agreed by the St. Gallen group the Christie Hospital criteria was used (i.e. 
without using age), Table 4.45 . The Kaplan-Meier curves were obtained for 5 and 10 years of 
follow up for the BCCA data set and 5 years for Christie Hospital data set.  
Figure 4.41 represents the KM curves, applying the consensus rules agreed by the St. 
Gallen group to Christie and BCCA data sets. All but risk group 1 and 2 from the training data 
set show distinct survival, as these have a p-value of 0.0599. The survival curves for the 
training and validation data set are very similar where for the 10 years of follow up, the 
survival is lower, as it was expected. The risk group membership was also compared with the 
Cox proportional hazards and PLANN-ARD modeling followed by the regression tree 
stratification methodology, presented in Table 4.46. It can be noticed that, as it exists less of a 
risk group, that the membership is very sparse, for both training and validation data set. 
However, the membership ratio presented on each cell of the training cross-tabulation is very 
similar to the ratio presented on the validation data set. Moreover, it can also be concluded 
that this membership relation is less sparse than the one obtained for the TNM classification 
scheme.  
 
 
Low risk  Nodes involved=1 and Pathsize=1 and Histological grade=1 
 Nodes involved=2 and Oestrogen=2 Intermediate risk 
 Nodes involved=1 and (Pathsize=2 or Histological grade=2 or 3 ) 
High risk  (Nodes involved=2 and Oestrogen=1) or Nodes involved=3 
Table 4.45 – Risk group consensus rules agreed by the St. Gallen group. 
The known consensus rules were adapted in order to use the variables available at Christie Hospital 
and BCCA data sets. 
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Figure 4.41 – Consensus rules agreed by the St. Gallen group KM survival curves. 
The rules were applied to the Christie Hospital data set and BCCA data set, top and bottom figures, 
respectively. The bottom left picture represents a 5 year follow up and the bottom right picture a 10 
year follow up. 
 
 
  Cox  
  1 2 3 4 Total
1 57  14  0 0 71 
2 223  248  24 5 500 
3 13 74  53 32  172 
St
. G
al
le
n 
Total 293 336 77 37 743 
 
 
  Cox  
  1 2 3 4 Total
1 248  5  0 0 253 
2 1116  1680  232 81 3109 
3 34 234  200 186  654 
St
. G
al
le
n 
Total 1398 1919 432 267 4016 
 
Table 4.46 – Cross-tabulation between different classification schemes. 
These classification schemes are the consensus rules agreed by the St. Gallen group, Cox proportional 
hazards and PLANN-ARD using the regression tree stratification methodology for the training and 
validation data sets, on the top and bottom tables respectively. 
  PLANN-ARD 
  1 2 3 4 Total
1 55 16 0 0 71 
2 227  190  61  22 500 
3 11  41  43  77  172 
St
. G
al
le
n 
Total 293 247 104 99 743 
  PLANN-ARD 
  1 2 3 4 Total
1 225  24 0 4 253 
2 1252 1080  510  267 3109
3 33  112  122  387  654 
St
. G
al
le
n 
Total 1510 1216 632 658 4016
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4.10 - PLANN-ARD prognostic indexes and comparison with Cox prognostic 
index 
In prognostic modelling it is important to define an adequate prognostic index that ranks 
patients by the severity of illness. The output of the PLANN-ARD modelling is the hazard for 
each patient and for each time of follow up. Four different prognostic index calculations for 
the PLANN-ARD modelling were considered, analysed and compared in the next sections. 
Moreover, they were compared with the prognostic index obtained with Cox proportional 
hazards modelling. 
4.10.1. Analysis of the different PLANN-ARD prognostic indexes calculation 
The definition of PLANN-ARD prognostic index has been achieved after the analysis of 
different proposals. At the beginning there were four hypotheses to define the prognostic 
index, such as: 
 
1. The mean of the hazard hp(tk, xp)  of the 10 imputed data sets (characterized as PI A 
hereinafter). 
2. The ln
hp (xp,tk )
1− hp (xp,tk )
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟ e , where hp(tk, xp) is the mean of the hazard of the 10 imputed data set 
(characterized as PI B hereinafter) 
3. The mean of S(t −1) × ln hp (xp,tk)
1− hp (xp,tk)
⎛ 
⎝ 
⎜ ⎜ 
⎞ 
⎠ 
⎟ ⎟  of the 10 imputed data sets (characterized as PI C 
hereinafter). 
4. The ln(-ln(1-CCI)) = ln(-ln(S(t))) (characterized as PI D hereinafter). 
 
The different prognostic indexes calculations must be compared in order to verify the 
differences between them. However, patients must be stratified in different risk groups. This 
allocation into different risk groups was developed with a robust bootstrap log-rank 
aggregation method, where it identifies the cutpoints that separate the patients into statistically 
significant risk groups by overall mortality, based on the different prognostic index mentioned 
before. All the different prognostic indexes applied to the bootstrap methodology finalized 
with 4 different risk groups. This analysis was computed for the previously identified model, 
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with 6 significant variables and the KM curves are plotted in Figure 4.42. Comparing all the 
survival curves it can be concluded that they broadly agree in terms of survival.  
   
 
 
Figure 4.42 – KM curves for the different PI calculation for the training data set. 
The top left picture represents the mean hazard prognostic index. The top right picture represents the 
PI B prognostic index. The bottom left picture represents the PI C prognostic index and the bottom 
right picture represents the CCI prognostic index 
 
The cross-tabulations for the different risk group membership was obtained (Table 4.47) . 
It can be noticed that the patients risk group allocation is very similar for all the prognostic 
indexes, especially for the prognostic index obtained as the mean of the hazard and the PI B,
 
where it only exists 2 patients which do not belong to the same risk group. Both, the PI C 
prognostic index and the PI D prognostic index are more conservative than the others in terms 
of patient allocation. However, the PI D prognostic index is more conservative than PI C 
prognostic index. This conclusion increases our expectation that the CCI prognostic index is 
the one that must be used. 
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Table 4.47 – Cross tabulations between different PI calculations for the training data set. 
4.10.2. Cox proportional hazards and PLANN-ARD prognostic indexes 
comparison  
The previously mentioned prognostic indexes obtained with PLANN-ARD modelling were 
compared with the prognostic index obtained with Cox proportional hazards modelling. It 
must be mentioned that the model used to compute this prognostic index incorporate the 
missing impute data and was developed for the 6 established variables as the most predictive 
ones.     
Figure 4.43 presents a scatter plot comparing the different prognostic indexes obtained with 
PLANN-ARD and Cox proportional hazards. It can be noticed that for all the prognostic 
indexes, the Cox prognostic index is non-linear related with PLANN-ARD. In particular it 
seems that the PLANN-ARD model compresses all but the mean of the hazard prognostic 
index calculation, in the extreme sectors but extends the dynamic range for the middle sector. 
This can be because the non-linear algorithm implicitly models interactions between 
covariates. However, it can be analysed that the prognostic index range obtained with Cox is 
equal to the PI C
 
prognostic index and higher than both the PI B and the PI D prognostic 
index. 
 
  Mean hazard 
   1  2  3  4 Total 
 1 357 0 0 0 357 
 2 2 156 0 0 158 
 3 0 0 169 0 169 
 4 0 0 0 0 59 M
ea
n 
lo
g 
(h
az
ar
d)
 
Total 359 156 169 59 743 
  Mean hazard 
  1 2 3 4 Total 
1 354 4 0 0 358 
2 5 142 3 0 150 
3 0 10 151 0 161 
4 0 0 15 59 74 
M
ea
n 
lo
g 
ha
za
rd
*s
ur
vi
va
l 
Total 359 156 169 59 743 
  Mean log hazard*survival 
  1 2 3 4 Total 
 1 325 0 0 0 325 
 2 33 147 1 0 181 
3 0 3 146 0 149 
4 0 0 14 74 88 
C
C
I 
Total 358 150 161 74 743 
  Mean Hazard 
  1 2 3 4 Total 
 1 325 0 0 0 325 
 2 34 147 0 0 181 
3 0 9 140 0 149 
4 0 0 29 59 88 
C
C
I 
Total 359 156 169 59 743 
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Figure 4.43 – Scatter plots comparing different prognostic indices. 
Comparison between different PLANN-ARD prognostic index calculations with the Cox proportional 
hazards prognostic index for the training data set. 
4.11 - Models with different variables’ comparison 
Four good breast cancer prediction models were previously identified, one with 5 variables 
(Histological Grade, Histological Type, Oestrogen, Age, Nodes ratio), one with 6 variables 
(Histological Grade, Histological Type, Oestrogen, Age, Pathological size, Nodes Ratio), one 
with also 6 variables (Histological Grade, Histological Type, Oestrogen, Age, Pathological 
size, Nodes involved) and another one with 7 variables (Histological Grade, Histological 
Type, Oestrogen, Age, Pathological size, Nodes Ratio, Menopausal status). 
It was already demonstrated that all models have a high similarity on the prognostic 
indexes range, predict well, are very well calibrated and have a very good discrimination. 
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However, the 6 variable model including Nodes Ratio was considered the one that predicts 
better.  
Nevertheless, the patients’ risk group allocation must be also analysed for the different 
models. This allocation into different risk groups was developed using the robust bootstrap 
log-rank aggregation method, where it identifies the cutpoints that separate the patients into 
statistically significant risk groups by overall mortality, based on the prognostic index given 
by the βx of the Cox proportional hazards modelling. Table 4.48 represents the different 
cross-tabulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
able 4.48 – Cross tabulation between patients’ risk group allocation. 
This was performed for the 5, 6 and 7 variables different models. There are two different models with 
6 variables, one including Nodes ratio variable and another one including Nodes involved variable 
 
  6 variables Model (Nodes 
ratio) 
  1 2 3 4 Total 
1 292 82 2 0 376 
2 33 94 115 4 246 
3 0 5 31 52 88 
4 0 0 2 32 33 5 
va
ri
ab
le
s 
M
od
el
  
Total 325 181 149 88 743 
  6 variables Model (Nodes 
involved) 
  1 2 3 4 Total 
1 277 71 28 0 376 
2 50 71 121 4 246 
3 0 9 48 31 88 
4 0 0 9 24 33 5 
va
ri
ab
le
s 
M
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el
 
Total 327 151 206 59 743 
  7 variables Model 
  1 2 3 4 Total 
1 285 85 6 0 376 
2 31 101 114 0 246 
3 0 1 81 6 88 
4 0 0 3 30 33 5 
va
ri
ab
le
s 
M
od
el
 
Total 316 187 204 36 743 
  6 variables Model (Nodes ratio) 
  1 2 3 4 Total 
1 288 28 0 0 316 
2 37 123 27 0 187 
3 0 30 122 52 204 
4 0 0 0 36 36 7 
va
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M
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Total 325 181 149 88 743 
  6 variables Model (Nodes 
involved) 
  1 2 3 4 Total 
1 267 37 12 0 316 
2 58 80 47 2 187 
3 2 34 136 32 204 
4 0 0 1 25 36 7 
va
ri
ab
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s 
M
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el
 
Total 327 151 206 59 743 
  6 variables Model (Nodes ratio) 
  1 2 3 4 Total 
1 275 52 0 0 327 
2 41 76 33 1 151 
3 9 53 107 37 206 
4 0 0 9 50 59 
6 
va
ri
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s 
M
od
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 (N
od
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ed
) 
Total 325 181 149 88 743 
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Analysing all the cross-tabulations in terms of risk allocation, it is verified the the 5 
variables model is less conservative than the other 3 models, that is, the patients are allocated 
in lower risk groups, comparing with the other models. The 7 variables model is generally 
more conservative in terms of patient allocation than both the 6 variables models, with the 
exception of the first risk group. The patients in the cross-tabulation between the 6 variables 
model including Nodes Ratio and the 6 variables model including Nodes involved are very 
spread, making it impossible to define the most conservative model. There is however an 
exception, which is in the higher risk group, where the model including Nodes Ratio is more 
conservative than the model including Nodes involved. Figure 4.44  presents the KM curves 
for the different variables’ models.  
 
  
Figure 4.44 – KM curves for the different four variables models, for the training data set.  
The top left pictures represents the 5 variables model; the top right picture represents the 7 variables 
model. The bottom left picture represents the 6 variables model including Nodes involved and the 
bottom right picture the 6 variables model including Nodes ratio. 
 
Analysing Figure 4.44 it can be supported that all curves have a distinct survival between 
the groups and have a very similar shape and survival between them, with the exception of the 
4th risk group where the survival is higher for the 6 variables model including Nodes Ratio. 
This analysis increases the study already performed that has determined the 6 variables model 
including Nodes Ratio as the most predictive model. 
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4.12 - Treatments distribution  
The treatments applied to the patients on the training and validation data set were recorded 
and divided in four categories: None, Hormone, Chemotherapy or Combined. Considering 
their distributions by the risk groups, applying the regression tree stratification methodology 
to PLANN-ARD and Cox prognostic models, it can be noticed any trend about the treatments 
that should be applied. Table 4.49 and Table 4.50 contain these distributions for the training 
data set, while Table 4.51 contains the distribution considering the NPI classification scheme, 
applied to the training data set. 
 
 1 2 3 4 Total 
None 170 (58%) 125 (37%) 7 (10%) 4 (11%) 306 
Hormone 111 (38%) 161 (48%) 55 (71%) 18 (49%) 345 
Chemo 11 (3%) 50(15%) 15 (19%) 15(40%) 91 
Combined 1(1%) 0 0 0 1 
Total 293 336 77 37 743 
 
Table 4.49– Distribution of the different treatments for the different risk groups. 
These risk groups were obtained for Cox modelling followed by the regression tree stratification 
methodology, for the training data set. 
 
 1 2 3 4 Total 
None 166 (57%) 106 (43%) 24 (23%) 10 (10%) 306 
Hormone 112 (38%) 115 (47%) 59 (57%) 59 (60%) 345 
Chemo 14 (4%) 26 (10%) 21 (20%) 30 (30%) 91 
Combined 1(1%) 0 0 0 1 
Total 293 247 104 99 743 
 
Table 4.50 – Distribution of the different treatments for the different risk groups. 
These risk groups were obtained for PLANN modelling followed by the regression tree stratification 
methodology, for the training data set. 
 
 1 2 3 4 Total 
None 67 (74%) 184 (64%) 55 (16%) 0 306 
Hormone 24 (26%) 97 (34%) 207 (62%) 17 (57%) 345 
Chemo 0 7 (2%) 71 (21%) 13 (43%) 91 
Combined 0 0 1(1%) 0 1 
Total 91 288 334 30 743 
Table 4.51 – Distribution of the different treatments for the different risk groups. 
These risk groups were obtained for NPI classification scheme, for the training data set. 
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For the three risk group stratifications (Cox, PLANN-ARD and NPI), the treatment with 
the biggest patients’ ratio in the 1st risk group is None, with 58%, 57% and 74%, respectively. 
For the 2nd risk group membership, Cox stratification has Hormone as the biggest ratio for 
treatment, NPI stratification has None as the biggest ratio and PLANN, has a very similar 
ratio for None and Hormone Treatment. For the 3rd and 4th risk groups membership, the three 
different stratifications (Cox, PLANN and NPI) have Hormone as the biggest treatment ratio.  
Table 4.52 indicates, for each model, Cox, PLANN-ARD and NPI, the risk groups with the 
higher number of patients treated with each treatment. 
 
 Cox PLANN-ARD NPI 
None Risk group 1 Risk group 1 Risk group 2 
Hormone Risk group 2 Risk group 1 and 2 Risk group 3 
Chemo Risk group 4 Risk group 4 Risk group 4 
Combined Risk group 1 Risk group 1 Risk group 3 
 
Table 4.52 – Higher Treatments’ Risk group Ratio for different models, for the training data set. 
 
The biggest coherency for treatments is for Chemotherapy where the majority of patients 
are allocated in the same risk group for the different stratifications. On the other hand, 
Hormone treatment is the one where is more spread through the 4 risk groups. 
The results previously obtained on the training data set were also obtained for the 
validation data set. Table 4.53  and Table 4.54 contain the treatment distributions for the 
validation data set, while table 4.54 contains the distribution considering the NPI 
classification scheme, applied to the validation data set. 
 1 2 3 4 Total 
None 893 (64%) 801 (42%) 89 (20%) 29 (11%) 1812 
Hormone 362 (26%) 592 (31%) 171 (40%) 107 (40%) 1232 
Chemo 83 (6%) 342(18%) 112 (26%) 70(26%) 607 
Combined 60(4%) 184(9%) 60(14%) 61(23%) 365 
Total 1398 1919 432 267 4016 
 
Table 4.53 – Distribution of the different treatments for the different risk groups. 
These risk groups were obtained for Cox modelling followed by the regression tree stratification 
methodology, for the validation data set. 
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 1 2 3 4 Total 
None 969 (64%) 550 (45%) 174 (28%) 119 (18%) 1812 
Hormone 375 (25%) 398 (33%) 228 (36%) 231 (35%) 1232 
Chemo 97 (6%) 160 (13%) 165 (26%) 185 (28%) 607 
Combined 69(5%) 108(9%) 65(10%) 123(19%) 365 
Total 1510 1216 632 658 4016 
 
Table 4.54 – Distribution of the different treatments for the different risk groups. 
These risk groups were obtained for PLANN modelling followed by the regression tree stratification 
methodology, for the validation data set. 
 
 
 1 2 3 4 Total 
None 235 (84%) 823 (72%) 721 (35%) 33(6%) 1812 
Hormone 39 (14%) 243 (21%) 747 (37%) 203 (37%) 1232 
Chemo 7 (2%) 61 (5%) 371 (18%) 168 (31%) 607 
Combined 0 24(2%) 202(10%) 139(26%) 365 
Total 281 1151 2041 543 4016 
Table 4.55 – Distribution of the different treatments for the different risk groups. 
These risk groups were obtained for NPI classification scheme, for the validation data set. 
 
 
As cofirmed in training data set data set, for the three risk group stratifications (Cox, 
PLANN and NPI), the treatment with the biggest patients’ ratio in the 1st risk group is None, 
with 64%, 64% and 84%, respectively. For the 2nd risk group membership, all the three 
different methodologies have a biggest ratio for None, with 42%, 45% and 72% respectively, 
which is not similar with the training data set for Cox and PLANN stratification. For the 3rd 
and 4th risk group membership, Cox and PLANN stratifications have Hormone as the biggest 
treatment ratio, with 40% and 36%, respectively for the 3rd risk group and 40% and 35% for 
the 4th risk group. NPI, opposed to the training data set, has for the 3rd group a similar ratio for 
None and Hormone and for the 4th risk group a similar ratio for Hormone and Chemotherapy.  
Table 4.56 indicates, for each model, Cox, PLANN-ARD and NPI, the risk groups with the 
higher number of patients treated with each treatment. 
 
 Cox PLANN-ARD NPI 
None Risk group 1 Risk group 1 Risk group 2 
Hormone Risk group 2 Risk group 1 and 2 Risk group 3 
Chemo Risk group 2 Risk group 2,3,4 Risk group 3 
Combined Risk group 2 Risk group 4 Risk group 3 
Table 4.56 - Higher Treatments’ Risk group Ratio for different models, for the validation data set. 
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Opposed to Christie, here there is not much coherency between the treatments and the 
different stratification methodologies, where the biggest one is for None treatment for Cox 
and PLANN. 
These known distributions can help in treatments’ decision making when obtaining a 
prognosis for a new patient, as it is acknowledged the ratio for each risk group.  
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Chapter 5 - 
Online Breast Cancer decision support 
systems  
Many studies noticed that many women with breast cancer are requesting more 
information about their disease and also suggest that they have an increasing desire to be 
involved in decisions about their care (Ravdin, Siminoff, Harvey,1998). However, in order to 
participate in decision making, the patient needs accurate information about the disease. A 
growing number of clinical tools have been developed in order to address the problems 
identified by clinical studies with both determining the risk of recurrence for individual 
patients and communicating this information in the clinical consultation. A number of these 
clinical tools are easy to use and some are accessible over the Internet. While studies have 
shown some of these instruments to improve patient knowledge and facilitate shared decision 
making, a number of basic questions still remain unresolved and need to be addressed with 
the aim to involve patients more on decision making regarding the breast cancer disease 
(Whelan, Loprinzi, 2005), (Fonseca, Mora, Barroso, 2006).  
Several online breast cancer prognostic tools exist. However there are two that are widely 
known and used clinically, namely Adjuvant! (Olivotto, Bajdik, Ravdin, Speers, Coldman, 
Norris, Davis, Chia, Gelmon, 2005)  and Numeracy (Loprinzi, Thome, 2001). These are 
computer-based programs designed to assist in adjuvant therapy decision making. Both 
programs determine a patient’s baseline risk of recurrence and/or death at 10 years without 
adjuvant therapy, based on prognostic factors. Despite providing similar estimates of baseline 
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risk and absolute benefits, the instruments do differ (Whelan, Loprinzi, 2005). 
Firstly in this chapter, it is explained a web decision making tool which can be accessible 
on the Internet, Adjuvant!. It has been chosen this particular interface because it appears to be 
readily accepted by practicing clinicians and it is used to validate the model, the same data set 
that it was used to validate the developed approaches in this thesis, the BCCA data set. Finally 
a Web decision support system is exhibited and its functionalities are explained. It is 
important to mention that this Web decision support system includes all the modelling and 
stratification methodologies improved and developed, presented on this thesis.     
5.1 -   Online breast cancer prognostic estimate – AdjuvantOnline 
Adjuvant! is a computer program designed to produce prognostic estimates of outcome 
with and without therapy, based on estimates of individual patient prognosis. Adjuvant! 
Online was developed as a decision-making tool for health care professionals and patients 
with early cancer to discuss the risks and benefits of adjuvant therapy following surgery. The 
Web site states that its goal is to help health professionals estimate the risk of negative 
outcome (cancer-related mortality or relapse) without systemic adjuvant therapy, estimate the 
reduction of these risks afforded by therapy and estimate the risks of side effects of the 
therapy.  
Version 2.2 (2001) (Ravdin, Sminoff, Davis, Mercer, Hewlett, Gerson, Parker, 2001) of 
this program includes the estimation of risk of breast cancer death at a 10-year follow-up on 
tumour size, the number of involved nodes and Oestrogen status. Patients included in the 
initial analysis were woman who had invasive, unilateral, noninflamatory disease, had 
undergone definitive surgery and had axillary staging with at least six nodes sampled. 
Furthermore, patients must not have known residual or metastatic disease. The parameters 
used for adjuvant therapy decision-making are entered in the online software. Age is used by 
the program to calculate the expected natural mortality and to produce the default estimate of 
menopausal status. Comorbidity is also a parameter that must be inserted and is an estimate of 
the general health of the individual for whom the estimates are being made. For Adjuvant! the 
number of positive nodes, together with tumor size are the main factors used to make 
estimates of patient prognosis. 
The output shows the outcomes for survival in terms of Overall Survival at 10 years, 
estimates of remaining life expectancy and long term survival curves. It also shows outcomes 
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for DFS (disease-free survival) at 10 years. The existing bar-graphs show the percentage of 
patients died of breast cancer, the percentage died of non-breast cancer causes of death and an 
estimate of the increased percentage of patients alive at 10 years because of specific adjuvant 
therapy chosen. There are also bar graphs which show the percentage of patients who are 
alive without breast cancer at 10 years, what percentage are expected to relapse with breast 
cancer and what percentage died of other non-breast cancer causes of death. These estimates 
are shown for scenarios where adjuvant therapy is either used or not, allowing to view the 
additional percentage of patients who remain disease-free at 10 years because of adjuvant 
therapy. It is also possible to toggle between different adjuvant treatment options and examine 
the impact on DFS. A criticism of Adjuvant! is that it does not provide estimates with 95% 
confidence intervals. 
The assumptions inherent in Adjuvant! and its applicability to woman beyond the range of 
ages used to develop the model were only independently validated in 2005 using a data base 
provided from BCCA (British Columbia Cancer Agency) (Olivotto, Bajdik, Ravdin, Speers, 
Coldman, Norris, Davis, Chia, Gelmon, 2005). 10-year predicted OS, BCSS and EFS values 
were determined from each patient using Adjuvant! version 5.0. Patient age, tumour size, 
number of positive nodes, grade, ER status and adjuvant systemic therapy used were entered 
in the model and 10-year OS, BCSS and EFS values were calculated. The default comorbidity 
assumption of “minor health problems” was used. The study demonstrated that the predicted 
outcomes of Adjuvant! were valid with the exception of a few specific subgroups of patients.  
Other studies were carried out in order to validate this software, as it is widely used and 
consulted by clinicians and patients and has been shown to influence patient choices in the 
clinical setting (Peele, Siminoff, Xu, et al, 2005), (Ozanne, Braithwaite, Sepucha, Moore, 
Esserman, Belkora, 2009) tested the hypothesis that Adjuvant! predictions would be sensitive 
to comorbidity inputs. In contrast with the other inputs, the assessment of patient 
comorbidities is highly subjective questioning the reliability of Adjuvant! This variable inputs 
for Adjuvant! model includes: perfect health, minor problems, average for age, major 
problems (+10;+20;+30), where documentation offers little guidance regarding these 
definitions of comorbidity. (Ozanne, Braithwaite, Sepucha, Moore, Esserman, Belkora, 2009) 
concluded that comorbidity influences mortality predictions, specially for woman older than 
60 years old it is the most influential input. In addition, the changes in the comorbidity 
outputs are significant enough that they are likely to affect patients’ treatment choices. 
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It is however important to mention that, although the model is described quantitatively in 
(Ravdin, Sminoff, Davis, Mercer, Hewlett, Gerson, Parker, 2001), the true dynamics of the 
model remain unpublished. Therefore, all kind of validation is a first-order approximation, as 
there is no evidence of relationships between variables or interaction terms in the model.  
 
 
5.2 - Proposed Breast cancer survival Web decision support system 
A web clinical decision support system was developed in order to assist the clinicians to 
perform more accurate decisions about breast cancer treatments and prognostic outcome of 
survival, based on patients’ characteristics. It is important to mention that the aim of this web 
system is to keep and expand current practices rather than replace them. The present decision 
support system makes an important contribution to both technical innovation and clinical 
application as several important novelties were added or changed to current practice. Previous 
developments have already presented a web decision support system as a relevant innovation 
(Jarman et al, 2008), (Lisboa, Etchells, Jarman, Ramsey, 2007). However, the proposed 
system improves upon these systems by resolving and improving some particular issues. 
This web clinical decision support system incorporates three breast cancer prognostic 
methodologies previously mentioned, namely the Cox proportional hazards modelling, the 
PLANN-ARD and the NPI. The decision support system indicates, not only the prognostic 
index calculated for a single patient, but also its prognostic risk group, which is 
straightforward for NPI and obtained through a methodology explained previously, based on 
regression trees, when applied to the Cox proportional hazards and PLANN-ARD modelling. 
It is important to mention that missing data was incorporated in the prognostic models 
available in the web decision support system, which was overcome using multiple imputation 
techniques. This web system also has the advantage of saving patients’ prognosis as well as 
their clinical data, providing a patient history based on prognosis and treatments. This history 
can be analysed and compared over time, which may help and improve clinicians’ medical 
decisions. 
Chapter 5- Online Breast Cancer decision support systems 
171 
 
Figure 5.1 – Home page of breast cancer decision support system 
 
Figure 5.2 – Home page of breast cancer decision support system after the introduction of a 
registration user 
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The web site can be reached trough the link http://bcsurvival.pt.la/, where it is visualized 
the web page shown in Figure 5.1. In this web page it is possible to register a user and 
therefore access to the entire web site potential, first presented as in Figure 5.2 . The 
functionalities that are available for use are: 
1. My Profile 
In this web-site section it is presented the user’s personal information and his 
publications. All the information can be also updated.  
2. Manage Patients 
This feature allows the user to insert or edit the information of a patient, manage all 
the patients who were previously created and visualise all predictions previously 
assessed by this web site, indicating the date that was saved. 
3. Prognostic assessments 
In this web-site section the output of three prognostic models combined with the 
stratification methodology can be analysed together, that is NPI versus Cox, NPI 
versus PLANN-ARD and Cox versus PLANN-ARD. Cox and PLANN-ARD model 
estimate the risk of breast cancer death at a 5-year follow-up based on 6 predictive 
variables, namely Age, Histological type, Nodes ratio, Oestrogen, Histological grade 
and Pathological size. Patients included in this analysis are post-operative female 
cancer patients with primary invasive carcinoma of the breast at clinical stage T1-2 
(tumours with maximum diameter of less than 5 cm), node stage N0-1 (no nodes 
affected in the axilla or mobile nodes) and metastasis stage M0 (no evidence of distant 
metastic spread of the tumour). The remaining patients were excluded from the study. 
The Cox proportional hazards and PLANN-ARD model were trained using a data set 
of 743 patients, collected at the Christie Hospital data set, from 1990-94.  
The different predictions models can be compared two by two. For this purpose the 
user must choose the ones he want to compare and analyse. After entering the patient 
variables’, both the prognostic indices and the prognostic risk group are obtained. It is 
visualized a scatter-plot of the prognostic indices as well as the risk group of all 
patients used to train the models, for the two models chosen previously. In addition 
this section also presents the patient individual prognosis with 95% confidence 
intervals, derived by using the PLANN-ARD model with Monte Carlo methods. 
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Figure 5.3  presents an example of a web-page in which the NPI and PLANN-ARD 
prognostic models were chosen. After introducing the patient characteristics  and 
pressing the Prognosis button, the prognostic index is obtained, the prognostic risk 
group, for each the selected models and the individual prognosis obtained for the 
patient.  
Pressing the View Treatments button, the patient’s information section is replaced by 
the percentages for each treatment that was received by the patients in the training 
data set, divided in hormone, chemotherapy, combined or none. 
Pressing the Switch View button, a different view of the prognostic assessments can be 
observed. It can be examined survival for patients groups within each matrix cell 
using KM estimated survival curves, also indicating the mean survival estimates and 
the 95% confidence intervals, in order to discover heterogeneity in estimated survival 
for any of the models prognostic group. These differences in survival are an indication 
of the added value of cross-matching the different prognostic models. For each 
survival curve it is indicated the number of patients and deaths that were considered 
for the training data set. Figure 5.5 represents an example of this matrix, where it 
demonstrates how it is possible to draw misleading conclusions and shows the benefit 
of combining information.  
The obtained prognostic as well as the patient information can be also saved for 
further analysis. This must be associated to a certain patient, previously inserted in the 
area “Manage patients”, by selecting the sought patient followed by the button Save 
values.  
By clicking above of each KM curve, it is possible to visualize it with more detail, as 
it is demonstrated on figure 5.6 . 
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Figure 5.3 – Prognostic assessments for a particular patient. 
Patient with age between 20 and 39 years, with histological type equal to invasive ductal, with Nodes 
ratio from 0 to 20%, with Oestrogen from 0 to 10, with Histological Grade moderately differentiated, 
with pathological size from 2 to 5 cm and with Nodes involved equal to 0. Here it is compared the NPI 
prognostic mode with PLANN-ARD prognostic model, followed by a stratification methodology. 
 
 
Figure 5.4 – Treatments information on the web-site.  
This information substitutes the patient information in the web page, when the View Treatments button 
is pressed. 
 
Similar patients have received 
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Figure 5.5 – Matrix with KM curves for a patient choosing NPI and PLANN-ARD. 
This comparison shows a significant difference in survival between the NPI (risk group 3) and 
PLANN-ARD modelling. Note that within NPI group 3, the top group experiences an incidence of 
death at 5 years of less than 5%, the next two groups together 15%, three times higher, and the last 
group over 40%, more than double the previous group.    This raises the prospect of under- or over-
treatment within this single clinical risk group. 
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Figure 5.6 – KM curve after clicking in the cross-matching survival curves web-page. 
 
Combining all the elements described above provides an integrated intelligent web support 
decision tool, achieved by the cross-matching matrix where each column represents patients 
in a prognostic risk group determined by a prognostic model and each row represents the risk 
group determined by another prognostic model. This can inform the user on a patient’s 
survival outcome, allowing accessing the heterogeneity in survival within a prognostic risk 
group. The different perspectives given by this web decision tool can also indicate whether a 
particular patient is an outlier of the model when occupies an empty or sparsely populated cell 
or if the patient borders on other cells of the matrix. 
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Chapter 6 - 
Conclusions and Future Work 
 
This breast cancer prognostic modeling study followed a precise methodology and has 
identified six predictive variables, which are consistent with those used in clinical practice. 
The thesis proposes a methodology for incorporating missing data into generic non-linear 
modelling with the Partial Logistic Artificial Neural Network (PLANN) regularised within the 
evidence-based framework with Automatic Relevance Determination (ARD) by multiple 
imputation and model averaging over samples of the imputed distribution. This methodology 
is shown to be effective and enables predictions to be made on data sets with a different 
pattern of missing data, which is essential for external validation as well as to used data from 
training data with missing values to make inferences for future patients.  
While the linear (Cox proportional hazards) and flexible models (PLANN-ARD) are 
comparable in their discrimination ability evaluated using the Ctd index, there are also 
important differences between the two models.  The PLANN-ARD is mainly proposed as a 
predictive model providing individual interval estimates of the hazard and survival for 
individual patients, overcoming the limitation of the proportionality of hazards.  Furthermore, 
the dependence of the hazard prediction as a function of covariates and over time is estimated 
directly and can be visualised over time. Secondly, the calibration of the models in external 
validation shows a marginal advantage for the neural network. Concerning discrimination, the 
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results are not surprising since the intrinsic limitation in the available data was not expected to 
support a major improvement in the capability of ranking prognosis according to covariate 
values, especially given that they are available only after discretisation onto non=linearly 
spaced groups, which effectively turns the Cox regression model into a piecewise linear 
model. However, the calibration performances of PLANN-ARD over the standard Cox 
regression model suggest the relevance of non-additive and time dependent covariate effects 
for predicting on new patients.  
It should be emphasised that when the data satisfy the assumptions of piecewise linear 
model such as Cox regression with discrete variables, then a well regularised non-linear 
model will behave similarly to a linear model.  Residual interactions can result in marginal 
benefits for the non-linear model. Actually, the limited information available in the pre-
categorised data from few predictor variables, as in the present case, should limit the final 
performance of any modelling tool.   
Avoiding the binning of the individual covariates would help to remove unintended 
subjective effects currently recognised by the clinical community as damaging to the 
consistency in delivery of care for this important disease category. A relevant consideration 
here is the forced categorisation of histological tumour grade, which is subject to subjective 
effects in borderline cases between two grades, whose effect would be much reduced by 
reporting the underlying numerical score resulting from the histological observations. 
The ability to avoid discretisation of continuous variables further enhances the advantage 
of flexible models over standard linear approaches.  
A prognostic index was defined which may be used to stratify patients into risk groups 
with statistically significant grouped outcomes, utilizing the PLANN-ARD model. The 
proposed use of the Crude Cumulative Incidence rate as the basis of the prognostic index 
calculation means that this approach will extend from single to competing risks modelling.  
Four stratification strategies were applied. Pure clustering of the population of covariates 
without reference to the prognostic indicator results in coherent patient groups but with 
relatively poor specificity for outcome, as measured by the separation between the group 
means of the overall mortality rates. Regressing the distribution of prognostic scores with 
rule-based trees (CART) succeeds in separating patient groups with statistically different 
mean survival and coherent membership within each group. Another approach stratifies the 
prognostic index directly, which can result in mixed populations within single risk groups, 
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which the application of an automatic rule extraction method (OSRE) identified and 
characterized. This showed the composition of the risk groups to be no more complex than for 
the groups identified by CART and the mean grouped survival show similar, statistically 
significant, separation. In contrast, informed clustering with the Fisher information matrix as a 
metric has the merit of permitting a specific definition of the patient population, from which 
to forward predict grouped survival, instead of inferring a threshold back from the log-rank 
separation index.  
Therefore, while all methods generalized well to the validation data set, thresholding of 
the prognostic index using the regression tree methodology (CART) is the only methodology 
to offer both specificity to outcome and transparency of group composition. This method 
generalized in external validation as required by a staged methodology for the development of 
decision support systems in medicine and offers a possible route to a clinically useful patient 
stratification index that is expressed in the form of straightforward Boolean rules.  
The work developed in this study has also enabled the combination of different breast 
cancer prognostic methodologies including those currently used in clinical practice, such as 
NPI, TNM and St. Gallen. This consensus approach helps in building a more robust allocation 
into different prognostic groups and consequently in the decision about the therapies to apply, 
by providing a triangulation of several plausible and validated prognostic indices.  
Finally, the thesis describes a web decision support system for breast oncology which 
shows the value of the new prognostic models and stratification methodology to discriminate 
patients by risk of overall mortality. This tool starts with patient specific variables entered by 
the clinician and identifies the risk group allocation for the three prognostic models: NPI, Cox 
proportional hazards, PLANN-ARD, together with the Boolean rules that explain each risk 
group. A cross-matched matrix of grouped survival and the cell where the particular patient’s 
parameters reside within the matrix is also presented, leading to better insights about the 
accuracy of the risk group allocation for each specific prognostic model.  
Future work should compare the predictions obtained with Adjuvant! and the proposed 
methodologies, using the BCCA data set to validate the prognostic model, since it is the data 
utilized to validate Adjuvant!. However, prognostic predictions for 10 years of follow-up are 
required, which was not possible with the available data from the Christie Hospital since this 
has only 5 year follow-up. In addition, it was necessary to obtain the individual predictions 
from Adjuvant! for each patient in the validation data set, which has not been forthcoming 
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from the Adjuvant! group. Overcoming these two barriers, it would be extremely interesting 
and indeed important from a clinical point of view to compare, both historically for 
retrospective routinely acquired hospital data bases and for individual patients prospectively 
assessed, the prognostic inferences obtained with the range of widely used online breast 
cancer decision support system, as well as Adjuvantonline! and the predictions obtained from 
the proposed methodology proposed in this thesis. 
 
 181 
References 
 
(Altman, Lausan, Sauerbrei, Schumacher, 1994) Altman, Gouglas G., Lausan, Berthold, Sauerbrei, 
Willi and Schumacher, Martin, “Dangers of using “Optimal” cuptoints in the evaluation of prognostic 
factors”, Journal of the National Cancer Institute, Vol. 86, No. 11, pp 829-835 (1994). 
 
(Altman, Royston, 2000) Altman, Doug G. and Royston, Patrick, “What do you mean by validating a 
prognostic model?”, Statistics in Medicine, Vol. 19, pp 453-473, (2000). 
 
(Altman, Vergouwe, Royston, Moons, 2009) Altman, Gouglas, Vergouwe, Yvonne, Royston, Patrick, 
Moons, Karel, “Prognosis and prognostic research: validating a prognostic model”, BMJ;338:b605, 
(2009). 
 
(Amari, 1998) Amari, Shun-ichi“Natural gradient works efficiently in learning”. Neural Computation, 
vol. 10, no. 2, pp. 251–276, (1998). 
 
(Ambrogi, Biganzoli, Boracchi, 2008) Ambrogi, Frederico, Biganzoli, Elia, Boracchi, Patrizia, 
“Estimates of clinically useful measures in competing risks survival analysis”, Statistics is Medicine, 
Vol. 27(30), pp. 6407-6425, (2008). 
 
(Antolini, Boracchi, Biganzoli, 2005) Antolini, Laura, Boracchi, Patrizia and Biganzoli, Elia, “A time-
dependent discrimination index for survival data”, Statistics in Medicine, 24: pp 3927-3944 (2005). 
 
(Bacciu, Starita, 2008) D. Bacciu and A. Starita, “Competitive repetition suppression (CoRe) 
clustering: A biologically inspired learning model with application to robust clustering”. Neural 
Networks, IEEE Transactions, vol. 19, no. 11, pp. 1922–1941, (2008).  
 
(Bacciu, Jarman, Etchells, Lisboa, 2009) Bacciu, Davide, Jarman, Ian H F., Etchells, T.A., Lisboa, 
P.J.G., “Patient stratification with competing risks by Multivariate Fisher distance”, Proceedings of the 
2009 international joint conference on Neural Networks, pp 3453-3460, (2009). 
 
(Bakker, Heskes, 1999) Bakker, Bart and Heskes, Tom, “A neural-Bayesian approach to survival 
analysis”, Artificial Neural Networks, Vol. 2, pp 832-837 (1999). 
 
References 
182 
(Bar-Yam, 1997) Bar-Yam,Yaneer, “Dynamics of complex system”,  Addison-Wesley, Chapter 2 
(1997). 
 
(Biganzoli, Boracchi, Mariani, Marubini, 1998) Biganzoli, E., Boracchi, P., Mariani, L. and Marubini, 
E., “Feed forward neural networks for the analysis of censored survival data: A partial logistic 
regression approach”, Statistics in Medicine, 17, 1169-1186 (1998). 
 
(Biganzoli, Boracchi, Mariani, Marubini, 1998) Biganzoli, Elia, Boracchi, Patrizia,Mariani, L. and 
Marubini, Ettore, “Feed forward neural networks for the analysis of censored survival data: a partial 
logistic regression approach”, Stat. Med, 17, pp 1169-1186 (1998). 
 
(Biganzoli, Boracchi, Marubini, 2002) Biganzoli, Elia, Boracchi, Patrizia and Marubini, Ettore, “A 
general framework for neural network models on censored survival data”, Neural Networks, 15, pp 
209-218 (2002). 
 
(Bishop, 2006) Bishop, C. M., “Pattern recognition and Machine learning”, Springer (2006). 
 
(Boracchi, Coradini, Antolini, Oriana, Dittadi, Gion, Daidone, Biganzoli, 2008) Boracchi, P., 
Coradini, D., Antolini, L., Oriana, S., Dittadi, R., Gion, M., Daidone, M.G., Biganzoli, E., “A 
prediction model for breast cancer recurrence after adjuvant hormone therapy”, The international 
journal of biological markers, Vol. 23 no.4, pp 199-206, (2008). 
 
(Bradburn M.J., Clark, Love, Altman, 2003) Bradburn, M.J., Clark, T.G., Love, S.B. and Altman, 
D.G., “Survival Analysis Part III: Multivariate data analysis – choosing a model and assessing its 
adequacy and fit”. British Journal of Cancer, Vol. 89, pp 605-611, (2003). 
 
(Bradburn, Clark, Love, Altman, 2003) Bradburn, M.J., Clark, T.G., Love, S.B. and Altman, D.G., 
“Survival Analysis Part IV: Further concepts and methods in survival analysis”. British Journal of 
Cancer, Vol. 89, pp 781-786, (2003). 
 
(Brand, 1998) Brand, J.P.L., “Development, implementation and evaluation of multiple imputation 
strategies for the statistical analysis of incomplete data sets”, Academic thesis, Erasmus University, 
Rotterdam, (1998). 
 
(Breiman, Friedman, Olsen, Stone, 1984) Breiman, L., Friedman, J.H., Olsen, A.R, Stone, C. J., 
References 
183 
“Classification and Regression Trees”, The Wadsworth & Brooks, (1984). 
 
(Burke, 1994) Burke, H.B., “Artificial neural networks for cancer research:outcome prediction”, 
Seminars in surgical oncology; Vol 10 73-79 (1994). 
 
(Clark, Stewart, Altman, Gabra, Smyth, 2001) Clark. T.G., Stewart, M.E., Altman, D.G., Gabra, H., 
Smyth, J.F., “A prognostic model for ovarian cancer”, British Journal of Cancer, 85, 944–52 (2001). 
 
(Clark, Altman, 2003) Clark, Taane G. and Altman, Douglas G., “Developing a prognostic model in 
the presence of missing data: an ovarian cancer case study”. Journal of Clinical Epidemiology, Vol. 
56, pp 28-37, (2003). 
 
(Collet, 2003) Collet, David, “Modelling Survival data in medical research”, Chapman & Hall/CRC, 
(2003). 
 
(Collins, Altman, 2009) Collins, Gary, Altman, Gouglas, “An independent external validation and 
evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study”, BMJ, 
339:b2584, (2009). 
 
(Computation in the brain) Computation in the brain. Available at: 
http://www.willamette.edu/~gorr/classes/cs449/brain.html 
 
(Concato, Peduzzi, Holford, Feinstein, 1995) Concato, John, Peduzzi, Peter, Holford, Theodore R. and 
Feinstein, Alvan R., “Importance of events per independent variable in proportional hazards analysis. 
I. Background, Goals and General Strategy”, Journal of clinical epidemiology, Vol. 48, Nº12, pp 
1495-1501, (1995). 
 
(Concato John, Peduzzi, Holford, Feinstein, 1995) Concato, John, Peduzzi, Peter, Holford, Theodore 
R. and Feinstein, Alvan R., “Importance of events per independent variable in proportional hazards 
regression analysis. II. Accuracy and Precision of regression estimates”, Journal of clinical 
epidemiology, Vol. 48, Nº12, pp 1503-1510, (1995). 
 
(Concato, Peduzzi, Holford, Kemper, Feinstein, 1996) Concato, John, Peduzzi, Peter, Holford, 
Theodore R., Kemper, Elizabeth and Feinstein, Alvan R., “A Simulation Study of the number of 
References 
184 
events per variable in Logistic Regression Analysis”, Journal of clinical epidemiology, Vol. 49, Nº12, 
pp 1373-1379, (1996). 
 
(Cox, 1972) Cox D. R., “Regression models and life tables”. Journal of the Royal Statistical Society, 
B. Vol. 74, pp 187-220, (1972). 
 
(D’Agostino, Nam, 2004) D’Agostino, R.B., Nam, B.H., “Evaluation of the performance of survival 
analysis models: discrimination and calibration measures”. N. Balakrishnan, C. Rao (Eds.), Handbook 
of Statistics, 23rd ed., Elsevier, Amsterdam, 1-26, (2004). 
 
(D’Eredita, Giardina, Martellotta, Natale, Ferrarese, 2001) D’Eredita, G., Giardina, C., Martellotta, 
M., Natale, T., Ferrarese, F., “Prognostic factors in breast cancer: the predictive value of the 
Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single 
institution”, European Journal of Cancer, 37, pp 591-596, (2001). 
 
(Delen, Walker, Kadam, 2005) Delen, Dursun, Walker, Glenn and Kadam, Amit, “Predicting breast 
cancer survivability: a comparison of three data mining methods”, Artificial Intelligence in Medicine, 
34, pp 113-127 (2005). 
 
(Eleuteri, Aung, Taktak, Damato, Lisboa, 2007) Eleuteri, A., Aung, M.S.H., Taktak, A.F.G., Damato, 
B. and Lisboa, P.J.G., “Bayesian Neural Networks for survival analysis: A comparative study”, 
Proceedings of CIMED 2007 ,(2007). 
 
(Etchells, Lisboa, 2006) Etchells T.A. and Lisboa P.J.G., “Orthogonal Search-Based Rule Extraction 
(OSRE) for trained Neural Networks: A practical and efficient approach”, IEEE Transactions on 
Neural Networks, Vol. 17, No. 2, (2006). 
 
(Etchells, Fernandes, Jarman, Fonseca, Lisboa, 2008) Etchells, T.A., Fernandes, A.S., Jarman, I.H., 
Fonseca, J.M., Lisboa, P.J.G., “Stratification of severity of illness indices: a case study for breast 
cancer prognosis”, accepted KES2008 Zagreb, Croatia, 3-5 September, (2008).  
 
(Fernandes, Jarman, Etchells, Fonseca, Biganzoli, Bajdik, Lisboa, 2008) Fernandes A.S., Jarman I.H., 
Etchells T.A., Fonseca J.M., Biganzoli Elia, Bajdik Chris and Lisboa P.J.G., “Missing data imputation 
in longitudinal cohort studies – application of PLANN-ARD in breast cancer survival”, Machine 
Learning and Applications, ICMLA08, pp 644-649, (2008).  
References 
185 
 
(Fonseca, Mora, Barroso, 2006) Fonseca, José Manuel, Mora, André, Barroso, Pedro,  “The web and 
the new generation of medical information systems”, Outcome Prediction in Cancer, Section 5 – 
Chapter 14, Elsevier, Studies in Multidisciplinarity series, (2006). 
 
(Galea, Blamey, Elston, Ellis, 1992) Galea, M.H., Blamey, R.W., Elston, C.E., Ellis, I.O., “The 
Nottingham Prognostic Index in primary breast cancer”. Breast Cancer Res Treat, 22:207–19, (1992). 
 
(Greenland, Finkle, 1995) Greenland, S., Finkle, W.D., “A critical look at methods for handling 
missing covariates in epidemiologic regression analysis”, Am J Epidemiology, 142(12): 1255-64, 
(1995). 
 
(Guerra, Algorta, Diaz de Otazu, Pelayo, Farina, 2003) Guerra, I., Algorta, J., Diaz de Otazu, R., 
Pelayo, A., Farina, J., “Immunohistochemical prognostic index for breast cancer in young women”, 
Journal Clinical Pathology: Molecular Pathology 56, 323–327 (2003). 
 
(Harbeck, Jakesz, 2007) Harbeck, Nádia, Jakesz, Raimund, “St Gallen 2007:Breast Cancer Treatment 
Consensus Report”, Breast Care, 2:130-134, (2007). 
 
(Harrel, Lee, Califf, Pryor, Rosati, 1984) Harrel, F.E., Lee, K.L., Califf, R.M., Pryor, D.B., Rosati, 
R.A., “Regression modelling strategies for improved prognostic prediction, Statistics in Medicine”, 
Volume 13, 1501-1511, (1984). 
 
(Harrell Jr., Lee, Mark, 1996) Harrell Jr., Frank E., Lee, Kerry L. and Mark, Daniel B., “Tutorial in 
Biostatistics: Multivariable Prognostic Models: Issues in developing models, evaluating assumptions 
and adequacy, and measuring and reducing errors”, Statistics in Medicine, Vol. 15, pp 361-387, 
(1996). 
 
(Harrell, 2001) Harrell, F.E., “Regression Modeling Strategies: With Applications to Linear Models, 
Logistic Regression and Survival Analysis”; Springer-Verlag; (2001). 
 
(Haybittle, Blamey, Elston, Johnson, Doyle, Campbell, Nicholson, Griffiths, 1982) Haybittle, J.L., 
Blamey, R.W., Elston, C.W., Johnson, J., Doyle, P.J., Campbell, F.C., Nicholson, R.I. and Griffiths, 
K., “A prognostic index in primary breast cancer”, British Journal of Cancer, 45, 3621 (1982). 
References 
186 
 
(Heller, Venkatraman, 1996) Heller, Glenn and Venkatraman, E.S., “Resampling procedures to 
compare two survival distributions in the presence of right censored data”, Biometrics, Vol.52, nº 4, 
pp 1204-1213, (1996).  
 
(Hippisley-Cox, Coupland, Vinogradova, Robson, May, Bringle, 2007) Hippisley-Cox, Julia, 
Coupland, Carol, Vinogradova, Yana, Robson, John, May, Margaret and Bringle, Peter, “Derivation 
and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: 
prospective open cohort study”, BMJ, 335:136, (2007). 
 
(Hippisley-Cox, Coupland, Vinogradova, Robson, Bringle, 2008) Hippisley-Cox, Julia, Coupland, 
Carol, Vinogradova, Yana, Robson, John and Bringle, Peter, “Performance of the QRISK 
cardiovascular risk prediction algorithm in an independent UK sample of patients from general 
practice :a validation study”, Heart, 94, 34-39, (2008). 
 
(Jarman et al, 2008) Jarman, I.H., et al "An integrated framework for risk profiling of breast cancer 
patients following surgery", Artificial Intelligence in Medicine, Vol. 42, Issue 3 pp 165-188, (2008). 
 
(Jordan, 1995) Jordan, Michael I., “Why the logistic function? A tutorial discussion on probabilities 
and neural networks; Massachusetts Institute of technology”, Computational Cognitive Science, 
Technical report 9503 (1995).  
 
(Kappen, Neijt, 1993) Kappen, H.J., Neijt, J.P., “Neural Network analysis to predict treatment 
outcome”, Annals of oncology; Vol.4 Supplement S31-S34 (1993).  
 
(Kaski, Sinkkonen, Peltonen, 2001) Kaski, S., Sinkkonen, J. and Peltonen, J. “Bankruptcy analysis 
with self-organizing maps in learning metrics”. Neural Networks, IEEE Transactions, vol. 12, no. 4, 
pp. 936–947, (2001). 
 
(Lisboa, 2002) Lisboa, P.J.G., “A review of evidence of health benefit from artificial neural networks 
in medical intervention”, Neural Networks, Invited Paper, Vol. 15, issue 1, pp 9-37, (2002). 
 
(Lisboa, Wong, Harris, Swindell, 2003) Lisboa, P.J.G., Wong, H., Harris, P. and Swindell, R., “A 
Bayesian neural network approach for modelling censored data with an application to prognosis after 
surgery for breast cancer”. Artificial Intelligence in Medicine, Vol. 28, issue 1, pp 1-25, (2003). 
References 
187 
 
(Lisboa, Etchells, Jarman, Ramsey, 2007) Lisboa, P.J.G., Etchells, T.A., Jarman, Ian H F. and 
Ramsey, Philip; ‘A prototype Integrated Decision Support System for Breast Cancer Oncology’, 
Lecture Notes in Computer Science, 4507, pp. 996–1003, (2007). 
 
(Lisboa, Etchells, Jarman, Aung, Chabaud, Bachelot, Perol, Gargi, Bourdès, Bonnevay, Négrier, 2008) 
Lisboa, P.J.G., Etchells, T.A., Jarman, Ian H,, Aung, M.S., Chabaud, Sylvie, Bachelot, Thomas, Perol, 
David, Gargi, T., Bourdès, V., Bonnevay, S., Négrier, Sylvie, “Time to event analysis with artificial 
neural networks: An integrated analytical and rule-based study for breast cancer”, Neural networks, 
vol 21(2-3), pp. 414-426, (2008). 
 
(Loprinzi, Thome, 2001) Loprinzi, C, Thome, S.D., “Understanding the utility of adjuvant systemic 
therapy for primary breast cancer”, Journal of Clinical Oncology, 19, 972-979, (2001). 
 
(Mackay, 1992) Mackay, D.J.C., “The evidence framework applied to classification networks”, Neural 
computation; 4(5) 720-736(1992). 
 
(Mackay, 1995) MacKay, D.J.C., “Probable networks and plausible predictions – a review of practical 
Bayesian methods for supervised neural networks. Network”, Computation in Neural Systems.,6: 469-
505 (1995). 
 
(Marubini, Valsecchi, 1995) Marubini, E., Valsecchi, M., “Analysing survival data from clinical trials 
and observational studies”, John Wiley and Sons, (1995). 
 
(McGuire, Tandon, Allred, Chamness, Ravdin, Clark, 1992) McGuire, W.L., Tandon, A.K., Allred, 
D.C., Chamness, G.C., Ravdin, P.M., Clark, G.M., 2Treatment decisions in axillary node-negative 
breast cancer patients”, Monograohs-National Cancer Institute; Vol.11 173-180 (1992).  
 
(Neal, 2001) Neal, Radford M., “Survival analysis using a Bayesian Neural Network”, Joint Statistical 
Meetings report, Atlanta (2001). 
 
(Newgard, Haukoos, 2007) Newgard, Craig, Haukoos, Jason., “Advanced statistics: Missing Data in 
Clinical Research – Part 2: Multiple Imputation ”, Society for Academic Emergency Medicine, 669-
678, (2007).  
 
References 
188 
(Ohno-Machado, Walker, Musen, 1995) Ohno-Machado, L., Walker, M.G. and Musen, M.A., 
“Hierarchical Neural Networks for Survival Analysis”, Proceeding of the eight congress on Medical 
InformaGcs, 8: pp 828-832, (1995). 
 
(Olivotto, Bajdik, Ravdin, Speers, Coldman, Norris, Davis, Chia, Gelmon, 2005) Olivotto, I.A., 
Bajdik, C.D., Ravdin, P.M., Speers, C., Coldman, A., Norris, B., Davis, G.J., Chia, S. and Gelmon K., 
"Population-based validation of the prognostic model ADJUVANT! for early breast cancer". Journal 
of Clinical Oncology, Vol. 23 (12), pp 2716-25, (2005). 
 
(Ozanne, Braithwaite, Sepucha, Moore, Esserman, Belkora, 2009) Ozanne, Elissa, Braithwaite, 
Dejana, Sepucha, Karen, Moore, Dan, Esserman, Laura, Belkora, Jeffrey, “Sensitivity to Input 
Variability of the Adjuvant!Online Breast Cancer Prognostic Model”, Journal of clinical oncology, 
vol. 27, no. 2, pp. 214–219, (2009). 
 
(Peele, Siminoff, Xu, et al, 2005) Peele, P., Siminoff, L., Xu, X, et al.,“Decreased use of adjuvant 
breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk 
information”, Medical Decision Making, vol. 25, pp. 301–307, (2005). 
 
(Pop, Hayward, Diederich, 2009) Pop, E., Hayward, R., Diederich, J., “RULENEG: extracting rules 
from a trained ANN by stepwise negation”. QUT NRC technical report. Queensland, Austrália: 
Queensland University of Technology, Neurocomputing Research Centre, (2009). 
 
(Ravdin, Clark, 1992) Ravdin, P.M., Clark, G.M., “A practical application of neural network analysis 
for predicting outcome of individual breast cancer patients; Breast cancer research and Treatment”, 
Vol. 22, 285-293 (1992).  
 
(Ravdin, Clark, Hilsenbeck, Owens, Vendely, Pandian, McGuire, 1992) Ravdin, P.M., Clark, G.M., 
Hilsenbeck, S.G., Owens, M.A., Vendely, P., Pandian, M.R., McGuire, W.L., “A demonstration that 
breast cancer recurrence can be predicted by neural network analysis”, Breast cancer research and 
Treatment; Vol. 21 47-53 (1992).  
 
(Ravdin, Siminoff, Harvey,1998) Ravdin, P.M., Siminoff, I.A., Harvey, J.A., “Survey of breast cancer 
patients concerning their knowledge and expectations of adjuvant therapy”. Journal of Clinical 
Oncology, 16:515-521, (1998).  
 
References 
189 
(Ravdin, Sminoff, Davis, Mercer, Hewlett, Gerson, Parker, 2001) Ravdin, Peter, Sminoff, Laura, 
Davis, Greg, Mercer, Mary, Hewlett, Joan, Gerson, Nancy and Parker, Helen., “Computer program to 
assist in making decisions about adjuvant therapy for women with early breast cancer”, Journal of 
clinical oncology, vol 19, No 4 (February 15), pp 980-991, (2001). 
 
(Ripley, Ripley 1998) Ripley, B.D. and Ripley, R.M., “Neural Networks as Statistical Methods in 
Survival Analysis”, In R. Dybowsky, & V. Gant (Eds.), Artificial neural networks: Prospects for 
medicine. Landes Biosciences (1998). 
 
(Rubin, 1987) Rubin, D.B., “Multiple imputation for nonresponse in surveys”, New York: John Wiley 
& Sons, Inc, (1987).  
 
(SAS software) SAS software. Available at: http://www.sas.com/ 
 
(Satagopan, Ben-Porat, Berwick, Robson, Kutler, Auerbach, 2004) Satagopan, J.M., Ben-Porat, L., 
Berwick, M., Robson, M., Kutler, D. and Auerbach, A.D., “A note on competing risks in survival 
analysis”. British Journal of Cancer, Vol. 91, pp 1229-1235, (2004). 
 
(Schafer, 1999) Schafer, J.L., “Multiple imputation: a primer”, Statistical Methods in Medical 
Research, Vol. 8, pp 3-15, (1999). 
 
(Schumacher, Hollander, Sauerbrei, 1997) Schumacher, Martin, Hollander, Norbert and Sauerbrei, 
Willi, “Resampling and Cross validation techniques: a tool to reduce bias caused by model building”, 
Statistics in Medicine, Vol. 16, pp 2813-2827 (1997). 
 
(Schwarzer, Vach, Schumacher, 2000) Schwarzer, Guido, Vach, Werner and Schumacher, Martin, 
“On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology”, 
Statistics in Medicine, Vol. 19, pp 541-561, (2000). 
 
(Sebastian, Gonzalez, Paricio, Perez, Flores, Madrona, Romero, Tebar, 2000) Sebastian S. Ortiz, 
Gonzalez, J.M. Rodrıguez, Paricio, P. Parilla, Perez, J. Sola, Flores, D. Perez, Madrona, A. Piñero, 
Romero, P. Ramirez, Tebar, F.J., “Papillary Thyroid Carcinoma: Prognostic Index for Survival 
Including the Histological Variety”, Archives of Surgery, 135 (2000). 
 
References 
190 
(Shafer, 1997) Shafer, J. L., “Analysis of incomplete multivariate data”, Chapman & Hall/CRC, 
(1997). 
 
(Silverstein, Buchanan, 2003) Silverstein, M.J., Buchanan. C., “Ductal carcinoma in situ: Ductal 
carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status”, The Breast, 
Volume 12, Issue 6, 8th International Conference on Primary Therapy of Early Breast Cancer, St 
Gallen, Switzerland, 457-471, (2003). 
 
(Steyerberg, 2009) Steyerberg, Ewout, “Clinical Predictions Models”, Springer, (2009). 
 
(Taktak, Antolini, Aung, Boracchi, Campbell, Damato, Ifeachor, Lama, Lisboa, Setzkorn, 
Stalbovskaya, Biganzoli, 2007) Taktak, A., Antolini, L., Aung, M.H., Boracchi, P., Campbell, I., 
Damato, B., Ifeachor, E.C, Lama, N., Lisboa, P.J.G, Setzkorn, C., Stalbovskaya, V. and Biganzoli, 
E.M. ‘Double-blind evaluation and benchmarking of survival models in a multi-centre study’ 
Computers in Biology and Medicine, 37 (8): 1108-1120 (2007). 
 
(Van Buuren, Boshuizen, Knook, 1999) Van Buuren S., Boshuizen H.C., Knook D.L.,“Multiple 
imputation of missing blood pressure covariates in survival analysis”, Statistics in Medicine, Vol 18 
(6), pp 681-94, (1999). 
 
(Whelan, Loprinzi, 2005) Whelan, Timothy, Loprinzi, Charles. “Physician/Patient Decision Aids for 
Adjuvant Therapy”, Journal of Clinical Oncology, Vol. 23,pp. 1627-1630, (2005).  
 
(Williams, Mandrekar, Mandrekar, Cha, Furth, 2006) Williams, B.A., Mandrekar, J.N., Mandrekar, 
S.J., Cha, S.S. and Furth, A.F., “Finding Optimal Cutpoints for Continuous Covariates with Binary 
and Time-to-Event Outcomes”, Technical Report Series #79, Mayo Clinic, Rochester, Minnesota, 
June 2006. 
 
 
 
 
 
 
 
 
